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Abstract
A physiological pharmacokinetic model was developed to investigate the fate of 
macromolecular drugs after intravenous injection. The purpose of the model was to 
examine the effect of molecular radius on the distribution of both negatively charged 
protein and uncharged macromolecular drugs in man, both in the absence and presence 
of hepatic metabolism. This was achieved by taking into account the regional capillary 
permeabilities to different size macromolecules, and the physiology and flow rates 
within each compartment. Mathematical models of capillary permeability were 
developed to allow the fitting of appropriate physiological experimental data from the 
literature. The latter models were used to develop intercompartmental rate constants 
used in the physiological three-compartment pharmacokinetic model. The major 
objective was to predict via simulations the effect of molecular radius on 
biodistribution, in particular access to interstitial fluids. In addition, the proposed 
model allowed calculation, for molecular radii from 20-70A, of the fraction of the dose 
present in the blood and the liver, the fractions of the dose excreted via the kidneys and 
metabolised by the liver, and the total fraction of the dose eliminated, as a function of 
time. A necessary objective of the study was the development of a computer 
programme named ‘MACROHOURS’ which had two main purposes; firstly to aid in the 
solution of cubic functions within the physiological three-compartment 
pharmacokinetic model equations, and secondly to perform simulations once the 
solutions to the model equations had been established.
Simulations suggested that generally molecular radii of 40-5 5A produce the greatest 
fraction of a macromolecular drug dose in the interstitial fluids, and that radii less than 
30A are excreted too rapidly to gain significant access to tissues. For a macromolecular 
drug which is metabolised very quickly, then optimum molecular radii for tissue uptake 
can be as low as 3 5A. Protein macromolecules (i.e. negatively charged species) were 
found to be better candidates than uncharged macromolecules for delivering the
greatest fraction of the dose to tissues. In the case of the protein macromolecules in 
the absence of hepatic metabolism or when the metabolic rate was low, the upper size 
range could be extended to 65A radius to give high concentrations in the tissues over 
very long time periods.
The model was used in subsequent work to compare simulations with experimental 
animal data of plasma clearance of proteins and drug copjugates in the rat. For 
albumin-methotrexate conjugates it was possible to estimate their rate of hepatic 
metabolism and use this to predict tissue uptake. Comparison of clearance data for 
proteins of various dimensions was less successful, due to variable metabolism. It was 
concluded that the model would be strengthened by obtaining more physiological data 
for the animal specifies of interest.
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Macromolecular prodrugs, pharmacokinetics and
cancer chemotherapy
1.1 Therapeutic failures in controlling the spread of cancer micrometastases
One of the most critical and difficult problems in the management of cancer is the control 
and treatment of cancer micrometastases [1, 2]. It is the ability o f these tiny malignant 
tumour cells to disseminate from a locally growing primary tumour and to form secondary 
tumours at near and distant sites in the body that is the most life-threatening aspect of 
cancer [1-3]. Completion o f this process means that cells released from the primary 
tumour must survive a series of complex interactions with host cells and tissues which are 
now widely accepted in the literature [1,3-7]. Typically, these are the growth and 
invasion of malignant cells at primary sites, followed by their penetration into local tissue, 
lymphatics and small blood vessels. Once in these new compartments, malignant cancer 
micrometastases cells can detach from the site o f penetration as either single cells or small 
emboli and be transported to near and/or distant secondary sites, where they can implant 
in and invade surrounding tissues. Here they survive in and respond to their new 
microenvironments, where they can proliferate, giving rise to a further tumour or tumours 
(secondary tumours) which subsequently metastasize themselves, producing more cancer 
micrometastases which continue to spread in this way (multiple secondaries) [1, 3-7].
In the treatment of cancer micrometastases there are frequent therapeutic failures [1,
2]. The lymphatic system together with the blood circulatory system is the main route 
by which cancer micrometastases traverse the body [2]. All cancer micrometastases 
take this route, regardless of whether they are micrometastases which have been 
produced by, and have broken away from, either a primary or a secondary tumour. 
Having detached from the primary tumour the cancer micrometastases ‘float’ in the 
interstitial fluid (tissue fluid) and either enter the blood circulation directly, or more 
frequently they enter into the lymphatic system [1-7]. In the former case, the cancer 
micrometastases either arrest in the walls of minor blood vessels and grow into a 
secondary tum our there, which then subsequently metastasizes, and/or extravasate 
freely into surrounding normal tissue, developing into a secondary tumour there. In the 
more common latter case, once in the lymphatic system the cancer micrometastases
either remain there, becoming trapped at the site of near and/or distant draining lymph 
nodes, developing into a secondary tumour which then metastasizes (the site of the 
lymph node closest to the primary tumour is often the location of the first secondary 
tumour), and/or are carried through the lymph node and lymphatic system, and are 
eventually emptied into the bloodstream. Once in the bloodstream via this route they 
subsequently extravasate freely into normal tissues in other parts of the body, 
developing into a secondary tumour there (the most frequent organ site of metastasis is 
often the first organ encountered by the circulating cancer micrometastases, and in 
distant metastasis this is often the lung). Consequently even if any visible tumour is 
either removed completely by surgery (if surgery is possible), or is destroyed with 
irradiation during radiotherapy, or is treated successfully using cytotoxic anticancer 
drugs during chemotherapy, or by various combinations of these treatments (depending 
upon the type of cancer and the location of the tumour), many cancer micrometastases 
of obvious great potential threat will still be lurking somewhere within the lymph 
compartment, i.e. the lymphatic system and the interstitial fluid (i.e. the total interstitial 
or extravascular fluid) [1, 2]. Hence in order to control and treat cancer successfully, 
these cancer micrometastases within the lymph need to be killed before they have a 
chance to develop into tumours either there, or following their distribution via the 
lymphatic and blood circulatory systems to any other parts of the body. Thus, a 
complete eradication of cancer micrometastases disseminated to a wide area of 
lymphatic involvement is required which is an extremely difficult task to accomplish 
[2]. The only efficient way to achieve this is to specifically target cytotoxic anticancer 
drugs to the lymph, since of the main cancer treatment methods, cytotoxic anticancer 
drugs used in chemotherapy are the most practical forms of treatment if the disease 
has become too widespread or secondaries are present (such drugs will need to have a 
high lymphotropic character [2]). Both surgery and radiotherapy can necessarily for 
practical and physiological reasons only be directed towards localised tumours together 
with some of the surrounding local tissue and associated local draining lymph nodes, 
rather than towards controlling the spread of cancer micrometastases [1]. This is
because in most cases of cancer the disease is often only diagnosed following the 
discovery of a visible growth, and by this time many cancer micrometastases could 
have already traversed further within the lymphatic system (and indeed the blood 
circulatory system), and will no longer be confined just to the local lymph nodes and 
local normal tissue surrounding the tumour from which they originally detached. The 
cancer micrometastases are also because of their extremely small size (radius less than 
150 |im), effectively invisible, making them impossible to locate individually, and also 
easily transportable, usually moving freely into and out of both the lymphatic and 
blood circulatory systems. As will be outlined in Section 1.2 along with some of the 
associated key pharmacokinetic studies in the literature, site-specific drug-delivery in 
the field of cancer chemotherapy is routinely distinguished into either actively or 
passively targeted macromolecular anticancer drug systems.
The situation is further complicated by the fact that in contrast to the targeting of 
anticancer drug systems to solid (vascularised) tumours, which have been shown to 
possess their own peculiar vascular properties, namely, (a) tum our angiogenesis 
resulting in an immature or vestigial tumour capillary basement membrane and hence a 
leaky tum our vasculature (hypervasculature) [8 -1 0 1 , (b) hyperpermeability of tumour 
blood vessels [11-16], mediated by enhanced vesicular transport or via transendothelial 
channels [11, 14], with the underlying physiological purpose to import sufficient fibrin 
which is essential for a functional tumour interstitium and development [1 2 ], and 
promoted by the existence of a tumour-secreted factor (Vascular Permeability Factor) 
[14, 17-20], a protein with sequence homology to platelet derived growth factor (PDGF) 
[21, 22], and/or kinin action [2, 23], (c) a complete absence of any organised lymphatic 
drainage system [2, 8 , 24-28], resulting in elevated tumour interstitial pressure and 
hence minimal tumour drainage, and (d) architectural incompleteness of tum our blood 
vessels resulting in increased extravasation rates [8 , 29]; the targeting of anticancer 
drug systems to the lymph is dependent upon normal vascular properties [2]. Hence 
when one considers the spread of cancer micrometastases via the lymph and the
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targeting of anticancer drug systems to the cancer micrometastases located there, 
normal vascular properties must be considered [2]. The key to this problem is 
molecular size, although other factors such as charge also influence the process, and 
requires consideration to be given to the exchange of macromolecules across the 
microcirculation, and this is described in Chapter 2.
1.2 Site-specific drug delivery in cancer chemotherapy
Site specific drug delivery is routinely categorised into either ‘active’ or ‘passive’ drug- 
targeting [30, 31]. In the field of cancer chemotherapy the former approach is 
characterised by the use of specific targeting residues, the best known of which are 
monoclonal antibodies and their various fragments and conjugates, which recognise 
many tumour-associated antigens. Conversely the latter approach relies on the 
physicochemical properties of the particular drug system to dispose it towards an 
elevated therapeutic index. The aim of both the active and passive approaches to drug- 
targeting is to maximise the therapeutic response to a drug by delivering it specifically 
to the target site, whilst minimising the toxic effects at non-target sites [32].
Until very recently, the main thrust of work in the field of cancer chemotherapy has 
been in the active-targeting area. This has led to the development of many sophisticated 
monoclonal antibody systems (many of which are of murine origin), which are protein 
based and macromolecular in nature, and which can be used specifically to mobilize 
endogenous defences and to direct attached low molecular-weight therapeutic 
anticancer agents, such as cytotoxic protein drugs, toxins, and radionuclides, to 
tumours. Indeed, they have already established themselves as valuable diagnostic 
agents for both primary and secondary tumour growths when bound to these low 
molecular-weight anticancer agents [33, 34]. Monoclonal antibodies used only in their 
naked form generally have little activity on the growth of the tum our themselves. There 
are many experimental studies of monoclonal antibody systems in the literature 
directed towards a variety of tumour types (many in mice bearing xenografts of various
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hum an carcinomas), using various routes of administration (mostly intravenous) and a 
variety of different fragments and conjugates, and utilizing various linkages (usually 
covalent bonding). Typical of these, and perhaps indeed the more appropriate to this 
study, are some of the more recent pharmacokinetic studies [35-71, 118-120].
Despite great advances in the technology of antibody production and in synthetic 
chemistry, and also in the performance of a large number of clinical trials, the obvious 
potential therapeutic benefits of these actively targeted monoclonal antibody systems 
does however remain to be realised. They have generally proved disappointing for 
several reasons, namely they (a) can never really be loaded with enough antibody to 
effect complete tumour death since high levels of circulating tumour antigen can form 
complexes with the administered antibody, leading to rapid clearance from the blood 
and reduction in tumour localisation, (b) show variable and often only relatively 
satisfactory degrees of specificity of monoclonal antibody-tumour antigen binding and 
tum our localisation due to (a), and also due to the fact that some antibodies are more 
tum our specific than others, (c) are prone to some localisation at other sites due to 
nonspecific uptake by the reticuloendothelial cells in some organs (e.g. lung and 
spleen), and also due to some antibody aggregation or cross-reactivity with normal 
tissue, (d) produce immunity to antibody if used extensively, (e) cause several unwanted 
site-effects, the most principal of which is myelosuppression, and (f) exhibit different 
and often only relatively satisfactory pharmacokinetics due to their limited and diverse 
size ranges [72-75]. There have recently been several reviews describing the many 
concepts and aspects involved in the use of monoclonal antibodies as therapeutic 
agents, and giving many of the recent studies and a historical summary of some of the 
key earlier studies, together with a discussion on the current clinical pharmacokinetic 
status using these actively-targeted systems [73, 75-80]. To date, the most interesting 
feature of monoclonal antibodies and their fragments and conjugates is that when they 
are administered intravenously for diagnosis or treatment of a cancer, they tend to 
distribute heterogeneously within the tumour substance [81-102]. This nonuniformity
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of distribution often reflects the intrinsic heterogeneity of the tumour mass with 
respect to factors such as antigen density, vascularization, capillary permeability, 
degree of necrosis, time, and interstitial pressure [14, 81-85, 89, 92, 107, 245]; but also 
may reflect inefficient penetration from the blood vessels into the tumour [8 6 , 90, 92, 
93, 101, 102]. In most cases the transport of bindable antibody through the tumour 
interstitium is retarded by its specific binding to tumour antigen. This has led to the 
concept of a "binding site barrier" [8 6 , 87, 90, 91, 97], since although formation of 
antigen-antibody complexes per se does not present a mechanical barrier to the 
uncomplexed monoclonal antibody, binding to antigens in the immediate proximity of 
the blood vessels does however significantly decrease the number of free, diffusable 
molecules available for penetration deeper into the tumour substance. Indeed, recent 
modelling [8 6 -8 8 , 90, 91, 94-98] and experimental [81, 83, 84, 101, 103-106, 245] 
studies have infact shown that antibody molecules (and other ligands) can be effectively 
prevented from penetrating the substance of a tumour by the very fact of their 
successful binding to tumour antigen, and that greater antigen density, higher 
monoclonal antibody affinity, and faster monoclonal antibody internalisation and 
metabolism by cells will increase the barrier effect, all else being equal [103].
Other examples of pharmacokinetic studies involving the use of actively-targeted 
systems include the sugar residues [108-113]. Carbohydrate and mannose receptors are 
found in liver hepatocyte and kupffer cells respectively [114-117].
In contrast to the extensive interest which has been shown towards the development of 
actively-targeted monoclonal antibody systems, the development of passively-targeted 
drug systems in cancer chemotherapy has until recently received comparatively little 
attention. This is however now changing, and has recently led to the development of 
several sophisticated soluble macromolecular drug conjugate systems which utilize 
various linkages (usually either biodegradable or covalent bonding) and administration 
routes (mainly systemic), are directed towards a variety of tumour types, and whose use 
offers many new therapeutic strategies. Typical examples of these, and perhaps indeed
the more appropriate to this study, are SMANCS (Styrene-Maleic Anhydride- 
Neocarzinastatin) [24, 25, 28], and the pharmacokinetic studies currently available in 
the literature involving the use of other passively-targeted macromolecular drug 
conjugate systems. Such pharmacokinetic literature is currently available for mitomycin 
C-dextran conjugates (MMC-D) [124-131], polyethyleneglycol (PEG)-interleukin 2 
conjugates [132-134], albumin conjugates of methotrexate [135] and 5-fluorouracil- 
acetic acid [136], various dextran-enzyme [137-140] and antibody-polymer [141-143] 
conjugates, and copolymers of N-(2-hydroxypropyl) methacrylamide (HPMA) containing 
adriamycin [144], or doxorubicin (DOX) or daunorubicin (DNR) and sugar residues such 
as galactosamine [145, 146, 169], or daunomycin (DNM) and anti-Thy 1.2 antibody 
[147], or transferrin, anti-transferrin receptor antibody or anti-Thy 1.2 antibody [148].
In addition to these conjugates, several other passively-targeted macromolecular drug 
conjugate systems have now been reported [121-123], including an oxidized dextran- 
anthracycline conjugate (OXD-DOX), a divinyl ether-co-maleic anhydride copolymer- 
neocarzinostatin conjugate (DIVEMA-NCS or Pyran-NCS), a human immunoglobulin G- 
melphalan conjugate (K-18), a DIVEMA-DOX copolymer, a pyran-DOX conjugate, an 
albumin-daunorubicin conjugate, a gelatin-interferon a  conjugate, a polyaspartic acid- 
DOX conjugate, poly-lysine-methotrexate conjugates, and anthracycline conjugates of 
DNA or dextran, however, the pharmacokinetic literature currently available on each of 
these systems is somewhat limited. In each of these passively-targeted soluble 
macromolecular drug conjugate systems the carrier macromolecule (polymer) which 
may be either of natural origin e.g. a protein such as albumin or a carbohydrate like 
dextran or DNA, or of synthetic origin e.g. polyethyleneglycol or HPMA etc [149, 162], 
and which usually constitutes at least 80% of the conjugates total molecular weight 
[1 2 1 ], significantly and favourably alters the biodistribution of the attached low 
molecular weight protein anticancer agent. This results in the attached anticancer agent 
exhibiting increased blood stability and circulation times, reduced rates of renal 
excretion, a reduced volume of distribution, increased and often substantially improved 
tumour accumulations of drug, increased lymphatic concentrations of drug, decreased
drug toxicity, decreased antigenicity, decreased immunogenicity, and hence increased 
therapeutic efficacy, compared to when the respective attached anticancer agent is 
administered in its free form. This enhanced tumour accumulation (and increased 
lymphatic concentration) is a direct result of the greatly improved pharmacokinetic 
properties which are achieved by attaching the anticancer agent to a macromolecular 
carrier, and are also indeed a result of the peculiar vascular properties of tumours 
themselves, and can generally be explained by the phenomenon termed as the 
‘Enhanced Permeability and Retention’ (EPR) effect [25], and its associated corollaries. 
The EPR effect, which results from the combination of poor tumour tissue drainage 
with increased tumour vascular permeability, is outlined in more detail in Chapter 2. 
The passive drug-targeting approach in cancer chemotherapy is consequently now 
attaining profound significance and interest since the inadequate pharmacokinetic 
properties which have generally limited the clinical use of most low molecular-weight 
protein anticancer drugs (agents) now seem to be manipulable by tailoring these drugs 
by attaching them to various natural or synthetic soluble macromolecular carriers 
(polymers) [2, 24, 28, 121-123, 150]. The potential advantages of this approach to 
cancer chemotherapy are obviously quite considerable, even more so if they can be 
used in conjunction with known tumour vascular permeability and hence tumour 
macromolecular drug accumulation enhancing agents such as the hypertension 
inducing agent angiotensin II which selectively increases blood flow in tumour tissue [2, 
151, 152], or kininase II inhibitor which inhibits kinin degradation and thus promotes 
both the leakage of macromolecules out of blood vessels and the accumulation of fluid 
in tumours [23, 153], or even both of these tumour vascular permeability enhancing 
agents combined [154]. To date however, the peculiar vascular properties of tumours 
and the EPR effect still remain to be fully exploited, and so far the investigation and 
development of such macromolecular conjugate systems has been surprisingly limited 
[121-123]. The many aspects of passive tumour-targeting using soluble macromolecular 
drug conjugate systems, together with the historical development which led to this 
approach of drug-targeting in cancer chemotherapy and all associated studies, have
recently been described in some excellent reviews [2, 24, 28, 121-123]. There have also 
recently been some excellent reviews discussing the studies, useage, important aspects, 
and pharmacokinetics of most of the commonly used low molecular-weight anti 
tumour protein drugs [155-159].
The key to successful pharmacokinetic properties for the passively-targeted 
macromolecular drug systems, and indeed for the actively-targeted macromolecular 
drug systems as well, is molecular radius size, although other factors such as charge, 
hydrophobicity, and the stability of the molecular bonds and linkages also influence the 
process [2, 24, 28, 121-123,160]. In the case of both the actively and passively targeted 
systems the respective optimal monoclonal antibody or monoclonal antibody fragment 
size and optimal soluble macromolecular carrier size, and hence the respective optimal 
conjugate size, have yet to be determined when targeting these systems to tumours 
under abnormal tumour vascular conditions. The optimal macromolecular size or size 
range which can deliver the greatest fraction of a macromolecular drug systems dose to 
the lymph under normal vascular conditions has yet to be considered. Also, almost all 
of the work in cancer chemotherapy using the active-targeting approach, and most of 
the work using the passive-targeting approach has been directed primarily towards the 
delivery of anticancer agents to vascularised tumours, which as already outlined 
possess their own peculiar vascular properties, rather than specifically to cancer 
micrometastases in the lymph (under normal vascular conditions), and have thus 
concentrated more on achieving the best therapeutic tumour accumulations of drug 
rather than making the achievement of the best lymph accumulations their primary or 
sole objective. The main exception to this being the passively-targeted soluble 
macromolecular drug conjugate system SMANCS [24], which is specifically designed to 
be lymphotropic as well as being tumouritropic by binding to serum albumin in vivo 
[161]. Clearly the ideal actively or passively-targeted macromolecular conjugate system 
will be both highly tumouritropic and lymphotropic [2]. The increased lymphatic 
concentrations of drug usually observed with the other passively-targeted
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macromolecular drug conjugate systems, and indeed some of the actively-targeted 
systems, is usually an important but nevertheless secondary objective (unless of course 
the targeted tumour is a lymphoma). In general, due to their increased blood circulation 
times and reduced rates of renal excretion, and also due to the peculiar vascular 
properties of tumours and the EPR effect, macromolecular drug systems larger than the 
renal threshold (60-70kDa) appear to accumulate relatively well in tumours and exhibit 
the better pharmacokinetic properties (and lymphatic concentrations) 12, 24, 25, 28, 
121-123] . Even more so if the conjugate system or the attached carrier macromolecule 
bears a negative [124, 128, 162, 163], or non-cationic [25, 129, 164] charge. A negative 
or neutral electric charge appears to be better since polycationic polymers are rapidly 
captured by the first pass effect and also during circulation [129]. As outlined in more 
detail in Chapter 2, the reason for this is that the endothelial surfaces of the blood 
capillaries are covered with negatively charged components such as chondroitin sulfate, 
heparan sulfate and glycocalyx, which therefore repels negatively charged molecules or 
polymers and thus aids in the extension of their blood circulation times, but makes 
polycationic molecules or polymers very bioadhesive. The peculiar tumour vascular 
properties mean there are often fewer restrictions on size compared to the normal 
vascular properties under which the targeting of macromolecular drug systems to the 
lymph must be considered [2]. The exchange of macromolecules across the 
microcirculation under normal vascular conditions is described in detail in Chapter 2. 
Additionally, carrier macromolecules which are of natural origin have the advantage of 
being usually biodegradable and generally demonstrating little polydispersity [168]. 
Synthetic carrier macromolecules are not usually biodegradable unless they have been 
specifically synthesised to include biodegradable bonds [165], as is the case for most of 
the afore-mentioned passively-targeted macromolecular drug conjugate systems which 
utilize synthetic polymers, and because they are man-made they are likely to be 
polydisperse. An advantage which synthetic polymers have over natural polymers is 
that they are less likely to evoke an immunogenic response in vivo [166], and they can 
be tailor-made to requirements of molecular weight, charge and hydrophobicity [167].
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Also, the majority of the pharmacokinetic studies using the actively-targeted 
monoclonal antibody systems, and virtually all of the pharmacokinetic studies using 
the passively-targeted soluble macromolecular drug conjugate systems, have been 
performed in animals rather than humans. In the case of the passively-targeted soluble 
macromolecular drug systems the fact that the use of macromolecular carriers is a new 
innovation has meant that only a few are currently scheduled for thorough clinical 
evaluation, including SMANCS (in Japan) and HPMA-DOX (in the UK) (121-123], 
and there is consequently relatively little published data available for these drug 
systems. One of the direct consequences of this from the point of view of trying to 
predict which macromolecular drug sizes are most effective in delivering the greatest 
fraction of a macromolecular drug dose to the lymph and hence to any cancer 
micrometastases present there, and indeed from the point of view of macromolecular 
drug disposition in general, is that there is a considerable lack of any particularly useful 
pharmacokinetic and tissue distribution data describing the time course of either 
actively or passively-targeted macromolecular drug systems in the human body for any 
of the key compartments of the body, i.e., the blood, the lymph, and the liver (the liver 
represents the site where any major drug toxicity may occur), or for the main 
elimination processes, i.e. renal excretion and hepatic metabolism (hepatic clearance), 
which arc important in both macromolecular drug distribution and the targeting of 
anticancer agents to micrometastases in the lymph. Most of the tissue distribution data 
which are available in the literature for both the actively and passively-targeted 
macromolecular drug systems is for animals rather than humans, often consists of only 
a few data points or plots without any published data, and is usually clearance data or 
tumour accumulation data rather than distribution data for key tissues. Similarly, most 
pharmacokinetic parameters which arc quoted in the literature (the four main 
pharmacokinetic parameters being clearance, volume of distribution, half-life and 
bioavailability) are those associated with, and therefore more appropriate to, the 
targeting of macromolecular drug systems to solid tumours, rather than to cancer 
micrometastases in the lymph. Any pharmacokinetic models given in the literature, of
which there are very few indeed, often take the form of simple classical 
pharmacokinetic models or non-compartmental pharmacokinetics (usually model- 
independent pharmacokinetics) to analyse the particular experimental data, but which 
due to this type of model are really generally inappropriate or inadequate for 
macromolecular drug disposition since they usually assume rapid distribution and 
equilibration. This general lack of particularly useful human or indeed animal 
macromolecular drug distribution data and inappropriate or inadequate 
pharmacokinetic models is also generally observed in much of the non-chemotherapy 
macromolecular drug pharmacokinetic literature, of which [170-194] are typical 
examples, and also for the interleukins [195-201] and interferons [202-210] as well. For 
the reasons outlined in section 1.3, more appropriate are the theoretical/predictive 
models in the literature, i.e. the physiological pharmacokinetic models, although as will 
be outlined in Chapter 5, in which the key models relevant to this study, i.e. the 
macromolecular anticancer drug and drug-targeting pharmacokinetic models are 
discussed in more detail, these physiological models do however also possess some 
important disadvantages when considering macromolecular drug disposition.
New pharmacokinetic models are therefore needed which can predict the fate of any 
macromolecular drug in the human body as a function of time (under normal vascular 
conditions) for any of the key compartments of the body (blood, lymph, and liver) and 
for the main elimination processes (renal excretion and hepatic clearance) which are 
important in both macromolecular drug distribution and the targeting of anticancer 
agents to micrometastases in the lymph (and which can also be used for fitting 
purposes if desired as well). The success of any macromolecular drug system depends 
upon such predictive macromolecular drug disposition models.
1.3 Pharmacokinetic models and processes
Pharmacokinetics is the study of the time course of drug and metabolite levels in 
different fluids, tissues, and excreta of the body, and of the mathematical relationships
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required to develop models to interpret such data. It is the study of "what the body 
does to a drug".
Before the many complex relationships involved in pharmacokinetic processes were 
understood, drugs were administered purely on an empirical basis. What happened to a 
drug after it entered the body, or how its fate might influence the therapeutic effect, 
was not appreciated. The birth of modem pharmacokinetics occurred in 1937 with the 
publication of two classic papers [240, 241], which gave the basic equations for drug 
absorption, distribution, and elimination following various types of administration. The 
next major resurgence of interest in pharmacokinetics, and one that continues to this 
day, occurred in the late 1950s and early 1960s. Today, pharmacokinetic concepts are 
used at all stages of drug discovery, development, and therapy, and pharmacokinetic 
principles are being used routinely in the design and optimization of drug formulation 
and dosage regimens.
Pharmacokinetics has tended to diverge into four nuyor philosophical approaches: 
classical linear compartment modelling, physiological compartment modelling, 
nonlinear compartment modelling, and noncompartmental modelling. Each of these 
different modelling approaches is described in this section. However, due to the 
voluminous amount of literature on the many different aspects of the subject of 
pharmacokinetics, and subsequently to avoid re-writing the major pharmacokinetic 
textbooks or important recent reviews or theoretical papers in which the various 
histories, theoretical concepts and processes, and most of the studies associated with 
these different modelling approaches are either already well established (ie. the 
classical linear compartmental modelling and nonlinear modelling approaches) or 
recently given (ie. the physiological modelling and noncompartmental modelling 
approaches), the following parts of this section consequently make reference to such 
major pharmacokinetic textbooks or key reviews or theoretical papers, as appropiate. 
Nevertheless, since the major objective of this study was the development of a 
physiological pharmacokinetic model, the part of this section which discusses the
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physiological modelling approach is necessarily and appropriately more detailed. The 
purpose of the development of any pharmacokinetic model is to describe or predict the 
time course of drug disposition throughout the body.
In the classical linear compartmental modelling approach, which is the oldest 
established of the pharmacokinetic modelling approaches and is consequently the 
approach which has received the most attention and has subsequently produced the 
most published literature, the body is represented as one or more compartments 
between which a drug or metabolite can be distributed. These compartments may be 
spacial or chemical in nature. In most cases however, the compartments are used to 
represent a body v olume, or a group of similar tissues or fluids with similar degrees of 
blood perfusion or with similar affinities for a particular drug. The compartments do 
not usually represent particular anatomic elements, and the complete model is often 
only a simple abstraction of body processes, tending to serve a descriptive function, 
usually with regard to drug profiles in plasma or urinary excretion. In these classical 
linear pharmacokinetic models, referred to as 'classical pharmacokinetic models’, the 
'volumes' of each compartment are assumed to be invariant, and drug distribution and 
elimination are assumed to be first-order processes with first-order rate constants 
which are also invariant.
As a consequence of this, the change in concentration of drug at a given 
time is dependent upon the concentration of drug present at that time, the
area under a curv e of blood level against time is proportional to the dose administered 
(assuming 100% bioavailability), the rate that the drug is cleared from the body is 
concentration dependent, the percentage of body drug load that is cleared per unit time 
is constant, and the drug has an elimination half-life. (If this is not the case then 
nonlinear compartment models apply.) Classical modelling approaches are usually 
based on the curve fitting of plasma concentration data (logjQ plasma concentration 
versus time) with single or multi-exponential equations, depending on the profile of the 
data, to obtain values of hybrid microscopic disposition constants. These hybrid 
microscopic disposition constants determine how many compartments, and therefore
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how many exponential terms, will be necessary in the model to describe the data, and 
are obtained either by the method of residuals (" feathering" or "exponential stripping"), 
or more accurately by nonlinear least squares regression analysis. Once the hybrid 
microscopic disposition constants are known, important pharmacokinetic parameters 
such as volume of distribution, clearance, half-life, and bioavailability can be 
determined. The hybrid microscopic disposition constants are used in conjunction with 
the method of Laplace transforms, inverse Laplace transforms, partial fraction theory 
and Cramer's rule to solve simultaneously for the differential equations describing the 
rate of change in the amount (or concentration) of drug as a function of time in 
peripheral compartments (in the case of more than one compartment) as well as the 
central compartment, and for the individual model rate constants. An alternative, but 
more general, method for performing these calculations with any first- or zero-order 
input process and with elimination occurring from any compartment is also available 
[213]. It involves the use of general input and disposition functions, a general theorem 
of partial fractions for solving Laplace transforms in pharmacokinetic analysis [214], 
and the use of a multiple dosing function. However, the use of this method does have 
some imposed restrictions [213, 214]. In any linear classical pharmacokinetic model 
where only the central compartment (a driving force compartment) is available for 
sampling the maximum number of solvable rate constants, Z, is given by the expression 
Z = 2(n-l) +1, where n is the number of driving force compartments in the model, and 
only one of the Z rate constants may unambiguously describe elimination of a drug 
from the model [213]. The ability to sample unchanged drug in additional non driving 
force compartments such as the urine would allow one to determine additional rate 
constants, though in most cases, these additional rate constants will only be part of a 
previously hypothesized elimination rate constant, and will not allow the investigator to 
determine the validity of the hypothesized model. For many drugs, particularly after 
bolus intravenous administration, a multi-compartment model provides a more 
accurate description of drug plasma profiles than a one compartment model. The multi­
compartment is frequently represented by a two-compartment model, although three
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compartment models are also sometimes used. Classical compartmental models 
consisting of more than three compartments are generally not used because, firstly, 
most plasma data can be adequately described by less than three compartments, i.e. a 
'central' compartment (plasma or blood compartment), and either one or two peripheral 
compartments which represent tissues in which the drug equilibrates at rapid, slow, or 
intermediate rates, and secondly, the mathematics becomes too complicated. Often the 
object of using classical compartment models is to obtain estimates of rate constants 
using nonlinear regression. This becomes a meaningless exercise when the number of 
parameters is too large. Therefore it is advisable to use the simplest appropriate model. 
Since the clinical analysis of most drugs is performed using the classical linear 
compartment modelling approach, a large number of papers have appeared in the 
pharmaceutical literature, describing the treatment of data, at first for the one- 
compartment model, then for the two-compartment model, and finally for various 
permutations of the three-compartment model. Most of these studies are now well 
established in the literature and are given, together with extensive detailed descriptions 
of the mathematical and pharmacokinetic processes involved in the classical 
compartmental modelling approach, including the different possible permutations of 
each type of model and the historical perspectives of this modelling approach, in the 
major pharmacokinetic textbooks [215-218].
In the physiological modelling approach the body is divided into compartments based 
on true anatomical regions or volumes. Unlike the classical linear compartmental 
modelling approach, in which drug movement between compartments is based largely 
on reversible or irreversible first-order processes, drug movement using the 
physiological modelling approach is based on blood flow rates through particular 
organs or tissues and experimentally determined blood-tissue concentration ratios or 
drug diffusion rates between blood and tissue, and usually mass balance equations.
The main advantages of physiological pharmacokinetic models compared with classical 
linear pharmacokinetic models is that drug movement can be predicted (simulated) in
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specific selected organs or tissues, and parameter values can be altered to allow for 
changes in physiological function and disease states. They address more specifically 
and accurately the actual time course of drug or metabolite disposition in particular 
body organs or tissues. The pharmacokinetic parameters used are realistic because they 
are based on observed or predicted physiological values. Total, free or bound 
concentration profiles can be predicted for selected regions of the body. The differences 
between animal and human experiments are easier to interpret. Also insight can be 
obtained regarding specific organ elimination processes and parameter values can be 
'scaled' for different animal species and humans. They allow the often more abundant 
and detailed data available for animals to be used and related to humans. In brief, they 
provide more information based on specific tissue localization of drugs. The main 
disadvantages of physiological pharmacokinetic models is that the associated 
mathematics can become very complex, unwieldy, and difficult to solve. Frequently, 
because of the large number of compartments and parameters that are involved in 
determining the model that is thought to be the most appropriate for the system to be 
studied, the model equations can only be solved by numerical techniques, either on 
personal computers, or often, on powerful main-frame computers, by using specifically 
written, powerful, or modified versions of, various published numerical computer 
programme packages. In such multi-compartment and multi-parameter physiological 
pharmacokinetic models this numerical rather than analytical method of solution 
means that exact or specific equations describing the amount (or concentration) of drug 
in each compartment as a function of time are not usually obtainable for any model, 
especially for those consisting of three compartments or more. Consequently 
physiological pharmacokinetic models tend necessarily to be used more for predictive 
purposes rather than for fitting purposes. Another disadvantage is that it is extremely 
difficult to validate a physiological model in animals and virtually impossible in 
humans because large numbers of tissue samples are required at different time 
intervals after dosing (it is often difficult to obtain these tissue samples, even more so 
tissue samples that are free of blood). In vitro testing is sometimes required to
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establish or validate model parameters. Model development requires a large data base 
for each drug or drug group in a particular species, and some of this information is not 
always available or easily obtainable. Species differences may also cause some 
complications. Often some of the physiological parameters used in the model are not 
available in the literature and have to be estimated. The blood flow rates and tissue 
volumes used are generally average values for a particular species, many of which, 
under normal conditions, are available in the literature, however, drugs are often given 
under disease conditions, and the drug may also affect the physiological conditions 
because of pharmacological actions, and these factors can sometimes perturb the 
model and lead to difficulty in interpretation. Also, despite their complexity, 
physiological models still contain many simplifying assumptions, certainly of a more 
microscopic nature than the comparatively gross assumptions associated with the 
classical compartment modelling approach (typical simplifying assumptions in the 
physiological models are often associated with the diffusion of drug into tissues, and 
the complete mixing with organs). In brief, because of the large number of 
compartments and parameters that are usually involved using this type of modelling 
approach, physiological models are necessarily more complicated than classical 
compartment models. The complications are such that physiological models have been 
developed for very few drugs, and are justified only to investigate specific tissue 
localization of drugs or to examine the detailed mechanisms of drug excretion or 
metabolism. This modelling approach is subsequently not of general application in 
most situations, but is used to solve particular distribution problems for drugs when 
tissue distribution is important, or when sites of elimination are critical. Thus, the 
physiological model applies naturally to anticancer drugs (and to drugs acting on the 
central nervous system), and consequently most of the published work has been done 
in this area. Most of this work has been in the form of either blood flow rate-limited 
models or membrane-limited models (although both flow-limited and membrane- 
limited compartments can exist within the same overall model, eg. [219, 220]). In the 
blood flow rate-limited models, for example [221-256], it is usually assumed that drug
transport across physiological membranes is very fast, drug distribution into a specific 
organ is limited only by blood flow rate into that organ (blood-tissue and tissue-blood 
concentration ratios are often assumed to be equal to unity), the concentration of drug 
in the emergent or venous blood from a particular organ is in equilibrium with the drug 
concentration in the intracellular fluid in that organ, and hence each organ can be 
represented by a simple single compartment. Membrane-limited models on the other 
hand assume that drug transport across physiological membranes and equilibration is 
not rapid. Membrane-limited models tend to generally fall into one of two categories; 
firstly, there are the compartmental based models in which drug transport across 
physiological membranes is controlled either by passive diffusion, or by saturable, 
active transport or Michaelis-Menten type processes, for example [256-261], and 
secondly and more recently, there are the geometrical models [86-98, 262, 263], in 
which drug transport across the physiological membranes in the particular geometric 
situation being studied is usually embodied in one or more equations which may be in 
the form of either a reaction-diffusion partial differential equation, a first-order rate 
equation, or a simple biexponential expression, or various combinations of these 
equations, and which also often invoke as part of the model system or equations, the 
Kedem and Katchalsky [264, 265] equations, or similar mass balance equations for the 
diffusive and convective transport of molecules across membranes, adapted in various 
ways depending upon the particular geometrical situation being studied and the 
assumptions being made. Almost all of the physiologically based models which have 
been applied to non-anticancer drugs, and most of the models which have been applied 
to free (non-macromolecular targeted) anticancer drugs, of which [221, 224-226, 228, 
229, 231, 235, 258] and [219, 220, 222, 223, 227, 230, 232-234, 236-239, 257, 259- 
261, 263] respectively are typical and perhaps the most frequently cited examples, 
together with a summary of this approach to pharmacokinetic modelling, including the 
history behind its development, have been described in a couple of excellent recent 
reviews [266, 267]. There has also fairly recently been a good review discussing the 
estimation of tissue-to-plasma partition coefficients often used in some of these
models [268]. A few of the non-macromolecular physiological modelling studies, and a 
description of some of the mathematical and pharmacokinetic processes involved in 
this type of modelling (the geometrical approach excepted), are also given in some of 
the major pharmacokinetic textbooks [269, 270]. Some of the mathematical and 
pharmacokinetic processes involved in this type of modelling (the geometrical approach 
again being the main exception) are also given in one of the afore mentioned reviews 
[267]. However, as already indicated in section 1.2, the key pharmacokinetic models in 
the literature which are relevant and appropriate to this study are the 
theoretical/predictive macromolecular anticancer drug system and drug-targeting 
pharmacokinetic models, ie. [86-98, 244-256, 262] (all of the geometric models are 
included in these references), and these are discussed in more detail in Chapter 5. Due 
to the reasons outlined above, each of these models is physiologically based.
Despite the wide diversity of the classical and physiological pharmacokinetic models, 
all of these models, with the exception of the physiological membrane-limited models 
which involve saturable or Michaelis-Menten type kinetics eg. [256-261], incorporate the 
common assumption that drug elimination from the body is a first-order process. 
Another assumption is that the rate constant for elimination is a true constant and is 
independent of drug concentration. In these cases, the rate that drug is cleared from 
the body is concentration dependent, the percentage of body drug load that is cleared 
per unit time is constant, and the drug has an elimination half-life. Many drugs, 
particularly those following oral administration, are however eliminated from the body 
by mechanisms that are potentially saturable and in these situations nonlinear 
compartment models apply (true first-order, nonsaturable elimination usually occurs 
only with drugs that are excreted in the urine via passive glomerular filtration). Most 
nonlinear compartment models are classical compartment models (usually of either one 
or sometimes two compartments) whose log^g plasma concentration versus time 
profile has shown the drug to be cleared by zero-order or Michaelis-Menten-type 
kinetics, i.e. not exhibiting a characteristic, constant elimination half-life. The nonlinear
21
physiological pharmacokinetic models, although less common, eg. [256-261], also 
exhibit these characteristics. In both of these types of nonlinear model the apparent 
half-life changes continuously with drug concentration in plasma. Several methods are 
available to obtain initial estimates for the Michaelis constants, and these, together with 
most of the classical, well established examples and studies which involve the 
application of nonlinear compartmental models, and descriptions of the mathematical 
and numerical methods employed in the solution of these models (numerical nonlinear 
fitting and integration programmes, and standard integration methods are usually 
used), are again given in the major pharmacokinetic textbooks [271-274J. There has 
also very recently been a review giving most of the classical, well established studies 
which have employed nonlinear compartmental methods, and most of the typical more 
recent studies as well, together with a description of some of the mathematical 
processes involved in this type of modelling, and a discussion of the clinical 
implications of nonlinear pharmacokinetics [275].
Model-independent pharmacokinetics represents a recent trend away from complex 
modelling systems towards a less complex noncompartmental approach, based purely 
on a mathematical description of blood or plasma profiles of drugs or metabolites, and 
the calculation of useful pharmacokinetic values without invoking a particular model. 
Model-independent pharmacokinetics is being applied if a simple single or multi­
exponential equation is used to describe the plasma or blood concentration profile of a 
drug, and further interpretation of this fitted equation is avoided. In this equation each 
exponential term(s) consists of a single pre-exponential coefficient and a single 
exponent, and these parameters can be used to calculate several important 
pharmacokinetic values such as the volume of the blood compartment, the terminal 
elimination half-life, the area under the drug-concentration curve, and the plasma 
clearance [276]. The overall drug distribution volume at steady-state, although more 
difficult to calculate, is also obtainable in model-independent [277], and model and rate 
constant-independent form [278]. This parameter is useful because it describes, in a
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model-independent manner, the distribution characteristics of a drug that has 
equilibrated into the various tissues and body fluids. Hence, the essence of this model- 
independent approach to pharmacokinetics is that it avoids the use of kinetic 
parameters that cannot readily be validated or which have little anatomical or 
physiological significance. This approach is useful in situations where kinetic 
parameters such as absorption and elimination rates and clearances are required, but 
specific distribution characteristics are less important. This is often the case in classical 
compartmental modelling, and it is consequently in this situation that the model- 
independent approach is usually invoked (the classical one-compartment model can be 
thought of as the simplest model-independent approach).
Another noncompartmental pharmacokinetic approach is also available. It is based 
upon the theory of statistical moments and mean residence times, and can be used to 
calculate absorption, distribution and elimination parameters by utilising plasma 
concentration-time profile data [279-284]. It is also implicated in the latter of the 
model-independent approaches described above, ie. [278]. Descriptions of the 
mathematical processes and concepts involved in this modelling approach, together 
with almost all associated studies, are given in the above theoretical papers [279-284], 
and in some very recent literature sources [285-287].
The most recent noncompartmental pharmacokinetic approach is population 
pharmacokinetics, which is based upon the concept of Bayesian parameter estimation 
[288], and involves the use of fractional data from individual patients to derive 
population pharmacokinetic parameters which are then used to derive individual 
patient parameters (via Bayesian estimation) again using fractional data from (different) 
individual patients. It utilizes specific software designed to handle such data, and is 
useful where drug concentrations are measured during relatively complicated dosage 
regimens, not at steady-state, and where only a few (1 or 2 ) concentration 
measurements are permissible. In these situations pharmacokinetic parameters 
(principally clearance and volume of distribution) can be estimated in an individual
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patient so that drug dosages can be adjusted to achieve specific target concentrations, 
by using the Bayesian method which allows the fragmentary concentration information 
to be used in conjunction with pre-existing information on the population 
characteristics (means and variances) of the pharmacokinetic parameters. This 
noncompartmental Bayesian parameter estimation and population pharmacokinetic 
approach, along with many typical examples of clinical studies which have employed 
population pharmacokinetic analysis, and a summary of the historical background 
which led to this latest approach, are given in some recent reviews [286, 289-292].
1.4 Objectives of this thesis
Naturally occurring or synthetic macromolecular drugs are potentially a new generation 
of drugs in the field of cancer chemotherapy, either as carriers for low molecular- 
weight anticancer agents or as drugs in their own right. The experimental and 
theoretical literature shows that both classical and non-classical pharmacokinetic 
models are relatively poorly developed or often inappropriate when applied to 
macromolecular drugs. The literature also shows that most of the work concerning 
these actively and passively targeted macromolecular drug systems has been directed 
towards solid tumours which are known to possess their own peculiar vascular 
properties, rather than considering their targeting under normal vascular conditions 
specifically to the lymph, and hence to any cancer micrometastases located there. There 
is also a lack of any particularly useful pharmacokinetic or tissue distribution data 
describing the time course of these macromolecular drug systems in the human body 
under normal vascular conditions for any of the key compartments (tissues) of the 
body, or for the main elimination processes, which are important in both 
macromolecular drug distribution and the targeting of anticancer agents to cancer 
micrometastases in the lymph. Key parameters affecting macromolecular drug 
distribution under normal vascular conditions, the most important of which being 
molecular size, need to be investigated. New pharmacokinetic models need to be 
developed which will predict the distribution and fate of macromolecular drugs in the
body. Models are required for different macromolecule sizes, appropriate for proteins 
and uncharged polymers, and which are able to distinguish metabolism from excretion.
The major objective of this study was therefore to develop a new physiological 
pharmacokinetic model based on the movement of macromolecules under normal 
vascular conditions between three important compartments of the body, i.e. the blood, 
the lymph, and the liver, and modelling the two major elimination processes, i.e. renal 
excretion and hepatic metabolism (hepatic clearance), which are important in both 
macromolecular drug disposition and the targeting of anticancer agents to cancer 
micrometastases in the lymph. The model was required to take into account that for 
macromolecules excretion and hepatic metabolism was effectively occurring from 
separate compartments. An objective of the model was to allow prediction of the effect 
of molecular radius on the distribution of both protein and uncharged macromolecular 
drugs in the human body, both in the absence and presence of hepatic metabolism. This 
was to be achieved by taking into account the regional capillary permeabilities to 
different size macromolecules, and the physiology and flow rates within each 
compartment, and involved the development of smaller mathematical models, the 
fitting of these to appropriate physiological experimental data in the literature, and the 
building of these smaller models and their parameters of best-fit, and other 
mathematical expressions which were also developed as part of the modelling process, 
into the proposed new physiological three-compartment pharmacokinetic model. A 
major aim was to predict via simulations the molecular radii which are most effective 
in delivering the greatest fraction of a macromolecular drug dose into the target site. 
The usual target site in cancer chemotherapy being the lymph, and subsequently any 
cancer micrometastases present there. In addition to predicting the fraction of the 
macromolecular drug dose present in the lymph, the proposed new physiological three- 
compartment pharmacokinetic model would also allow calculation for each molecular 
radius size, the fraction of the dose that is present in both the blood and the liver, the 
fractions of the dose which have been excreted via the kidneys and metabolised by the
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liver, and the total fraction of the dose eliminated, as a function of time. A necessary 
objective of this study was therefore to develop a computer programme which had two 
main purposes; firstly to aid in the solution of cubic functions within the new 
physiological three-compartment pharmacokinetic model equations, and secondly to 
perform simulations once the solutions to the model equations had been established.
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Chapter 2




A physiological three-com partm ent pharmacokinetic model was developed in several 
stages. Initially mathematical m odels were developed to describe the relationship 
between molecular radius and the ratios of concentration of m acromolecules present 
in the glomerular filtrate versus blood, and in the lymph versus blood. The latter 
models were devised with reference to the available data from the physiology literature. 
Data were available describing glom erular filtrate/plasm a ratios and lym ph/plasm a
ratios for proteins and non-ionic polym ers in a variety of animal species. The best 
model(s) and associated param eters of best-fit were then used in the proposed 
pharmacokinetic model to predict the first-order inter-compartmental param eters kexcr 
and k n which describe the rate of m ass transfer of macromolecules from the blood to 
the glomerular filtrate, and from  the blood to the lymph respectively. Other 
mathematical expressions used to represent the remaining first-order inter- 
compartmental param eters in the proposed pharmacokinetic model were also 
developed and built into the model at the appropriate stage. Prior to the development 
of the physiological three-com partm ent pharmacokinetic model, as one of the aids to 
its validation, simplified one-and two-com partm ent pharmacokinetic m odels were 
developed to describe the effect of molecular radius on the distribution of 
macromolecules in more simplified models of the body. The complexity of the three- 
com partment pharmacokinetic model required the development of a com puter 
programme which had two main purposes; firstly to aid in the solution of the cubic 
functions within the model equations, and secondly to perform sim ulations once the 
solutions had been established. The physiological three-com partm ent pharmacokinetic 
model and the associated com puter programme described here therefore represent the 
final stage of a system atic sequence of developments. At each state of development the 
appropriate physiological data were introduced into the model.
This chapter describes the development, strategies and solution of all the models used, 
and describes the systematic sequence in which the modelling was performed. Models
describing the relationship between molecular radius and the glomerular 
filtrate/plasma concentration ratios (F/P ratios) and lymph/plasma concentration ratios 
(L/P ratios) of macromolecules are presented in section 2.2. The section also 
summarises the strategies and methods used in their development, and the criteria for 
selection of the physiological data to be fitted. A review is presented of the main 
physiological, structural and physicochemical factors important to macromolecular 
drug distribution including extravasation in the different regional capillary beds 
appropriate to this study. The physiological three-compartment pharmacokinetic model 
and its solution are presented in section 2.3, together with a summary of the methods 
used in validation and the development of the computer programme. A summary of the 
key features of the new model are presented in section 2.4.
2.2 Modelling of lymph/plasma and filtrate/plasma ratios as a function of
molecular radius
2.2.1 Introduction
The first stage of development was to propose mathematical models to describe the 
relationship between molecular radius and the concentration ratios of macromolecules 
extravasating from the blood to the glomerular filtrate, and from the blood to the 
lymph. The first task was to select the most appropriate experimental data describing 
the relationship between molecular radius and extravasation. Measurements have been 
made of the ratio of drug concentration between the blood and the glomerular filtrate 
(F/P ratio data), and also between the blood and the lymph (L/P ratio data). Selection of 
data required a thorough survey of the literature regarding the exchange of 
macromolecules across the microcirculation. The selection of this data together with a 
summary of the main physiological, structural and physicochemical factors important 
in macromolecular drug distribution, are described in subsection 2.2.2. Subsection 2.2.3 
then describes the experiments performed to establish the best models describing the 
relationship between molecular radius and the F/P and L/P ratios. Nonlinear regression
29
analysis was performed to obtain parameters of best-fit. Subsection 2.2.4 summarises 
the main conclusions of this part of the work.
2.2.2 Extravasation of macromolecules from different capillary beds.
2.2.2.1 Introduction
The exchange of macromolecules across the microcirculation has fascinated 
physiologists for many decades and consequently there is a considerable amount of 
literature on many aspects of the subject. The theory and techniques used to assess 
macromolecule permeability, the regional differences in capillary permeability, and the 
mechanisms and pathways of macromolecule exchange, have recently been extensively 
reviewed [293], and many important features governing the egress of macromolecules 
from the blood circulation are known [293-296]. The features and mechanisms which 
have important implications for the therapeutic use of soluble macromolecular drugs 
and their distribution in biological systems have also been reviewed [32, 121, 297-299]. 
However, despite a large literature on the subject, the movement of macromolecules 
through the different capillary membranes remains unclear to a certain extent. The 
physiological features discussed in this subsection therefore represent a summary of 
what are generally believed to be the main physiological and physicochemical factors 
important in the distribution of therapeutic macromolecules, and their extravasation in 
the different regional capillary beds appropriate to this study.
2.2.2.2 General characteristics of blood capillaries
Current literature describes three main types of capillary in mammalian species; 
continuous (normal), fenestrated, and sinusoidal (discontinuous) [293]. Each capillary 
type has characteristic permeabilities to macromolecules, with the continuous 
capillaries being the least permeable and the sinusoidal capillaries being the most 
permeable [293]. In each class of capillary the size of the macromolecule is the main 
determinant of its vascular permeability, with increasing macromolecule size resulting 
in a decreasing likelihood of extravasation [293]. Indeed there are effective molecular
size limits above which macromolecules have negligible permeability through the 
various endothelial layers. However, other factors, the most notable of which being 
molecular charge, also influence the rate of extravasation [293].
The lumenal surface of each capillary is composed of flattened endothelial cells, 
approximately 20-40 pm  long, 10-15 pm  wide and 0.1-0.5 pm  thick. A
giycosaminogiycan coat about 1 0 - 2 0  nm thick covers the lumenal surface of each 
endothelial cell. The function of this giycosaminogiycan coat is still not fully 
understood, although it has been suggested that it may influence extravasation [295], 
particularly in fenestrated endothelia, as it is believed to be negatively charged [300]. 
The capillary endothelium plays an important role in regulating the distribution of 
macromolecular drugs and has characteristic permeability depending upon the 
particular organ or tissue [301]. A significant contribution to control of extravasation is 
provided by the extracellular basement membrane [293], present at the basalateral 
surface of continuous and fenestrated endothelia, but absent in sinusoidal capillaries 
[302].
The two possible routes of extravasation common to each class of capillary are believed 
to be (1 ) passage through the intercellular gaps (the size of which depends upon the 
capillary type), known as the paracellular route, and (2 ) transcapillary pinocytic 
processes (pinocytic vesicles occupy a relatively large volume of the endothelial cell and 
are considered to move freely (kinetically) from one side of the capillary membrane to 
another, and fuse with the plasma membrane, carrying with them plasma, including 
some dissolved macromolecules [293]). The paracellular route may be significant for 
extravasation of medium sized molecules (molecular-weight (MW) between 1,000- 
20,000 Da) from continuous endothelia, but as size increases the vesicular transport 
becomes more important e.g. the transport of albumin (MW 69,000) from continuous 
endothelia is thought to be mainly vesicular. Electron microscopy studies reveal that 
some organs (e.g. endocrine glands, the kidney, the mesentery bed of the small 
intestine) have distinct pores in their capillary endothelia [303, 304], so called
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fenestrae. Passage of macromolecules through fenestrae is likely to be the dominant 
process in these tissues [293]. Sinusoidal capillaries, which are found almost 
exclusively in organs of the reticuloendothelial system (liver, spleen and bone marrow) 
[303, 304], have pronounced gaps [303, 305, 306], which allow virtually free passage of 
particles up to 50-100 run in diameter [293]. The structural features and possible 
transport pathways for macromolecules across the continuous, fenestrated, and 
sinusoidal capillaries are shown in figure 2 .1
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Figure 2.1. Diagrammatic representation of possible transport pathways for 
macromolecules across (a) continuous, (b) fenestrated, and (c) discontinuous or 
sinusoidal capillaries. For the continuous capillary (a), pathways 1-4 represent a 
pioncytic vesicle, an interendothelial cell junction, a transendothelial cell channel, and 
the basement membrane, respectively. For the fenestrated capillary (b), pathways 1-5 
represent the pinocytic route, an open fenestration, a diaphragmed fenestration (the 
diaphragm usually carries a net negative charge, although it can also be neutral), an 
interendothelial cell junction, and the basement membrane, respectively. For the 
discontinuous or sinusoidal capillaries (c), pathways 1 and 2 represent the pinocytic 
route and the freely permeable interendothelial cell spaces, respectively.
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The reviews outlined earlier present detailed descriptions of the possible mechanisms 
and pathways of the kinetic (diffusive and convective) movement of the 
macromolecules through each capillary type, together with detailed descriptions of the 
possible nature, organisation and function of the structures that contribute to the 
transport characteristics of each regional capillary wall. These phenomena are 
summarised for each class of capillary in sections 2.2.23  - 2.2.2.5.
The capillary endothelial barrier has classically been described by physiologists from a 
phenomenological standpoint as an impermeable layer that is perforated with two types 
of pores [307]. These have been classified for continuous endothelia as large pores with 
a diameter of 50-70 nm and a frequency of 1 pore/20 |Hm2  and small pores with a 
diameter of 6-9 nm and a frequency of 10-15 pores/pm 2. This theory has arisen from 
theoretical considerations using various pore-models, and led to the proposal by Kedem 
and Katchalsky of simple equations which equate solvent and solute flow across porous 
barriers [264, 265]. In addition Patlak included a selectivity factor in his equation since 
he believed that not all macromolecules would be able to pass through the pores at the 
same rate [308]. Indeed, over the years several theoretical equations have been 
developed to describe the exchange of molecules across capillary membranes. By far the 
most popular and most widely used of these, either in their original or various adapted 
forms, are the Kedem and Katchalsky equations which describe the diffusive and 
convective movement (flux) of solvents and solutes across biological membranes [264, 
265]. However, as will be discussed in Chapter 5, when the Kedem and Katchalsky 
equations are used within physiological pharmacokinetic models, their inclusion 
presents some important disadvantages particularly in the context of macromolecular 
drug distribution. In general, the experimental data describing hydrodynamic size 
limits of the main extravasation pathways in each capillary type, which have usually 
involved the simultaneous measurement of the concentration of macromolecules in 
plasma and lymph, has supported the two pore theory, and some physiological 
estimates for small and large-pore populations in fenestrated and discontinuous
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endothelia have also been suggested (pore radii 46-53 A and 180-250 A respectively for 
fenestrated endothelia, and approximately 90 A and 330 A for discontinuous 
endothelia). However, more recent investigations using electron microscopy have failed 
to identify two pore types in each class of capillary. Currently the large pores are 
believed to be explained by plasmalemmal vesicles, transendothelial channels or 
fenestrae. The smaller pores, although more difficult to equate, are believed to be 
explained by the gap junctions which are found in post-capillary junctions [307]. 
Consequently, most capillaries are considered to be heteroporous. Detailed descriptions 
of this pore work is given in a couple of excellent reviews [293, 309].
2.2.2.3 Extravasation from continuous capillaries
Capillaries with continuous endothelia and an uninterrupted basement membrane are 
the most widely distributed in mammalian tissues. They are found in skeletal, heart, 
and smooth muscles, and in lung, skin, subcutaneous tissue, and serous and mucous 
membranes [303, 304]. The ultrastructural appearance of these capillaries has generally 
led physiologists to assume that they offer more restriction to macromolecule transport 
than other capillary types. Hence their permeability characteristics have received far 
more attention, mainly in the form of experiments to determine lymph/plasma (L/P) 
ratio.
In the majority of continuous endothelial layers, the cells are connected together tightly 
by protein junctions and fusion of their glycocalyx layers. The resulting intercellular 
gaps in the capillary bed are generally impermeable to macromolecules greater than 2 0  
A diameter [300, 310], although junctions are typically looser in the post-capillary 
venules [307, 311-315], where 2596-30% of the junctions appear open with gaps 
measuring approximately 20-60 A in width. Transcapillary vesicular traffic and/or 
transendothelial channels (formed by the fusion of two or more pinocytotic vesicles) 
are believed to account for the extravasation of macromolecules greater than 
approximately 20-60 A diameter. Pinocytic, plasmalemmal or transcytotic vesicles are
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thought to have internal radii of approximately 200-250 A. However, as in all classes of 
capillary, the density and frequency of vesicles within a cell is dependent upon the 
organ within which it is found, with endothelial cells found in capillaries at the venular 
end, or within venules themselves, often demonstrating the highest density of vesicles. 
For instance the vesicle population in tissues which possess continuous capillaries is 
for example greater in muscle than in the lung, and greater in the lung than the brain 
[307, 313, 314, 316-318]. The relative frequency of transendothelial channels also 
increases from the arterial end to the venous end of the capillary [307, 316, 319, 320]. 
This variable density and frequency of vesicles and transendothelial channels, together 
with the tight intercellular junctions, and the presence of an uninterrupted basement 
membrane, results in the continuous capillaries exhibiting the lowest permeability 
characteristics of all the capillary types. The tight intercellular junctions mean that 
vesicular transport from high endothelial venules tends to be the dominant 
extravasation route in continuous capillaries, although evidence both for and against 
this as the major pathway has been presented [321-325]. The high endothelial venules 
are also implicated in chemotactic movement of leukocytes from capillaries, though a 
relationship between the two processes is not clear.
2.2.2.4 Filtration through the fenestrated capillaries of the kidney
Capillaries with fenestrated endothelia and a continuous basement membrane are 
found in organs whose functions demand high rates of fluid exchange i.e. the kidney, 
small intestine, salivary glands and other exocrine and endocrine glands [303, 304]. The 
physiological and physicochemical aspects of macromolecule permeability have been 
studied in most detail for the glomerular endothelium (mainly in the form of F/P ratio 
studies). This endothelium is known to be relatively permeable, and hence has provided 
much of the theoretical and experimental framework for the current concepts of 
exchange across fenestrated endothelia. Details of the nature of the endothelia in the
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other organs listed above is relatively scarce, which limits current understanding of 
how varied are fenestrated capillaries.
Glomerular filtration plays a key role in the distribution and excretion of 
macromolecular drugs [121, 293]. The capillaries of the renal glomerulus are 
structurally unique and are designed to permit rapid extravasation of small polar 
molecules [326, 327]. This specialised endothelium features a large number of 
intercellular fenestrae (pores) [328, 329]. The endothelium is supported by a thick 
basement membrane to which adhere interdigitating foot processes of tubular 
epithelium (podocytes), which are separated by distinct spaces [328, 329]. The spaces 
between the podocytes are spanned by a diaphragm (the filtration slit membrane) [328, 
329]. The basement membrane exerts a strong overall negative charge because of the 
presence of many sialylated glycoproteins and mucopolysaccharides [330, 331]. 
Fenestrae are also gated by negatively charged macromolecules which together with the 
basement membrane are considered to be the main limiting restrictive barriers to the 
movement of macromolecules from the blood to the glomerular filtrate of the 
Bowman's space [331], although the epithelial filtration slit membranes may also play a 
contributory role [327, 331, 332]. Consequently, molecular size is the main determinant 
of whether a substance will be filtered or not, with molecular charge also influencing 
the rate of filtration [293, 331].
Fenestrated capillaries are freely permeable to water and small solutes such as glucose 
and urea, have limited permeability to larger macromolecules (with permeability 
decreasing as molecular size increases), and are almost completely impermeable to the 
cellular elements of blood [326, 327]. Water and dissolved material entering the 
interstitium passes into the kidney tubule where most of the water, hydrophobic small 
molecules, (and some macromolecules) are reabsorbed by the tubular epithelial cells 
[326, 327]. These reabsorbed materials pass into the post-glomerular capillaries, whilst 
other products are lost into the urine. A largely protein-free ultrafiltrate passes into the 
Bowman's space from the glomerular capillaries [327]. The capillary filtration rate is
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known as the glomerular filtration rate (GFR) which differs between animal species, but 
is well quoted in the literature as being about 125 ml/min for man under normal 
conditions 1326, 333-339]. Detailed descriptions of the structural and functional basis 
of the glomerular permeability is provided in several treatises 1391, 340-3451.
Materials are able to escape from the glomerular capillaries mainly through the 
fenestrae which are circular openings with radii of 250-500 A within the attenuated 
body of the endothelial cells [328, 329]. The glomerular fenestrae are unique since they 
are devoid of the 'diaphragms' which commonly subtend the fenestrae of other tissues 
[302]. (Over 60% of the fenestrae found in the other organs which possess a fenestrated 
endothelium are believed to be provided with a 'diaphragm' (or gate) and are 
consequently relatively more restrictive to the movement of macromolecules than the 
remaining diaphragm-less or open fenestrae; the open fenestrae in these tissues are 
believed to offer minimal restriction to the transport of macromolecules with radii 
between 25 and 150 A [303, 304, 307, 320, 346, 347]). The frequency of the fenestrae 
in the glomerular capillaries (and in the capillaries of the other tissues which possess a 
fenestrated endothelium) increases from the arterial end to the venous end of the 
capillary [307, 320, 346, 347]. Another mechanism of extravasation is believed to be via 
pinocytotic vesicles which allow access of molecules between 25 and 150 A radii into 
their vesicular structure. The rate of transport of macromolecules by this vesicular 
process has been shown to be approximately 3-8 times slower than exit through the 
fenestrae [307, 320, 346, 347], and will clearly be a function of size. Extravasation of 
macromolecules through the intercellular junctions is likely to be relatively 
unimportant given the pressure of the fenestrae because the intercellular junctions are 
believed to be impermeable to molecules greater than radii 25A [346, 347]. The main 
barrier to the extravasation of larger macromolecules in the fenestrated glomerular 
capillaries seems to be the basement membrane [293, 331, 346, 347], which is generally 
very poorly permeable to macromolecules greater than about 40-45 A radius.
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The size-selective properties of the glomerular capillaries have mainly been derived
from studies of differential solute clearance. Generally the urinary excretion of the test
macromolecule is compared with that of a reference solute, such as inulin. Inulin, a
hydrophilic polysaccharide of low molecular-weight, is commonly used since it appears
in the glomerular filtrate at the same concentration as in plasma. Assuming both the
test and reference solutes are neither actively secreted nor reabsorbed, the fractional
clearance is equivalent to the concentration of the macromolecule in the glomerular
C
filtrate relative to that in the plasma water i.e. , and is usually referred to as the F/P
Cp
ratio.
A survey of the literature from such studies revealed that the most comprehensive sets 
of data available are for dextrans (anionic [348], uncharged [348], cationic [349]) in the 
rat, and for proteins in the dog [326]. This datum is summarised in tables 2.1 and 2.2 
respectively and is used in the modelling studies described in subsection 2.2.3. Figure
2.2 illustrates these data graphically. These F/P ratios were obtained in healthy animals 
under normal conditions. There is limited F/P ratio data for humans, or indeed for 
other animal species. However, the available datum does suggest that the relationship 
between molecular radius and fractional clearance of macromolecules from the blood 
to the glomerular filtrate is similar between mammalian species, although the 
relationship is different for each respective class of macromolecule. The restricted 
glomerular filtration of albumin is crucial to its physiological function and its 
molecular dimensions are similar in mammalian sepcies, which also suggests that 
extravasation in the kidney is similar amongst mammals.
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Table 2.1 F/P ratio data for dextrans (anionic [348], uncharged [348], cationic 
[349]) in the rat
Molecular radius (A)
F/P ratio 
Anionic Dextran Uncharged Dextran Cationic Dextran
18 0.56 1.0 1.0
20 0.35 0.97 0.99
22 0.19 0.87 0.97
24 0.11 0.73 0.93
26 0.06 0.60 0.87
28 0.032 0.45 0.80
30 0.02 0.32 0.74
32 0.013 0.22 0.66
34 0.007 0.15 0.56
36 0.003 0.09 0.44
38 0.0009 0.045 0.32
40 0.0004 0.022 0.20
42 0.0002 0.008 0.11
44 0.0001 0.002 0.04
Table 2.2 F/P ratio data for protein macromolecules in the dog [326]
Substance Molecular radius (A) F/P ratio
Lysozyme 19 0.75
Myoglobin 18.8 0.75
(3 Lactoglobulin 21.6 0.39
Ovalbumin 27.3 0.20
Bence Jones protein 27.7 0.09
Hemoglobin 31.8 0.04








Figure 2.2 Relationship between F/P ratio and molecular radius for dextran (anionic, 
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The F/P ratio is unity for molecules of radius less than about 15-20 A. However, for 
molecular radii (a) greater than about 15-20 A the F/P ratio declines with increasing 
molecular size, the rate of decline being partly dependent on molecule charge. At a 
equals approximately 40-50 A the F/P ratio approaches zero and excretion becomes 
difficult to quantify. The available data also indicate the effect of charge on 
transglomerular movement of macromolecules. For each molecular radius the F/P ratio 
is greater for cationic dextran than uncharged dextran, greater for uncharged dextran 
than anionic dextran, and somewhat similar for both anionic dextran and endogenous 
protein molecules. This reflects the net negative charge on most proteins at neutral pH. 
For example, the F/P ratio for serum albumin which has a molecular radius of 35.5 A 
(molecular weight 69,000Da), and pi of about 5, is approximately one-twentieth that of 
uncharged dextran molecules of the same molecular radius. This suggests that the 
fixed negatively charged components of the glomerular capillary wall impede/repel 
negatively charged molecules and thereby hinder or prevent their filtration. In contrast 
they facilitate relatively faster movement of positively charged macromolecules, into 
the Bowman's space from the blood [348-352]. There appears to be an effective 
molecular size cut-off for all molecules, with the cut-off for glomerular filtration of 
proteins and negatively charged molecules occurring at the size of serum albumin, 
whilst the cut-off for neutral and positively charged molecules occurs at slightly larger 
radii of a equals 42-45 A. Consequently any macromolecules with a radius of above 
about 4.4 nm are generally not transported from the blood into the urine [3531, and 
there is restricted glomerular filtration of macromolecules smaller than this size [326, 
348, 349, 354].
Other factors which have been found to influence the ability of macromolecules to pass 
through the glomerular endothelium, to a considerably lesser extent, are the physical 
flexibility of the molecular structure [326], and the stability of the intramolecular bonds 
of the macromolecule [353, 355]. For example, the pressure gradient across the 
glomerular endothelium (estimated at up to 26 N/sq m  [298]) may cause deformation
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of flexible molecules [356], hence because many uncharged macromolecules such as 
PVP and dextran tend to take on a comparatively loose tertiary structure with little 
intramolecular bonding, they may deform more easily than the more rigid protein 
macromolecules and therefore may be able to pass more easily through spaces which 
would otherwise restrict them [356-359]. However, this idea does not meet with 
universal acceptance, and some authors have estimated that the applied pressure 
difference across the glomerular endothelium is insufficient to induce any significant 
molecular deformation, and that deformability of molecules is not an important 
parameter in regulating extravasation [360].
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2.2.2.5 Extravasation through the sinusoidal capillaries of the liver
The distribution of discontinuous or sinusoidal capillaries in the body is much more 
limited than other capillary types. They are found almost exclusively in the liver, spleen 
and bone marrow [303, 304]. These capillaries are characterised by large gaps in the 
endothelial wall, and the basement membrane is absent or discontinuous.
In the sinusoidal vasculature of the liver the endothelial gaps (intercellular junctions) 
have diameters ranging between 0.1 and 1 pm  [303, 305, 306].These large gaps are
believed to account for almost all of the extravasation which takes place in the liver. 
Pinocytotic vesicles are also present in significant numbers in the endothelial layer of 
the liver sinusoidal capillaries, but they are probably associated with uptake into the 
endothelium itself and are generally considered to be of negligible significance in terms 
of macromolecule transport into the liver [303].
Macromolecules pass freely from the sinusoidal blood capillaries into the space of 
Disse and hence to the functional units of the liver (the hepatocytes and Kupffer cells). 
Macromolecules are also able to move freely from the space of Disse back to the 
sinusoidal blood capillaries. Indeed, this phenomenon is perhaps the main reason why 
there are few data relating the concentration of macromolecules in the hepatic blood 
capillaries to their concentration in the extravascular spaces of the liver. The free- 
passage in both directions might be expected to lead to a concentration ratio close to 
unity unless the molecules are very large. In reality there are some constraints on 
movement which lead to concentration ratios less than unity [293], but there is 
insufficient datum available at present to be of use in the modelling studies described 
here. The data available also suggests that plasma/liver concentration ratios are very 
sensitive to blood pressure [361-363], making their measurement subject to 
considerable variation.
Macromolecules may interact with Kupffer cells which are fixed macrophages within 
the hepatic vascular system [116]. Hydrophobic colloids are phagocytosed rapidly by
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these cells and the degree of uptake will depend on the physicochemical properties of 
the macromolecule in question. Hydrophilic polymers lacking mannose residues or 
other residues recognised by Kupffer cells will generally avoid uptake by these cells of 
the mononuclear phagocytic system (or reticuloendothelial system), and will gain 
acccess to the space of Disse.
Once in the extravascular spaces of the liver macromolecules either move into the 
hepatocyte cells where they undergo the processes of metabolism or bile secretion, or 
they remain within the space of Disse unaltered. In general larger macromolecules tend 
to remain in the space of Disse longer than smaller macromolecules [293], because 
diffusional processes play a role [361, 364, 365]. The pressure in the sinusoidal 
capillaries is low so that virtually all of the plasma proteins which have entered the 
space of Disse can also easily move directly (freely) back into the bloodstream, and 
those which do not are returned via the lymphatic system which is connected directly to 
the space of Disse. The extreme permeability of the liver sinusoidal capillaries brings 
both arterial and venous blood into close contact with the hepatocytes and Kupffer 
cells, thus facilitating rapid exchange of the subsequent high concentration of nutrient 
materials between the blood and the liver cells. Hydrophobic low molecular weight 
molecules gain access by passive diffusion where metabolism can occur. In the case of 
polar macromolecles, unless a specific receptor for the molecule exists, it is likely that 
the only mechanism of uptake by hepatocytes is pinocytosis. Thus uptake of molecules 
such as plasma proteins and their subsequent metabolism may be comparatively slow. 
Molecules which bind non-specifically to membrane lipids or glycolipids would be 
expected to be taken up more rapidly by adsorptive endocytosis, and 
asialoglycoproteins, for example, would be taken up by receptor-mediated endocytosis 
[114, 115]. Detailed descriptions of the structural and functional units and 
characteristics of the liver are given in a couple of voluminous literature sources [366, 
367].
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Most literature reports that in a 70 kg man approximately 1100 ml/min of blood flow 
through the liver sinusoidal capillaries from the portal vein [368], and that about an 
additional 340 ml/min flow into the liver sinusoidal capillaries from the hepatic artery 
[368], making a total blood flow to the liver of approximately 1440 ml/min [368-369].
In a 70 kg man the total volume of blood in the body vasculature is approximately 5600 
ml [370], and the normal blood volume of the liver is 560 ml (i.e. about 10% of the 
total blood volume [368]). In the modelling studies described below the total volume of 
blood in the body was represented by the parameter Vc (i.e. the volume of the blood 
was defined as the central compartment) and the blood volume of the liver was 
represented by the parameter VH (i.e. the volume of the liver which is subject to 
extraction was defined as the hepatic compartment). The central compartment was 
assumed to have a volume equal to the total blood volume, since macromolecules are 
not able to diffuse freely to and from the vasculature. For simplicity during this study it 
was assumed that for all macromolecules, irrespective of their size, there was free 
movement from the sinusoidal blood capillaries into the extravascular spaces of the 
liver, and also free movement back again. Hence the capillary permeability ratio of polar 
macromolecules extravasating from the sinusoidal blood capillaries into the 
extravascular spaces of the liver, and the corresponding concentration ratio of the 
movement back again, are both assumed to be equal to one. However the model 
developed was designed to allow estimates of liver/plasma filtration ratios to be built 
into the model, should reliable data for sinusoidal filtration of macromolecues be 
available in the future. This study also assumed that the total blood flow rate from the 
liver is equal to the total blood flow rate to the liver (i.e. 1440 ml/min in man). This is a 
reasonable assumption, since if this were not the case then there would either be a 
build-up or a deficit of blood in the liver.
When the term metabolism is used here it refers to the metabolic clearance of 
macromolecules from the liver rather than the periphery. This is likely to be the site of 
metabolism which has most influence on distribution unless metabolic enzymes are
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present in the plasma. The background to this study relates more to slowly metabolised 
molecules rather than to proteins or peptides with very short half-lives in the plasma so 
plasma metabolism was not included in the model. Likewise peripheral metabolism, 
which in reality would be significant for that proportion of the dose which entered cells 
of the periphery, was ignored for simplicity. Peripheral metabolism could be included in 
a numerical solution of more complex models in future studies. In this study an 
algebraic solution was desired which necessitated a reductionist approach. Thus the 
rate of the metabolism (km) used here refers to a first order rate of loss from the pool 
of macromolecules within the liver. For macromolecules of interest this could be 
estimated experimentally in vitro using isolated enzymes. However, in this study a 
hypothetical approach was used to simulate the effect of metabolic rate by studying the 
influence of a range of rates. The assignment of the liver as the compartment from 
which metabolism occurred allowed the relative clearance due to excretion to be 
separated from that due to metabolism.
2.2.2.6 Movement of macromolecules into the extracellular interstitial fluid and 
lymphatic system
The mechanisms by which large molecules cross capillary walls and gain access to the 
interstitial fluids and lymphatic system has intrigued physiologists for many years, yet 
even today, the mechanisms and processes of this movement still remain unclear [293]. 
It has long been assumed that the composition of lymphatic fluid is identical to that of 
interstitial fluid under steady-state conditions [371]. This has been shown to be the 
case by sampling prenodal lymph at steady-state [372, 373], and is generally believed to 
be the case for postnodal lymph obtained at steady-state as well, although postnodal 
lymph may sometimes have been modified slightly within the lymph nodes [374]. 
However, direct comparisons of interstitial fluid samples with lymph collected 
simultaneously from the same tissue generally support the contention that the 
concentrations of macromolecules in lymph and interstitial fluid are identical [293], 
and most literature consequently assumes that the compositions of lymphatic and
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interstitial fluids are the same. In practice it is extremely difficult to distinguish or 
establish the exact locations where the interstitial fluid and lymphatic system meet and 
to sample the fluids. Accordingly most lymph permeability studies necessarily treat 
blood to lymph transport as a single process, even though it actually proceeds in two 
stages, blood to interstitial space, and interstitial space to lymphatic system. Some 
reabsorption of water is implied in the first process, though there is no direct route 
back into blood for macromolecules which have entered tissues. This modelling study 
therefore also assumes that blood to lymph transport is a single process, and 
subsequently also assumes that the term lymph (or lymph compartment) refers to the 
lymphatic system and interstitial fluid combined as one, i.e. the total extracellular or 
interstitial fluid. This assumption has often been made in the literature.
Published literature suggests that the lymph draining from different organs contain 
varying concentrations of macromolecules and that the concentration of a 
macromolecule in the lymph compartment is a function of its molecular size [293, 301, 
375J. The principal barrier between blood and lymph transport is at the blood capillary 
wall, rather than at the lymphatic capillary or within the interstitial space [376]. Once 
extravasation from the blood-capillaries has taken place, molecules within the 
interstitial fluid can re-enter the bloodstream either directly via back-diffusion, or they 
can enter the lymphatic drainage system [121, 376]. Smaller macromolecules are able to 
take the former route [298], whilst the larger macromolecules (greater than about 15- 
25A molecular radius) are forced to take the latter route due to their size [32, 377-380]. 
Hence there is a considerable degree of selection of macromolecules depending upon 
their molecular size [293], and the lymphatic circulatory system plays a vital role by 
returning extravasated blood proteins back to the bloodstream [376], and by recovering 
macromolecules from tissues [381-383]. At any instant approximately 5096 total body 
albumin (total mass 120g) is in the extravascular space [384]. The lymphatics originate 
in tissues as open ended capillaries, lined by a single layer of endothelium [376], into 
which macromolecules move largely by convective uptake. They begin in the areas
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containing tissue fluid beyond the blood capillaries and the tissue cells, have enlarged 
interendothelial cell junctions and lack a well-formed basement membrane [376-378], 
and are consequently believed to be freely permeable to macromolecules within the 
interstitial fluid [121]. Accordingly, the lymphatic system represents the main route by 
which metastatic tumour cells gain access to the blood circulation and are transported 
within the body [2 ], since they, as well as most macromolecules, have relatively easy 
access into the lymphatic system. The lymphatic fluid is drained via a complex series of 
lymphatic vessels and nodes, which empty back into the venous circulation [376].
Hence all macromolecules within the lymph compartment are returned back to the 
bloodstream in due course.
Extravasation across continuous endothelia is a critical process influenced by 
hydrodynamic size [293]. Following extravasation from the blood capillaries the rate of 
movement of macromolecules through the interstitial fluid and into the lymphatics 
generally remains unclear [293]. Molecular size appears to be the main factor 
determining this rate of movement, at least from subcutaneous sites, with the larger 
macromolecules tending to also be hindered more by interstitial fluid components 
[385], although charge and flexibility may also influence the process [385-387]. In 
general the movement of both positively and negatively charged molecules is believed 
to be retarded in some way, since the positively charged molecules tend to interact with 
negatively charged interstitial components, and the negatively-charged molecules to be 
repelled by many tissue components [385]. These concepts suggest therefore that 
uncharged molecules may move most quickly through the interstitial space.
Very little information is available regarding the relative rate of movement of 
macromolecules from the blood to the lymph, however, several literature sources report 
the lymphatic flow rate (LFR or lfr) as being approximately 2 ml/min for a 70 kg man 
[388, 389]. Since there is free movement for all macromolecules from the lymphatics 
back into the blood, then the effective concentration ratio (plasma/lymph ratio) of this 
movement is unity. Consequently it is reasonable to assume that all macromolecules
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can move freely from the lymph compartment back into the blood (via the lymphatic 
system) at a rate controlled by the lymphatic flow rate. The assumption made in this 
study therefore is that the blood to lymph flow rate (BLFR or blfr) is assumed to be 
equal to the lymph to blood flow rate (i.e. the lymphatic flow rate) i.e. BLFR = LFR (= 2 
ml/min in an average 70 kg man). This will certainly be an understatement of the 
volume of plasma water which leaves the vasculature, since there is some reabsorption 
of water into the venuous circulation. However the effective passage of macromolecules 
into lymph will not be underestimated in the modelling studies, since the physiological 
data used (i.e. lymph/plasma ratio) samples the lymph itself. The discussion above also 
explains why it is neccessary to assume that blood to lymph transport is a single 
process. In this study the total volume of the lymph compartment i.e. the lymphatic 
system and interstitial fluid is represented by the parameter VL. Most literature reports 
that the volume of total interstitial or extracellular fluid in a 70 kg man is 11200 ml, i.e. 
16% total body weight [390]. The values of LFR, BLFR and VL are of course different for 
other animal species.
Although this study is primarily concerned with predicting which molecular sizes are 
optimal in achieving the greatest fraction of a macromolecular drug into the lymph, and 
hence to any cancer micrometastases there, it is perhaps also appropriate here to briefly 
outline the situation for vascularised tumours. Macromolecular distribution to larger 
solid tumours is believed to be different, since as has already been highlighted in more 
detail in Chapter 1 (Section 1.1), solid tumours lack any recognised system of lymphatic 
drainage [2, 8 , 24-28], and recruit their own blood capillaries and exhibit wide variation 
in the structure and arrangment of tumour blood vessels [14, 15]. Molecules within the 
tumour interstitial fluid can be drained either via entry into the postcapillary venules or 
are driven by elevated interstitial pressures through the tumour interstitium, eventually 
oozing from the periphery and then being drained by the lymphatics in surrounding 
normal tissue. This means that macromolecules which have been able to enter the 
vascularised solid tumour interstitium by extravasation, and which are unable to return
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to the postcapillary circulation, do not have any effective method of drainage. These 
macromolecules are generally unable to penetrate the dense mass of necrotic tissue 
within the tumour, and consequently tend to remain close to the living tissue within 
the tumour. The consequence is that the vascularised tumours tend to act as molecular 
sieves, preferentially retaining hydrophilic macromolecules. This concept forms part of 
the basis of the "Enhanced Permeability and Retention" (EPR) effect [251, which may be 
exploited for selective tumour therapy. Enhanced permeability is believed to be 
common because the features regulating extravasation of materials through tumour 
endothelium are different from those in normal tissue; there are often fewer 
restrictions on size (although substrate charge may be an important factor), but the 
high interstitial pressures [27, 89, 91, 92, 391, 392], resulting in decreased rates of 
fluid translocation and convective transport, mean that diffusion of macromolecules 
becomes a significant factor governing their rate of entry into the tissue [391, 393,
394]. Also vascularised tumours tend to have larger interstitial spaces than normal 
(non-neoplastic) tissues, and their interstitial matrix frequently shows variable 
composition, notably in its content of macromolecules such as hyaluronic acid which is 
thought to retard fluid movement [393]. Many tumours are reported to have levels of 
hyaluronic acid substantially lower than in normal tissues [391], suggesting that rates 
of macromolecular movement in tumours may be relatively higher [385]. The peculiar 
vascular properties of tumours which are responsible for these unusual characteristics 
have already been outlined in section 1.1. It is clear that these characteristics could be 
exploited, but the main concern of chemotherapy should be to eradicate 
micrometastases before they develop into larger vascular tumours. To exploit the EPR 
effect the tumour must have developed into a nodule of considerable size (perhaps 1 
cm in diameter). Therefore the phenomenon of macromolecular EPR should be regarded 
as an added bonus of the use of macromolecular drugs. Attention should be focussed 
primarily on delivering macromolecules to micrometastatic lesions within tisssues, 
which requires passage across normal endothelia.
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Most of the capillary permeability studies which have been perform ed with different 
size macromolecules compare the concentration of an intravenously infused test
macromolccule in the lymph com partm ent (usually by sampling the lym phatic fluid,
C
although the interstitial fluid has also been sampled) to that in the plasm a, i.e. ——, and
Cp
usually refer to this ratio as the L/P ratio. Although some other m ethods have been 
employed to evaluate capillary permeability, the L/P ratio studies are the m ost 
frequently used, and have produced the best available data. A survey of the literature 
from such L/P ratio studies concluded that the best available data bo th  in term s of 
quality and quantity related to m easurem ents in the lung [395-409] and subcutaneous 
skin [306, 372, 373, 410-415]. The capillaries found in these tissues are of the 
continuous type, with continuous endothelia and an uninterrupted basem ent 
membrane. This u ltrastructural appearance has generally led physiologists to assum e 
that they offer more restriction to macromolecule movement than other capillary types, 
and consequently their permeability characteristics have received far m ore attention. 
There are some data for other tissues with continuous capillary beds (i.e. skeletal 
muscle [375, 416-426]) and also some data for tissues with fenestrated (i.e. 
gastrointestinal organs [419, 427-434]) or discontinuous (i.e. liver [301, 361, 375, 419, 
427, 432 —140]) endothelia. However the datum  available does not allow a full 
understanding of the effects of size on extravasation from fenestrated or sinusoidal 
capillaries.
A summary of the available L/P ratio data is discussed in a recent review [293]. Figures 
2.3.1 to 2.3.5 show the most useful data for the lung, subcutaneous skin, skeletal 
muscle, gastrointestinal organs, and liver respectively.
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Figure 2.3.1 Relationship between L/P ratio and m olecular radius for various















20 40 600 8 0  100 120 140
O Protein fraction (sheep;[395])
•  Protein fraction (sheep; [396]) 
V PVP (sheep; [397])
▼ Protein fraction (sheep; [397]) 
□ Protein fraction (lamb; [397]) 
■ Protein fraction (dog; [398])
A Protein (sheep; [399])
A Protein (dog; [400]) 
o Protein (dog; [401])
♦  Protein (lamb; [402])
M o l e c u l a r  R a d i u s  ( A n g s t r o m s )
Figure 2.3.2 Relationship between L/P ratio and m olecular radius for various 
m acrom olecules in the subcutaneous tissue of different mammals.
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Figure 2.3.3 Relationship between L/P ratio and m olecular radius for various
m acrom olecules in the skeletal muscle of different mammals.
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Figure 2.3.4 Relationship between L/P ratio and m olecular radius for various 
m acrom olecules in the gastrointestinal organs of different mammals.
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Figure 2.3.5 Relationship betw een L/P ratio and m olecular radius for various
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Figure 2.3.1 shows the lung L/P ratio data as a function of molecular radius for several 
protein, endogenous protein fraction, and povidone (PVP) macromolecules in sheep and 
dog. There is no human data. The capillaries in the lung demonstrate selectivity, since 
in all cases the L/P ratio decreases with increasing molecular size. The datum suggests 
that the lymph collected in the two animals were similar. For molecules with molecular 
radius less than 17A there is free filtration. As molecular radius increases from 
approximately 37 to 110 A, L/P ratio decreases from approximately 0.7 to 0.25. In 
addition these data demonstrate that the L/P ratio decreases to approximately 0.4 at a 
molecular radius of 60A and thereafter decreases at a much slower rate as the radius of 
the molecules increases. This relationship is similar to that observed in most other 
tissues. Clearly a molecule of the dimensions of albumin (a = 37A) has good access to 
the lung.
Figure 2.3.2 illustrates the relationship between L/P ratio and molecular radius in the 
subcutaneous tissue of dog, rat and rabbit, for protein and dextran macromolecules. 
Limited human data are also available for proteins. The data show no clear delineation 
between species and no distinciton in the ratios derived from lymphatic fluid or 
interstitial fluid. As a whole the data show a rapid decline in L/P ratio for solute radii 
below 40A. Above 40A, L/P ratio remains somewhat constant up to a solute radius of 
130A. There is free-filtration for molecules with molecular radii 10-20A and less.
Figure 2.3.3 represents a plot of the best of the available L/P ratio data as a function of 
molecular radius for skeletal muscle. The data are for dextran, protein, and PVP 
macromolecules in the dog, cat, rat and rabbit. Some limited human data are also 
available. Although skeletal muscle comprises the largest percentage of the total body 
mass, surprisingly little information is available regarding the permeability 
characteristics of capillaries in this tissue. This is because it is frequently very difficult 
to acquire lymph that is uncontaminated by sources outside of muscle. The available 
data for proteins show that the value of the L/P ratio decreases from approximately 0.7 
to 0.07 as the molecular radius increases from 37A to 120A. Similar relationships
between L/P ratio find solute radius are observed for the PVP and dextran fractions. The 
available data once again demonstrate selectivity and there is free-filtration for 
molecules with molecular radii less than approximately 15A.
Figure 2.3.4 illustrates the relationship between L/P ratio and molecular radius for 
various protein and endogenous protein fraction macromolecules in dog, calf and cat 
gastrointestinal organs. There is very limited human data. The limited data show a 
steep fall in permeation of solute in the size range below a radius of 60A. Above 60A 
there is an extension in residual permeability with little decrement in L/P ratio for 
molecules with radii as large as 135A. The lack of data for low molecular radii solutes 
make prediction of sizes at which free-filtration occurs difficult.
Figure 2.3.5 shows the relationship between L/P ratio and molecular radius for various 
protein and endogenous protein fraction macromolecules in the liver for several animal 
species, although the data are somewhat limited. Hepatic lymph is unique because it 
flows at a high rate and has the greatest protein concentration of all regional lymphs 
[293]. Under normal experimental conditions the ratio of total protein concentration in 
lymph to that in plasma generally ranges between 0.8 and 0.95, whereas a L/P ratio of 
1.0 is commonly reported for albumin. In spite of the high L/P ratio values for albumin 
and total protein, analyses of L/P ratio for macromolecules of various sizes indicate 
that there is selectivity at the liver blood-lymph barrier under normal conditions, 
although the lack of useful data currently available make it difficult to confirm this.
The datum does however show that the liver sinusoids are very permeable. There 
appears to be free-filtration for molecules with molecular radii less than approximately 
37A and even molecules with radii greater than 70-120A produce high L/P ratios. The 
unique features of hepatic lymph does however make interpretation of this data 
difficult and correspondingly limits its usefulness.
Figures 2.3.1 to 2.3.5 therefore illustrate a number of interesting featues, the most 
obvious of which is that all capillaries demonstrate selectivity to macromolecules. In all
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cases the L/P ratio decreased with increasing molecular radius size, but the capillary 
permeability varied between tissues. The data also show that the differences between 
lymph collected in various mammalian species were limited suggesting therefore that 
the data for non-human mammals are a good estimate of L/P ratios for humans. There 
are clear differences in the L/P ratio data between tissues of different capillary types, 
the liver sinusoidal capillaries being permeable to molecules of radius greater than 70A. 
There are also some differences between tissues of the same general capillary type i.e. 
the subcutaneous skin appears to be much more restrictive (tighter) in terms of 
permeability than the lung. However, there are also some general similarites between 
different tissues i.e. the lung L/P ratio data show some general similarity to the L/P 
ratio data for the gastrointestinal organs.
Figures 2.3.1-2.3.5 show that the L/P ratio data for tissues other than the lung and the 
subcutaneous skin is not as comprehensive and therefore not as useful for the 
proposed physiological modelling. There are fewer data for these other tissues, and also 
a large proportion of what is available tends to be in a single or a few data points per 
experimental report. L/P ratio studies which report data for a range of different 
macromolecules by the same researcher were considered to be more useful as model 
data though an understanding of the accuracy of the data can be gained by comparing 
data from single point studies or by pooling data. In order to investigate the effect of 
molecular radius on the distribution of both protein and uncharged macromolecular 
drugs in the body, L/P ratio data were needed for both classes of macromolecules, and 
ideally the pairs of data would be for the appropriate animal species. However, such 
data are not available. As in the case of the F/P ratio data, there are very little L/P ratio 
data for humans. In the absence of human data it was necessary to use the best 
available animal data. There were various considerations for and against the selection 
of the best data, and indeed whether or not to pool any data from various species. For 
these modelling studies it was decided to use the lung and subcutaneous skin data 
which covered a wide range of molecular radii. This datum is presented in tables 2.3 to
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2.6 respectively and is used in the modelling studies described in subsection 2.2.3. The 
lung and subcutaneous skin are also tissues possessing continuous capillaries, and this 
type of capillary offers more restriction to macromolecule movement and distribution 
than other capillary types. The lung data are particularly appropriate to this study since 
the lung is often the site where cancer micrometastases develop into secondary 
tumours.
Table 2.3 Pooled endogenous protein L/P ratio data for the sheep lung [395- 
396] (postnodal lymph measured at normal lymph flow).
Endogenous protein fraction Molecular radius (A) L/P ratio
[395] [396]
I 35.3 0 .8 0.77
II 42 0.76 0.72
III 45 0.72 0.67
IV 48 0.74 0.69
V 62 0.63 0.62
VI 72 0.60 0.62
VII 82 0.46 0.40
VIII 96 0.40 0.42
Table 2.4 Endogenous protein L/P ratio data for the dog lung [398] 
(prenodal lymph measured at normal lymph flow)
Endogenous protein fraction Molecular radius (A) L/P ratio
I 37 0.85
II 40 0 .6 8
III 44 0.61
IV 53 0.56
V 1 0 0 0.31
VI 1 2 0 0.29
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Table 2.5 (PVP) Povidone L/P ratio data for the sheep lung [397] (postnodal 
lymph measured at normal lymph flow)
PVP Molecular radius (A) L/P ratio






G 34 0 .6 8
H 31 0.70
I 25 0.80
J 2 1 0 .8 8
K 17 1 .0 0
Table 2.6 Pooled uncharged dextran L/P ratio data for the dog and rabbit 
subcutaneous skin [372-373, 410]
Molecular radius (A) L/P ratio
Dextran [372] 21.5 0.40
(dog, prenodal lymph measured 23.3 0.56








Dextran [410] 20 1.00
(dog, prenodal lymph measured 26.4 0.50





FITC-dextran [373] 10.1 1.00
(rabbit, interstitial fluid 16.3 0.98







2.2.3 Development of mathematical models of the effect of hydrodynamic
radius on L/P and F/P ratios
2.2.3.1 Introduction
The purpose of this section was to develop mathematical expressions on an empirical 
basis which could describe the dependence of L/P and F/P ratios on hydrodynamic 
radius.
The parameters of best-fit for each of the models studied in this subsection were 
obtained using the nonlinear curve fitting computer programme Minsq [441]. A brief 
introduction and description of Minsq [441] is given in part 2.2.3.2. The models studied 
are presented in parts 2.2.3.3-2.2.3.5. A summary of the main conclusions is then 
presented in part 2 .2 .3.6.
2.2.3.2 Methods and strategies used in the selection of the best model(s) and 
determination of the parameters of best-fit.
Minsq [441] is a menu driven nonlinear curve fitting programme published by 
MicroMath Inc. Various options become available to the user only after they become 
logically possible during the sequence of events. The programme runs under MS-DOS 
on IBM clone PCs. The model equation(s) and associated data are entered by the user 
via the relevant menu options. Inital parameter estimates m ust also be entered before 
least-squares minimisation curve-fitting can take place. For a simple relationship the 
parameter estimates need not be accurate. However, a complex equation will require 
good parameter estimates. In this situation if the initial parameter estimates are not 
appropriate then Minsq [441] will fail to find the optimal parameter values. Minsq [441] 
employs a least-squares minimisation procedure to find a local minimum of the sum of 
squared deviations between observed data and model predictions/simulations. The 
algorithm employed is many times faster than more common microcomputer 
algorithms and is based on sequential searches using one parameter at a time. The 
algorithm is a hybrid that combines the reliability of a steep descent method with the 
speed (near convergence) of the Gauss-Newton method. Minsq [441] also has a
nonlinear simplex algorithm which can be selected for searching through the param eter 
space for the general location of a minimum, so that initial param eter estimates are 
improved prior to selecting the least-squares minimisation option. In performing its 
minimisation Minsq (4411 weights each datum  point according to a weighting factor 
inversely proportional to the observ ed value raised to some power given by the 
weighting factor, i.e. for the i,h point w(i)=l/(observation (i))UT, where \VF is the 
weighting factor. A weighting factor of zero (the default) causes all points to be 
weighted equally and does not introduce any bias into the fit, whilst a weighting factor 
of 2 results in weights inversely proportional to the squares of the observed values. The 
la tter choice is appropriate when m easurem ent errors are thought to be proportional to 
the observed data values. The other m ajor menu options within Minsq [441]are the 
sim ulation run, graphics and statistics options. The simulation option simulates the 
model using the current param eter values and gives a weighted sum  of squared 
deviations values, wss (as do the simplex and least squares options). The graphics 
options displays the data visually and can be used to generate hard copies of graphs. 
Both the simulation and graphics options should be used when trying to find the best 
initial choice of parameters. The statistics option is available after a least-squares 
m inimisation fit has been performed, and provides a variety of statistical information 
on the param eters of best-fit.
The purpose of the curve fitting described here was to arrive at a suitable mathematical 
model for the dependence of F/P or L/P ratio on hydrodynamic radius (a).
i.e. F/P = f (a)
and L/P = f’ (a)
A series of putativ e mathematical models were explored using an empirical approach to 
determ ine the most appropriate relationship.
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As indicated above, before any sensible simulations could be performed on Minsq [441], 
good initial parameter estimates for each respective model and data sets are required. 
Consequently the strategy used to determine these good initial parameter estimates for 
each of the models presented in this subsection, and the subsequent selection of the 
most appropriate model, is described in parts (i) to (v) below:
(i) The first step was to choose from each of the F/P and L/P ratio data sets either a
single or pair of data points which could be used in the calculations to find good initial 
parameter estimates. Each data point consisted of a given molecular radius 
(independent variable) with its associated F/P or L/P ratio value (dependent variable). 
The choice of whether one or two data points were selected depended both on the 
mathematical form of each of the models and their parameters, and on the data sets 
themselves. In general and indeed where possible, for each of the chosen data sets a 
data point with a molecular radius close to serum albumin was selected. In the cases 
when two data points were chosen, the second data point was usually chosen to cover a 
reasonable spread of the data, thus avoiding selection of two points too close to each 
other, and hence increasing the chances of finding good initial parameter estimates. For 
consistency, the same data point(s) (as appropriate) from each of the respective F/P 
ratio and L/P ratio data sets were selected to be used in the initial parameter estimation 
procedure in each of the models presented in this subsection.
(ii) For each data set the chosen data point(s) (as appropriate) in (i) were then 
substituted into the appropriate model equation. Equations were then solved by hand 
to yield the model parameters. In the models whose general form involved an exponent 
n, i.e. models A and B (as shown later), this procedure was repeated for varying positive 
whole numbers of n {n= 1, 2, 3 , . . . ) ,  so that for each choice of n, initial estimates for 
the model parameters were obtained, n was forced to take the value of positive whole 
numbers because otherwise the equations would become too complex.
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(iii) In the cases of models whose general form involved a power n, i.e. models A 
and B (as shown later), the next step was to decide for each of the chosen F/P ratio and 
L/P ratio data sets which power of n and its associated initial parameter estimates were 
most appropriate. This was achieved by simulating with Minsq [441] the appropriate 
model equation for each data set for each power of n and its associated initial 
parameter estimates. The simulation which produced the lowest wss value, between the 
observed and model predicted data, generally corresponded to the best choice of n and 
its associated initial parameter estimates. Although for the reasons outlined in (v), a 
graphical plot of the general shape of the curve had to be considered in conjunction 
with this. When the best choice of initial parameter estimates was still unclear, one of 
the least-squares methods outlined in (iv) was also used.
(iv) Once the choice of initial parameter estimates had been made, the next step was 
to use Minsq [441] to perform least-squares minimisation procedures to find the 
optimal parameters of best-fit. Minsq [441] offers two ways of performing this 
operation, both of which are perfectly acceptable. One method, the quicker of the two, 
is to go direct to a least squares minimisation fit. The other method, which takes longer 
but ensures the absolute best-fit, is to make use of all the tools provided by Minsq 
[441] by first simulating the model using parameter estimates, then performing a 
simplex search to further improve the initial parameter estimates, before carrying out 
the least-squares minimisation. Both methods were found to be acceptable if good 
initial parameter estimates were obtained. In general the wss value obtained after the 
least-squares minimisation fit was lower, and therefore better, if the simplex search 
was used. However there were often no significant differences between parameter 
estimates. For the sake of thoroughness both methods were used throughout the 
modelling experiments. A weighting factor of zero was used for all the fits throughout 
this subsection, unless otherwise stated, so that no bias was introduced into the fitting. 
The parameters of best-fit used in the later pharmacokinetic modelling studies 
(described in Chapter 3) were those obtained using a simulation run, a simplex search,
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then the least squares minimisation fit. When there was an e x p o n e n tin v o lv e d  in the 
model, it was held constant during the least-squares fitting process at its most 
appropriate positive whole number value as determined in (iii).
(v) Once the least-squares fits had been performed it was possible to select the best 
model(s) to describe the relationship between molecular radius and the F/P or L/P 
ratios. The selection of the best model(s) was based on the wss value between the 
observed data and model predictions following the least-squares fits. The model which 
produced the lowest wss value following the least-squares minimisation was 
considered to be the best model, although the graphics option was also employed to 
generate plots to support this assumption. In some cases models with similar wss 
values were observed to fit different parts of the data well. Thus some subjective 
assessment was necessary by considering the shape of the fit, to establish that the fit 
was reasonable for all the data. The 'model selection criteria' (MSC) value given in the 
statistics option of Minsq [441] was also used to support this selection.
The MSC is a modified Akaike Information Criterion (AIC), and is defined by the 
formula:
where n is the number of observations and p is the number of parameters (or 
equivalently, the number of degrees of freedom). The AIC is defined by the formula,
and attempts to represent the "information content" of a given set of parameter 
estimates by relating the coefficient of determination to the number of parameters (or 
equivalently, the number of degrees of freedom) that were required to obtain the fit.
2  pMSC =  I n  —n




When comparing two models with a different number of parameters, this criterion 
places a burden on the model with more parameters to not only have a better 
coefficient of determination, but quantifies how much better it must be for the model 
to be deemed more appropriate. The AIC is dependent on the magnitude of the data 
points as well as the number of observations. The advantage the MSC has over the AIC 
is that the MSC will give the same rankings between models as the AIC and has been 
normalised so that it is independent of the scaling of the data points, thus overcoming 
the disadvantages which the AIC has. In general, the higher the MSC value, the more 
appropriate the model (representing a higher "information content" of the model), with 
MSC values greater than about 1.5 being adequate. For each mathematical model 
examined a large volume of statistical information was obtained, however, not all of 
this is presented in the parameter of best-fit tables, since the MSC is the recommended 
criterion in preference to any of the other statistical measures of goodness of fit (eg 
coefficient of determination, correlation, R-squared, etc).
2.2.3.3 Model A
The first and simplest mathematical model proposed to describe the relationship 
between molecular radius and F/P or L/P ratio had the general form:
R  = Rq exp(-& (a)”) (A)
where R is the respective F/P or L/P concentration ratio, a is the molecular radius of the 
macromolecule (A), Rq is a parameter representing the theoretical value of R  at a  = 0,
and the parameters n and k  control the shape of the curve with k  representing the 
gradient (exponential gradient).
Model A was then fitted to each of the F/P ratio data sets presented in tables 2.1 and
2.2 and also to each of the L/P ratio data sets presented in tables 2.3, 2.4 and 2.5. The 
data points used to initiate the fitting procedure, the best initial parameter estimates, 
and the optimal parameters of best-fit (mean ± sd) for all of these fits, together with the 
wss values and the MSC where possible are presented in table 2.7. Figures 2.4A and
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2.4B illustrate these results in plot form for the parameters of best-fit obtained 
following a simulation run, a simplex search, then the least squares minimisation.
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Table 2.7
Initial parameter estimates and 
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*0=1.2146 ± 0.16940 
(wss 0.020736)
(MSC 1.7644)














*=0.019522 ± 0.00078146 





Least squares fit not possible, simplex parameters quoted as they offered small improvements on Initial parameter estimates. 
Least squares fit not possible, simplex offered no Improvement on Initial parameter estimates quoted.
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With n = 1 Model A was found to fit most of this datum reasonably well with good wss 
and MSC values in most cases, although its general form presented two disadvantages:
(i) In the cases of the uncharged [348] and cationic [349] dextran data least 
squares minimisation fits were not possible. This is almost certainly due to the 
relatively large values of n required and the very small values of the parameter k  in 
each case, making the calculations very difficult to perform. In the case of the 
uncharged dextran data set [348], the simplex search offered a small improvement on 
the initial parameter estimates, but in the case of the cationic dextran data set [349] no 
improvement on the initial parameter estimates was possible.
(ii) Although the pre-exponential coefficient in model A is mathematically 
correct, from a physiological point of view it is a meaningless value since the maximum 
value the extravasation concentration ratio R can have is in practice, R  = 1.0 (free- 
filtration). The consequence of using model A was to generate values of R^ >1 such that
for values of molecular radii between zero and an unknown radius at which free- 
filtration ceases to occur, Model A produces F/P ratio values which are nonsense. 
Furthermore, the general form of Model A does not include any parameter which 
represents the maximum molecular radius at which free-filtration occurs.
The considerations outlined above led to the development of the more complex 
mathematical model, Model B.
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2.2.3.4 Model B
The second model studied had the general form:
K = exp(-k(a-  ao)n) (B)
where R is the respective F/P or L/P concentration ratio, a is the molecular radius of the 
macromolecule (A), ao is the parameter representing the molecular radius at which the 
ratio R is 1.0, and n and the parameter k  control the shape of the curve, with k 
representing the gradient (exponential gradient).
Model B has the following important advantages over Model A:
(i) The presence of the parameter ao  meant there was no need for a pre­
exponential coefficient in Model B. This is an advantage because such a parameter has 
no physiological meaning. It should be noted that an important factor in the selection 
of all of the models presented in this subsection, was the desire to model the data 
adequately whilst keeping the number of parameters to a minimum.
(ii) The introduction of the parameter ao provides important information from the 
physiological point of view, since ao ensures that for each fit the value of the molecular 
radius at which the concentration ratio R equals 1.0 is obtained (i.e. at a = ao). Hence 
free-filtration can be assumed to occur for all molecular radii smaller than that 
respective ao value, whereas for molecular radii greater than ao the extent of 
extravasation decreases with increasing molecular radius. An important assumption 
with Model B therefore is that a >  ao (the actual value of ao will of course be different
for each data set the model is fitted to). It can be assumed that R  —1.0 (i.e. free- 
filtration) for all molecular radii within the range 0 <a<ao.
(iii) In the cases of the uncharged dextran F/P ratio data [348] and the cationic 
dextran F/P ratio data [349] (which proved difficult to fit to Model A) and as a 
consequence of (i) and (ii), the power of n was reduced, (and correspondingly the
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respective parameter k  in each case became larger) which enabled the least-squares 
minimisation fits to be performed for all of the chosen data sets.
Model B was fitted to each of the F/P ratio data sets presented in tables 2.1 and 2.2, and 
to each of the L/P ratio data sets presented in tables 2.3 to 2.6. The results obtained 
from these fits are presented in table 2.8. Figures 2.5A and 2.5B illustrate the results of 
the fits to the F/P ratio data and the lung L/P ratio data respectively in plot form. Only 
single data points were used to initiate the fitting procedure in this case, because it was 
often easy to estimate the size of ao from the datum itself.
72
Table 2.8  
Initial p a r a m e te r  es t im a tes  an d  
p a ra m e te r s  o f  b es t  fit for  
Model B
Model B:
(s, ratio) data point(s) 
selected to initiate 





Parameters of best-fit 
Simulation -* Least Squares Simulation —> Simplex -♦ Least squares
F
—  ratio data
F











*=0 26851 ± 0 0052884 
a0=15 890 ± 0.070977 
(wss 0 00051593)
(MSC 6 2623)













*=0.007333 ± 0 00014778 
50=17.612 ± 0.10185 
(wss 0.00049917)
(MSC 7 9236)













*=0 00011562 ± 1.3312E-5 










*=0.20950 ±0.021068  




*=0 20941 ± 0.021055 














*=0.010458 ± 0.00096525 




*=0.010454 ± 0.00096511 











*=0.013386 ± 0.0027232 




*=0.013375 ± 0.0027251 
50=14.581 ± 7.7374 
(wss 0.020736)
(MSC 1.7644)







*=0.019537 ± 0.00078171 
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k =0.0558385 ± 0 0060309 




* =0.054927 ± 0.0059965 
50=13.092 ± 1.1907 
(wss 0.30031)
(MSC 1.9652)
Figure 2.5A Model B fitted to the selected F/P ratio data.
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Model B was also fitted to each of the F/P ratio data sets presented in tables 2.1 and 2.2 
using Minsq [4411 with a weighting factor of 2.0, and these results are presented in 
table 2.9. In each case using a weighting factor of 2.0 tended to improve the quality of 
the fit slightly at higher molecular radii, but compared to a weighting factor of zero, did 
not fit nearly so well over the rest of the data, producing higher wss and lower MSC 
values. Consequently a weighting factor of 2.0 was not pursued any further.
The results in table 2.8 and figures 2.5A and 2.5B show that Model B fitted all of the 
data well, with low wss and high MSC values in every case. The wss and MSC values in 
table 2.8 were similar to those for Model A presented in table 2.7, though model B 
could be fitted to all of the data sets, giving it a clear advantage over model A. 
Interestingly, the similarities between the values of the parameters generated for the 
anionic dextran F/P ratio data [348] and the protein F/P ratio data [326] appear to 
clearly support the connection between fractional clearance and molecular charge as 
outlined in part 2.2.2.4. (Protein macromolecules which generally have net negative 
charge are believed to behave similarly to negatively charged polymers of the same size, 
due to the negative charge which is believed to be present on the luminal surface of the 
glomerular endothelium, as outlined in subsection 2.2.2.4.) The optimum values of n 
and the parameter k  also depended on charge with the smallest value of n, n = 1 , and 
the larger values of k reflecting the more restrictive permeability characteristics (steeper 
general curve shape) for the anionic dextran [348] and protein [326] F/P ratio data. 
Larger values of n and smaller values of k  modelled the more freely permeable 
characteristics of the uncharged [348] and cationic [349] dextran F/P ratio data. A 
similar trend was also shown in table 2.7 (where appropriate).
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Table 2.9
Model B using a WF = 2.0
Initial parameter estimates and 
parameters o f best-fit for Model B and  
the selected F/P
ratio data using a weighting factor o f  
2.0
(a, R)data points 
selected to initiate





Parameters of best-fit 
Simulation -> Least Squares Simulation -» Simplex -> Least squares






*=0.26850 ± 0.0052882 




*=0.26851 ± 0.0052884 
ao=15.890 ± 0.070977 
(wss 0.00051593)
(MSC 6.2623)







*=0.0072930 ± 0.0014658 









—  ratio data
P







*=0.00014097 ± 1.8627E-5 





















*=0.20941 ± 0.021055 
ao=17.486 ± 0.26119 
(wss 0.0080615)
(MSC 3.7726)
Various other conclusions can be drawn by reference to the parameters of best fit. The 
similarities between the estimates of parameters in table 2 .8  for extravasation of the 
pooled endogenous protein fractions in the sheep lung [395, 396], and the 
corresponding data for the dog lung [398] reflect the similarities between different 
animal species. The differences between the parameters of best-fit for the pooled 
endogenous protein fractions in the sheep lung [395, 396] and the PVP in the sheep 
lung [397] indicate the dependence of L/P on charge. The PVP data for the sheep lung 
[397] and the pooled uncharged dextran data for the dog and rabbit subcutaneous skin 
[372, 373, 410], reflect the differences in permeability of different tissue endothelia.
In summary Model B appeared to fit all of the data well and its general form had 
several important advantages over Model A. However, before choosing Model B as the 
best model to fit all of the data, further types of models with a common general form 
were also developed to see if any further improvements could be made. These models 
are presented in 2 .2 .2 .5.
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2.2.3.5 Models C
Visual observation suggests that the general form of plots of F/P or L/P ratios against 
molecular radius are sigmoidal. The idea behind the models presented here was to 
derive an equation which would produce a sigmoidal plot which might produce a better 
representation of F/P or L/P at low radii. Ideally low radii should all have a F/P or L/P 
value of unity. When a critical radius was reached the F/P or L/P ratio would start to 
decline and ultimately reach an asymptote. This would ideally allow the generation of 
physiologically relevant ratio values between zero and one for all molecular radii, 
including very small radii. This is in contrast to Models A and B since the general form 
of both these models meant that physiologically unrealistic ratio values (R > 1 .0 ) were 
obtained at low molecular radii, notably below the maximum radius at which free- 
filtration occurs. This objective initially led to the consideration of three further models 
whose basic general form can be represented as:
(O
1+X
where as x (which can be thought of as the molecular radius) becomes very large, the 
ratio R approaches zero, and conversely as x  approaches zero, the ratio R approaches a 
value of R — 1.0 (with R = 1.0 at x  = 0).
Three different models based on this concept were investigated:
R =  r — z r  ( C l )j  (a—mrrhi)
R  = --------1-----^  (C2)
1 + 1 o k{a~mrrh)
R  = ------^  « (C3)i , k(a-mrrh)l + e
where in each case, R is the respective F/P or L/P concentration ratio, a is the molecular 
radius of the macromolecule (A), mrrh is the parameter representing the molecular
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radius at which the ratio equals one half, and k  and z are parameters controlling the 
shape of the curve (both representing the gradient).
Models Cl, C2 and C3 were initially fitted to the uncharged dextran data for the rat
[348] only (presented in table 2.1) in order to establish which was the better of the 
three. All three of the models were found to work equally well, producing wss and MSC 
values almost identical to each other, with Model C3 being marginally the better of the 
three. However, the wss and MSC values for each of models Cl, C2 and C3 indicated a 
poorer fit of the data than that achieved with Model B or indeed Model A, where 
applicable, to the data. The data points used to initiate the fitting procedure, the best 
initial parameter estimates, and the optimal parameters of best-fit (mean ± sd) for each 
of these fits, together with the wss and MSC values are presented in table 2.10
Model C3 was subsequently selected to test with most of the other data. A criterion in 
selecting Model C3 in preference to Models Cl and C2 was also the presence of an 
exponential term in Model C3 which would make it easier to differentiate than Models 
Cl and C2 should such a situation ever arise. Model C3 was then subsequently fitted to 
each of the F/P ratio data sets presented in tables 2.1 and 2.2 and to the L/P ratio data 
sets presented in tables 2.3, 2.4 and 2.5. The data points used to initiate the fitting 
procedure, the best initial parameter estimates, and the optimal parameters of best-fit 
(mean ± sd) for each of these fits, together with the wss and MSC values are presented 
in table 2.11. Figures 2.6A.1-2.6A.4 and 2.6B.1-2.6B.3 illustrate these results in plot 
form for the parameters of best-fit obtained using a simulation run, a simplex search, 
then the least-squares minimisation.
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Table 2.10 Initial parameter estimates and parameters of best-fit following the fitting of Models Cl, C2 and C3 to the uncharged 
dextran F/P ratio data for the rat 1348]
(a, ratio)data points 
selected to initiate 





Parameters of best-fit 
Simulation Least Squares Simulation -» Simplex -» Least squares






mnfi=27.636 1 0.16966 
(wss 0.0089469)
(MSC 5.0375)
z=1.3648 ± 0.020200 
mrrh=27.623 ± 0.16985 
(wss 0.0089393)
(MSC 5.0384)






mrrf)=27.637 ± 0.16961 
(wss 0.0089503)
(MSC 5.0371)
*(=0.13509 1 0.0064156 
mrrf?=27.623 ± 0.16984 
(wss 0.0089393)
(MSC 5.0384)





fc=0.31172 ± 0.014820 









Initial parameter estimates and 
parameter of best-fit for Model C3
(a, ratio)data points 
selected to initiate 





Parameters of best-fit 
Simulation -» Least Squares Simulation -» Simplex -» Least squares











mrr/j=18.516 1 0.060299 
(wss 0.00070056)
(MSC 5.9563)
Uncharged dextran [348] 














—  ratio data
P
Cationic dextran [349] 














































Endogenous protein [398] 










mrrti=73.175 1 7.1586 
(wss 0.031177)
(MSC 1.3566)




































Figure 2.6A.1 Model C3 fitted to the rat
anionic dextran F/P ratio data [348].
Figure 2.6A.2 Model C3 fitted to the rat 
uncharged dextran F/P ratio data [3481.
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Figure 2.6B.1 Model C3 fitted to the 
pooled sheep endogenous protein fraction 
lung L/P ratio data [395, 396].






0 50 100 150 200 250 300
Molecular Radius (Angstroms)
Figure 2.6B.2 Model C3 fitted to the dog








0.2 0 - -
0.00
10050 150 2000 250
Molecular Radius (Angstroms)
Figure 2.6B.3 Model C3 fitted to the 
sheep PVP lung L/P ratio data [397].





2000 120 16040 80
Molecular Radius (Angstroms)
83
Table 2.11 and figures 2.6A.1-2.6A.4 and 2.6B.1-2.6B.3 show that Model C3 appeared to 
fit the data well, with the fits to the F/P ratio data sets being generally better than the 
fits to the L/P ratio data sets. However, the wss and MSC values were not as good as the 
corresponding values following the fitting of Model B and Model A and on closer 
inspection one can see why. It was impossible to find a value of k  (or z) which fitted the 
high ratio values since the curve began to decline before the data had been reached. 
Even the presence of the parameter mrrh, a similar parameter to ao  in Model B, did not 
overcome this problem.
A further development led to a modified form of Model C3 i.e. Model C4 whose general 
form was as follows:
where f  represents a ratio value R at which the curve levels off and becomes linear, and 
all the other parameters are as defined before. It was thought that this might be a better 
model for the L/P data.
Model C4 was fitted to each of the L/P ratio data sets presented in tables 2.3, 2.4 and 
2.5. The data points used to initiate the fitting procedure, the best initial parameter 
estimates, and the optimal parameters of best-fit (mean ± sd) for each of these fits, 
together with the wss and MSC values are presented in table 2.12. Figures 2.7A -2.7C 
illustrate these results in plot form for the parameters of best fit obtained using a 





Initial parameter estimates and 
parameter of best-fit for Model C4
(a, R)data points 
selected to initiate 





Parameters of best-fit 
Simulation -» Least Squares Simulation -» Simplex -> Least squares
Pooled endogenous 
protein fractions 







*=0.027741 ,± 0.010304 
m/rfr=79.164 ± 35.946











Endogenous protein [398] 











*=0.091021 .± 0.036201 
mr/h =45.003 ± 2.8574 
£=0.29865 ± 0.047952 
(wss 0.012699)
(MSC 1.9214)













=40.401 ± 2.3048 













Figure 2.7A Model C4 fitted to the pooled 
sheep endogenous protein fraction lung 
L/P ratio data [395, 396].
Figure 2.7B Model C4 fitted to the dog
endogenous protein fraction lung L/P rati
data [398].











0.2 0 - -
0.00
0 50 100 150 200 250
Molecular Radius (Angstroms) Molecular Radius (Angstroms)
Figure 2.7C Model C4 fitted to the 
sheep PVP lung L/P ratio data [397].





0. 2 0 - -
0.00
0 40 80 120 160 200
Molecular Radius (Angstroms)
86
Table 2.12 and figures 2.7A -2.7C show that although the wss and MSC values when 
Model C4 was fitted to the L/P ratio data sets were on the whole better than those when 
Model C3 was used, they were not as good as those obtained with Model B. The general 
shape of the curve produced by Model C4 and its f  parameter was such that at some 
value of f  the curve was forced to level off towards a constant value (representing 
filtration independence). This can be observed for L/P data at high radii, but it was not 
possible to generate realistic parameter estimates using the least squares method.
The main concern of the modelling described in this section was to establish which 
model best fitted the range of radii spanned by the experimental data, rather than being 
too concerned about very low or very high molecular radii outside the range of 
experimental data. A model which produces exactly a ratio of R = 1.0 for all molecular 
radii between zero and the maximum radius at which free-filtration occurs, and then 
declines down through the data, was not mathematically possible to develop, and 
although Models Cl, C2 and C3 come relatively close to this for the F/P ratio data, for 
the reasons already outlined, Model B was still the best of the models.
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2 .2 3 .6 Conclusions
The relationship between molecular radius and regional extravasation concentration 
ratios of macromolecules was modelled directly by each of models A, B and C. The 
general form of these models was based purely on this relationship, with the number of 
parameters in each model being deliberately kept to a minimum. Model A, Model B, and 
Models C represent the three possible different and most logical approaches to this type 
of modelling. The primary concern of each of these models was to ensure the best 
possible fits over the actual range of the chosen F/P ratio and L/P ratio data sets, since 
it was within this range that the molecular radii of the macromolecular drugs in which 
this study was most concerned he. In this respect, Model B was the best for each of the 
data sets. Consequently Model B was selected along with its appropriate chosen 
respective protein and uncharged parameters of best-fit to be developed at the 
appropriate stage of the modelling (as described in section 2.3) into the respective 
physiological expressions for the parameters kexcr and which determine the rate of 
movement of both protein and uncharged macromolecular drugs from the blood to the 
glomerular filtrate (the excretion process) and from the blood to the lymph (the target 
site) respectively (see page 91 for diagram). An important assumption of Model B is that 
a > ao. Another important assumption made by Model B, and indeed each of Models A,
Cl, C2, C3 and C4 is that each drug macromolecule is uniformly spherical (with 
molecular radius a). The parameters of best-fit selected for Model B were those 
obtained following the method of a simulation run, a simplex search, and then the least 
squares fit, and using a weighting factor of zero. The fits of Model B to the uncharged 
dextran rat F/P ratio data [348], the pooled protein macromolecule dog F/P ratio data 
[326], the pooled endogenous protein fraction sheep lung L/P ratio data [395, 396], the 
PVP sheep lung L/P ratio data [397], and to the pooled uncharged dextran dog and 
rabbit subcutaneous skin L/P ratio data [372, 373, 410], the results of which were all 
given in table 2 .8 , were selected to be used throughout the rest of this study to 
investigate the fate of protein and uncharged macromolecular drugs in the body. The
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parameters obtained following the fitting of Model B to the anionic [348] and cationic
[349] dextran rat F/P ratio data were used to show the effect of charge on glomerular 
filtration, they were not used in the major simulations described later in chapter 3 
because firstly there was no corresponding anionic or cationic L/P ratio data available 
to use, and secondly because this study was concerned with the two main types of 
macromolecular drug or drug carrier distribution, uncharged polymers and proteins. 
The parameters obtained following the fitting of this model to the endogenous protein 
fraction dog lung L/P ratio data [398], were used only in part 2.2.3.4 to illustrate some 
important permeability characteristics, and were not used for the major simulations 
described later in chapter 3 because the data were not so good as the pooled 
endogenous protein fraction sheep lung L/P ratio data.
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2.3 The development, solution and validation of a novel physiological three-
compartment pharmacokinetic model
2.3.1 Introduction
The major objective of this study was to develop a physiological pharmacokinetic 
model consisting of three compartments (tissues) of the body representing the blood, 
lymph and liver. The model was chosen to allow the two major elimination processes, 
i.e. renal excretion and hepatic metabolism (hepatic clearance), to be determined 
separately. The major rationale for design of the physiological model was the desire to 
examine the effect of molecular radius on the distribution of both protein and 
uncharged macromolecular drugs in the body both in the absence and presence of 
hepatic metabolism, taking into account the relevant different regional capillary 
membrane permeabilities to different size macromolecules. A practical objective of the 
study was to predict via simulations, the molecular radii which are most effective in 
distributing the greatest fraction of a macromolecular drug dose to a particular target 
site, the interstitial fluids or lymph, and thus to the site of cancer micrometastases 
present there. In addition to showing the fraction of the macromolecular drug dose 
present in the lymph, the model was required to show for each molecular radius size 
(within the range determined by the modelling process) over almost any desired interval 
of time, the fractions of the dose present in the blood and the liver, and also the 
fractions which have been excreted via the kidneys and metabolised by the liver. 
Another objective was to solve the model preferably using analytical techniques and 
where necessary numerical techniques so that equations describing the amount (or 
fraction) of the macromolecular drug dose in each compartment (tissue) with respect to 
time could be obtained. The study also involved the development of a specific 
computer programme written in BASIC which had two main purposes, firstly to aid in 
the solution of the model equations, and secondly to perform the simulations described 
in chapter 3. The advantages and disadvantages of this novel physiological three- 
compartment pharmacokinetic model over the key theoretical/predictive
90
macromolecular anticanccr drug and drug-targeting pharmacokinetic models in the 
literature, are discussed in chapter 5.
This current section of this chapter describes the development, solution and validation 
of this new physiological three-compartment pharmacokinetic model. The model, the 
associated equations, their method of solution and the development of the computer 
programme are described in 2.3.2. Also in 2.3.2 attention is paid to the use of Model B 
for calculating expressions for the param eters k^xcr and k12. 2.3.2 also describes the 
development of the other mathematical expression used in the modelling process. The 
methods used to validate the model are described in 2.3.3. A summary of the main 
features of the model is then presented in 2.3.4.
2.3.2 The model
2.3.2.1 Description and definition of terms
Consider the following model,
Intravenous bolus 
macromolecular 




B lo o d
kis L iv e r
>Volume=Vc Volume=VH








where an intravenous (i.v.) bolus dose D0 (mg) is injected into the blood compartment 
(compartment No. 1 or central compartment) at time t = 0. Therefore at time t = 0 there 
will be no drug in the lymph or liver compartments (compartments No. 2 and No. 3 
respectively). Let AP be the amount (mass) of drug in the blood compartment at time t, 
and let a\ be its Laplace transform. Similarly, let AL be the amount (mass) of drug in the 
lymph compartment at time t, and let a2 be its Laplace transform. Also let AH be the 
amount (mass) of drug in the liver compartment at time t, and let a3 be its Laplace 
transform. Since the dose D0 of the drug is in the blood compartment at time t = 0 the 
following set of initial conditions at time t = 0 can be defined; AP = D0 at t = 0, AL = 0 at 
t = 0 , and An = 0  at f = 0 .
Let the volume of the blood compartment be Vc, the volume of the lymph compartment 
be VL, and the volume of the liver compartment be VH. Now the rate of movement of the 
drug between the three compartments is controlled by the inter-compartmental 
parameters k l2, k 2V k ]3 and k 3] respectively (which are first-order rate constants), and
similarly the rates of excretion and metabolism (the elimination processes) of the drug 
are controlled by the first order parameters k ^  and km respectively. Hence k n 
determines the rate of movement of the drug from the blood to the lymph, k2X 
determines the rate of movement of the drug from the lymph to the blood, k]3 
determines the rate of movement of the drug from the blood to the liver, k 3] 
determines the rate of movement of the drug from the liver to the blood, k ^
determines the rate of movement of the drug from the blood to the glomerular filtrate 
(excretion via kidneys), and k m represents the rate of metabolism (hepatic clearance) of
the drug from the liver.
The set of differential equations which describe the model with respect to time are
therefore,
dA
“ (* 1 2  + k e x c r ) A P +  *21 A L +  ^31 A H  1
_  £ a  —k A*12/ i p  "71 L 2
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—7 T  =  ~ ( * 3 i  + * » ) ^ h  +k nAP dt :
The method of solution of this set of differential equations is described in 2.3.3.3. 
However, before describing the solution of the model equations, it is appropriate to 
define the mathematical expressions (models) representing the parameters k ^  and 
k n , and the expressions for the other intercompartmental parameters, and also to 
outline the assumptions made. These issues are presented in 2.3.2.2 below.
2.3.2.2 Development of mathematical expressions (models) to represent k m  
and k n , and other inter-compartmental parameters.
Following the selection of Model B as the best model to describe both the selected F/P 
ratio and L/P ratio data sets, the next step in the modelling process was to use this 
relationship to define the parameters and k n . This was achieved by considering
the pharmacokinetic principle of clearance of a drug from an organ (tissue) given by the 
relationship Clorgan =  VD k organ (equation 4) where VD is the volume in which the drug is
distributed and k organ is the rate at which the drug leaves the organ.
(i) A mathematical expression (model) for km
A mathematical expression (model) for k ^  was developed as follows,




^ A ro m  blood to glomerular filtrate p  tatio X GFR
FTherefore, ka v Vr = — ratio x GFR1 excr C p
—  r a t i o  x  G F Rp
so —---------------------excr . j r
V r
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Now from the modelling process described in section 2.2 Model B can be substituted 
for the F/P ratio to give,
exp( - k  [a -  ao)n) x GFR
= Vc
Hence the parameter now determines the rate of movement of macromolecular 
drugs from the blood to the glomerular filtrate, taking into account the different 
permeability of the fenestrated capillaries of the kidney to different size 
macromolecules by entering the desired molecular radius of the macromolecule a (with 
a >ad) and the appropriate parameters of best-fit. Since GFR is in units of ml/min, Vc is 
units of ml, and Model B is dimensionless, then k ^  is in units of m in 1.
(ii) A m athematical expression (model) for k n
Following the same principle used in (i), a mathematical expression (model) for k u was 
developed as follows,
Clj    from blood to lymph
*12“  yvc
and also,
Clbom blood to lymph = j r a t i c x B L F R
Therefore k n Vc = ^ r a t i o x  BLFR
^ra ticxB LF R
so k u =_  P Vc
Now from the modelling process described in section 2.2, Model B can be substituted 
for the L/P ratio to give,
exp{ - k { a  -  a o Y ) x B L F R
k\2 ~ Vc
94
Hence the parameter k n determines the rate of movement of macromolecular drugs 
from the blood to the lymph, taking into account the different regional permeabilities 
of the capillaries (lung or subcutaneous skin continuous capillaries) to different size 
macromolecules. For the reasons outlined in section 2.2 this study assumes BLFR = LFR. 
Since BLFR is in units of ml/min, Vc is in units of ml, and Model B is dimensionless, 
then k n is in units m in 1.
(iii) A mathematical expression (model) for k 2]
A mathematical expression (model) for k2] was developed as follows,
Cl,  ^  from lymph to blood . . v . i n n
21 = ------- ---------  and also C/from ^  t0 blood = 1 xLFR
* / 1 X L F RTherefore k 2l = ----------- -
For the reasons outlined in section 2.2 this study assumes that the concentration ratio 
of macromolecules moving from the lymph to the blood is one, i.e. there is free 
movement from lymph to blood for all macromolecules, and that this rate of movement 
occurs at the same rate as LFR. k 2X is in units of m in 1 because LFR is in units of ml/min
and VL is in units of ml.
(iv) A mathematical expression (model) for k u
A mathematical expression (model) for k n was developed as follows,
kn = “r 1'0"”  and also C/riomMoodtol„„ = 1X Total blood How rate to the liver
f'c
„  , 1X Total blood flow rate to the liverTherefore k u = -----------------------------------------  j
Vc
The parameter k n determines the rate of movement of macromolecular drugs from the 
blood to the extravascular spaces of the liver. For the reasons outlined in section 2.2 
this study assumes that the concentration ratio of macromolecules extravasating from 
the blood to the extravascular spaces of the liver is one i.e. free movement for all
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macromolecules from the blood to the extravascular spaces of the liver, and that this 
rate of movement therefore occurs at the same rate as the total blood flow rate to the 
liver. In practice the Liver/Plasma ratio is dependent on molecular radius at high radii 
but the extent of experimental data available do not allow Liver/Plasma ratio to be 
modelled effectively. Since the total blood flow rate to the liver is in units of ml/min, 
and Vc is in units of ml, then k ]3 is in units of m in 1.
(v) A mathem atical expression (model) for k3]
A mathematical expression (model) for k3l was developed as follows,
Clk 3] = — from liver to blood also C/from livcr t0 blood = 1X Total blood flow rate from the liver
Vfi
. lXTotal blood flow rate from the liverTherefore fc3] = ------------------------------------------ c
Vr
The parameter k 3X determines the rate of movement of macromolecular drugs from the 
extravascular spaces of the liver to the blood stream. For the reasons outlined in section
2 .2  this study assumes that the concentration ratio of macromolecules moving from the 
extravascular spaces of the liver back into the bloodstream is one, i.e. there is free 
movement from the extravascular spaces of the liver to the blood, and that this rate of 
movement therefore occurs at the same rate as the total blood flow rate from the liver, 
where it is also assumed that the total blood flow rate from the liver equals the total 
blood flow rate to the liver. Since the total blood flow rate from the liver is in units of 
ml/min, and VH is in units of ml, then &31 is in units of m in 1.
(vi) A mathematical expression (model) for k m
A mathematical expression (model) for k m was not fixed because macromolecular drugs
would be expected to be metabolised at different rates. The approach taken here was to 
vary the value of k m to model the influence of this parameter on macromolecular
disposition (see Chapter 3).
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2.3.2.3 Solution of the model equations and development of the com puter
programme
The complexity of the set of differential equations 1, 2 and 3 describing the three- 
compartment model meant that they had to be solved by the method of Laplace 
transforms, where in general notation, the Laplace transform f ( s) of a function F(t) is 
given by
l [ F ( f ) ]  =  f (s )  =  J  F(t)e~adt
0
where the function f(f) is multiplied by e 8t and then the product is integrated over time 
from t= 0 to t=oo. The Laplace transform rules used in the solution of the model 
equations 1, 2 and 3 were,
(i) the rule for constants
i.e. L[cF(t)\ = cL[F{t)]  if c is a constant 9 .1
(ii) the rule for linearity
i.e.
l [ c , f i ( < )  +  c 1 F 1 ( / ) + . . . + c . F . ( / ) ]  =  c 1l [ F 1 ( < ) ]  +  e , l [ F 2 ( / ) ] + . . . c . l [ F . ( / ) ]  9-2
(iii) the rule for first-derivatives
dFi.e. =  l [ F ' ( / ) ]  =  a L [ F ( * ) ] - F ( 0)  9 . 3
dt
where F (0 ) is the value of F(t)  at time f = 0 .
and the rule used for taking the inverse Laplace transform was,
(iv) since l \c e  <t>t = -  where c is a constant and 0 is a parameter (= a constant) 
L s + 0
then L-i = ce  ^ 9 . 4
s+(p
The full solution of equations 1, 2 and 3 by the method of Laplace transforms is 
described in Appendix A1 because the solution is a lengthy procedure. Both Cramers 
rule and the theory of partial fractions had to be used in the solution process, yielding
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the following equations describing the amount (mass) of the macromolecular drug 
dose, in the blood, lymph, and liver compartments with respect to time.
D0(k2i- r ) ( k , l +km- y ) e - r' D0 (k2i- g ) ( q - ( k 3X +k „,))*-» > D0(kn - f i ) ( k i l +kn -0 )e -*  
P ( r - o c ) ( r - p )  + ( y - a ) ( a - p )  + ( y - p ) ( a ~ p )
10
_  P 0kX2(k3X + k m ~y )e  ^(^31 ^ 0^ 12(^ 31 + km ~ P ) e *
L ~ ( r - a ) { r - P ) (y - a ) { a - p ) (y - p ) { a - p )
11
_  D 0k n ( k 2X — y ) e  7 Dp k n  (or — k 2l )e a ^ 0^13 (^21 ~  P ^ e ^
H ~  ( y - a ) { y - p ) { y  -  a ) { a  -  p )  ( y  -  p ) { a  -  f i )
12
where y, a and (3 can be expressed in terms of the inter-compartmental parameters in 
the following system of expressions,
(X +  J5 +  y  — kn +  2^1 1^3 “*■ 3^1 e^xcr  ^^
aP  + a y  + P y  = k2Xk3X 4-k2Xkm+ k X2k3X + kX2km+ k X3km
+ kx3k2X + kexcrk31 +  kexcrkm ^ k ^ k ^  ^
ccfiy — kx3k2] km +  kexcrk2\k3\ + kexcrk2Xkm 15
which upon solving produces the following cubic equation in general notation /{*) say 
as follows,
f ( x )  = a3 x 3 +ci2x 2 + a xx  + a0 = 0  
with
16
a3 = 1 17
a 2 = ~ ( k \ 2 + k 2 \ + k \ 3 + k 3 \ + k excr +  O  1 8
a\ ~  (^21^31 "*” ^21 k m “^ ^12^31 km k ]3k m + kx3k2x ^mk excrk3X + k excrkm + kexcrk2,) 19
a 0 = ~ (k u k2]km + kexcrk 2Xk3X + k ^ k ^ k j  19a
whose roots are actually y, a, and |3, with y > a  > (3 > 0. All the other terms in each of 
equations 10, 11 and 12 are as defined in parts 2.3.2.1 and 2.3.2.2. Equation 16 was
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solved numerically using the Newton-Raphson and synthetic division techniques to find 
the roots y, a and (3, using procedures described later.
Other related equations were developed as described below. The following equation for 
the concentration of the macromolecular drug in the blood compartment with respect 
to time can be obtained from equation 1 0 ,
Vc ( y - a ) ( r - p )  + Vc { y - a ) ( o c - p )  + Vc ( y - p ) { a - p )
20
Having obtained the equations for AP, AL and AH, the total mass of macromolecular 
drug eliminated with respect to time was described by the following equation,
a e =  A  - ( 4 >+ A + ^ H) 21
The rate of change in the amount (mass) of the macromolecular drug excreted by the 
kidney with respect to time was described by the following differential equation,
,JA EXCR _  / 4
^  excr P 22
and the rate of change in the amount (mass) of the macromolecular drug metabolised 
(hepatically cleared) by the liver with respect to time was described by the following 
differential equation,
_  1 A
~ d T ~  2 3
Equations 22 and 23 were both solved individually by direct integration between time 
t = 0  and t = t to give the following equations for the amount (mass) of the 
macromolecular drug excreted by the kidneys with respect to time (Aexcr ) and the 
amount (mass) of the macromolecular drug metabolised (hepatically cleared) by the 
liver with respect to time (AM ),
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, , „ \ (><l l - y ) ( k l, +km- y )  (*;,-«)(«-(*,,+*„)) (k2l- f i ) ( k„+km- f i )
E'™ '“r °[ r { y - c c ) { y - p )  a { y - a ) { a - f i )  p { y - p ) ( a - p )
(*21 -?)(* 31 +km-y)e~r' (*21 -«)(g-(*3i + )^)g~‘° (*2I ~l)(*3i +km- p ) e ' f‘
y ( y - a ) ( y - p )  a { y - a ) ( a ~ p )  P { y ~ P ) { a - p )
24
- ^  f ( * 2i ~y) («-*!■) ( * 2i -A)_________ ( * 2i — r)g~?t
" " 13 °l?'(r-a)(r-/8) «(r-a)(«-£) P { y - P ) { a - P )  y ( y - a ) ( y - p )
( a - k 2,)e-a { k ^ - p y *  1
a ( j ' - a ) ( a r - / 8 )  ^ ( r - y S ) ( a - ^ ) J
25
Since equations for ALxCr and AM were obtained, then the total amount of the 
macromolecular drug eliminated with respect to time, i.e. AE, was also equivalently 
described by the following equation,
~  A  e x c r  +  26
where ^ c a n  also be written as,
~  A eum 27
For the simulations described in chapter 3, and consequently also in the computer 
programme developed to perform these simulations described below, the dose D0 of 
the macromolecular drug was set to unity, i.e. D0 = 1, so that the fractions of a 
macromolecular drug dose in each of the blood, lymph and liver compartments, and the 
fractions of the dose excreted by the kidneys and metabolised by the liver, were 
predicted with respect to time for each molecular radius.
A computer programme (MACROHOURS) was written to solve for y, a  and p and to 
allow rapid calculation of the equations for AP, AL, AH, Aexcr. Am and AE. The 
programme was written in BASIC V a modified and expanded BASIC language which 
runs on the Acorn Archimedes RISC processor.
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Figure 2.8 shows the overall plan and structure of the computer programme 
MACROHOURS, which illustrates the main subroutines (procedures (PROC)) involved. 
The main features of these subroutines are summarised in parts (a) to (h) below, and 
the complete listing of the computer programme MACROHOURS is given in Appendix 
A3, to which the reader is referred.
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*(a) The preliminary definitions
The main function of the first few lines prior to the first subroutine PROCoriginal was 
to dimension the matrix A and the vectors AA, B, and XW. The matrix A contains all the 
values of the functions to be calculated by the following subroutines. The vector AA 
contains the coefficients a, of the cubic equation. The vector B contains the values of 
the new coefficients after the application of synthetic division. The vector XW stored the 
values of all the roots as they were determined. All the vectors were given the 
dimension of 20 for convenience, although a dimension of 3 would have been 
sufficient. The names of all the subroutines (procedures) to be used in the programme 
were required to be listed at this stage.
(b) The subroutines PROCoriginal and PROCparam
The subroutines PROCoriginal and PROCparam display on the screen the current 
baseline values of the parameters D0, GFR, BLFR, Vc. Jfei. ^13. ^31, km, kfiit, nfilt, nfilt, kiymph, 
aiymph and niymph, and their units, which have necessarily been built into the programme. 
The user is then given the option to change any, or all of these parameters accordingly. 
For example, the values kfllt, <zfilt, nmt, k]ymph, alymph and n]ymph, which the programme uses 
to represent the filtration (i.e. subscript filt) and lymph (i.e. subscript lymph) 
parameters of best-fit k, ao and n respectively following the fitting of Model B to the 
selected F/P ratio and L/P ratio data sets, would have to be changed accordingly 
depending upon whether the distribution of protein or uncharged macromolecular 
drugs was being simulated. The values of the parameters GFR, BLFR and Vc, and 
therefore correspondingly k2u k l3 and k3l would also have to be given different values if 
the simulations were for mammals other than man, as indeed would km. Baseline 
parameters in the programme represent uncharged macromolecules in man with the 
dose D0 set to unity.
(c) The subroutine PROCsize
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Having entered the desired protein or uncharged parameters of best-fit together with 
the other appropriate baseline parameters, the subroutine PROCsize then requests the 
user to enter the desired molecular radius of the macromolecule a to be simulated for. 
The subroutine PROCsize then calculates the values of the parameters k^,. and k 12 
(since a determines the values of these parameters), and then calculates the values of 
the coefficients a, of the cubic equation 16 via equations 17 to 19a respectively. These 
values of the coefficient aj are printed on the screen. (The programme uses the term 
HRADIUS to represent the molecular radius a.)
(d) The subroutines PROCcube, PROCsubcube and PROCrootfind
The subroutines PROCcube, PROCsubcube and PROCrootfind calculate the three roots 
of equation 16 for the selected molecular radius value. This is achieved by solving 
equation 16 numerically using the Newton-Raphson and synthetic division techniques 
described in parts (i) and (ii) respectively below:
(i) The first root of equation 16 is calculated using the Newton-Raphson formula
/ ( * » )Xn.} = Xn  t r 2.
/ ' ( * „ )
with an initial starting value for the root of Xj = 0.5 and the convergence limit for the 
root set at \ f { x n ) |  <  IE -1 4 ,  where / ( * „ )  in this case is equation 16 evaluated at xn
for iteration number n, and / ' ( * „ )  is its derivative, and where xn+l is calculated from
xn so that each successive newly found value is used as the starting point for each
subsequent repetitive iteration. This repetitive application is repeated until either a root 
has been found satisfying the convergence criterion |/ (x „ ) | <  IE - 14, or of course
/ ( * » )  = o, or the number of iterations has exceeded the iteration limit. In
MACROHOURS the convergence criterion has been set at IE —14 because this is the
lowest order of magnitude with which the Acorn Archimedes computer can work (this
also applies to PCs), The number of iterations was set to run from 0 to 400 in steps of
2 . Hence, if within the set number of iterations | f ( x n ) |  <  IE —14 (or of course
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/ ( x j  = 0) then this represents a root of equation 16. If however a root has not been
found within the set number of iterations, then this indicates that the convergence is 
very slow, and taking too long, and the user is subsequently requested to enter a new 
convergence limit, i.e. IE- 13, IE- 12 etc as appropriate to find the root. In practice the 
first root, and indeed the other roots, are usually found within approximately the first 
40 or so iterations (function calls) with the convergence limit set at IE - 14, hence 0 to 
400 iterations in steps of 2 is usually more than adequate. A starting value of Xj = 0.5 is 
used because the Newton-Raphson technique will obviously not commence unless such 
a value is given, and Xj = 0.5 is a sensible initial estimate, as indicated by the general 
form of equation 16. Any sensible starting value within the range of search could have 
been used to initiate the procedure, because the roots arrived at will of course be the 
same, although the order in which they are found and the number of iterations it takes 
to find them may vary. The three roots of equation 16 m ust be real, distinct and greater 
than zero, hence in MACROHOURS the range of search for the roots is defined to be 
between x = -10 and x = 10. The lower value of x = -10 was used for safety in case the 
smallest root was to be extremely close to, but not actually zero itself. The term
in equation 28, which represents the correction term applied to the previous
estimate of the root at each iteration, means that the value of x„+1 is obtained by moving 
from x„ to x n+1 in the direction of the tangent / ' ( * „ )  of the function f ( x n), hence
ensuring the eventual convergence to a root. The nature of the model and the inter-
compartmental parameters, and consequently the general shape of the curve given by
equation 16 mean that convergence is always guaranteed, with the convergence to a
- / ( * „ )
root being fast when the denominator in this term is large (due to a strong
vertical trajectory near the root), and slower when the denominator in this term is 
smaller (due to a less vertical, more horizontal trajectory near a root).
(ii) Once the first root of equation 16 has been found using the Newton-Raphson 
technique described in part (i) above, this root is then removed (factored out) from
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equation 16 by the process of synthetic division described below, thus reducing 
equation 16 to a quadratic equation (degree 2) with new coefficients. In general 
notation, for a polynomial of nth degree the new coefficients after application of 
synthetic division are given by,
where x* is the first root to be determined by part (i). The polynomial, in this case the 
cubic equation 16, is then reduced by one degree,
and the newly calculated coefficients of this reduced equation by degree one are 
renamed,
Part (i) is then repeated to find the next root, and once this has been found, this root is 
then factored out by synthetic division. This process is repeated until all roots of the 
original polynomial have been found.
Therefore, in general notation, if the first root of equation 16 is found by part (i) to be 
x* say, then since equation 16 has degree n = 3, then removing this root X* from 
equation 16 by synthetic division gives an equation of degree 2  (a quadratic equation) 
whose new coefficients are calculated as follows,
= a 2 +b2x *  
b0 - a x +b^x *
(where s are as defined by equation 17, 18 and 19 previously) and these newly 
calculated coefficients of the resulting quadratic equation are then renamed a i = bf for
Z = 0 ,1 ,2 . Hence having factored out the first root X*, the next root is then calculated 
from this quadratic equation by repeating part (i) again. This second root is then 




a i -  bi for 1 = 0 , 1,...,/! 29.2
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To check the validity of the roots determined MACROHOURS checks the quadratic 
equation for the presence of complex roots, and if there are any, the user is requested 
to enter a new molecular radius value. MACROHOURS also prints on the screen the 
number of steps (function calls) it takes to arrive at each of the three roots.
(e) The subroutine PROCassign
Once the three roots of equation 16 have been calculated for the selected molecular 
radius, the subroutine PROCassign then defines the largest of these three roots to be y, 
the middle (next largest) to be a, and the smallest root to be p since by definition 
y > a >  p > 0 .
(f) The subroutine PROCtimes
Having assigned the values y,  a  and p  such that y  > a  > p >  0, MACROHOURS then 
requests the desired time period for which the simulation is to be performed. The user 
is requested to enter the initial (starting) time for the simulation run, the final (end) 
time for the simulation run, and the time increment (all in hours).
(g) The subroutine PROCcalc
The subroutine PROCcalc simulates each of equations 20, 10, 11, 12, 24, 25, 26 and 21 
for the desired molecular radius over the selected time period. Thus giving the fraction 
of the dose in each of the blood (equation 1 0 ), lymph (equation 1 1 ) and liver (equation 
1 2 ) compartments, and also the fractions of the dose which have been excreted by the 
kidneys (equation 24) and metabolised by the liver (equation 25). The total fraction of 
the dose eliminated (equations 26 and 27, where of course equation 26 equals equation 
27), and the concentration of the dose in the blood compartment (equation 2 0 ).
(h) The subroutines PROCfilename, PROCdisc and PROCdiscgraph
The simulated results can then be printed to disc (inserted into drive 0 or A). Having 
entered the desired filename, the results are saved onto floppy disc as two ASCII files
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under the names 'filename' and 'Gfilename'. The former files can be printed out to give 
a table of simulated results (raw data) for the fractions of the dose in each 
compartment together with a summary of the baseline parameters used and the values 
of the three roots y, a, p. Files with prefix G can be imported into a worksheet of a 
suitable plotting programme to construct the desired plots. The figures presented in 
chapter 3 were all constructed by importing each appropriate 'G-file' into worksheets of 
the plotting programme Sigma Plot (Jandel). jn this way the transfer of data are 
accomplished without introducing errors.
Once the simulated results have been saved to disc (if desired), then either a new 
simulation time period, or a different molecular radius value, or new baseline 
parameters can be entered, and the procedures described in parts (a) to (h) are then 
repeated as appropriate.
One restriction of the use of MACROHOURS is that for the very large molecular radii of 
greater than about 7OA, the fractions of the dose excreted can be so small (less than 1E- 
14), that the computer cannot calculate these values. Hence the programme can be used 
when ao < a 70 A.
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2.3.3 V alidation of the m odel and the com puter program m e
The physiological three-compartment pharmacokinetic model and the computer 
programme MACROHOURS were validated in two ways which are described in parts (a) 
and (b) as follows:
(a) Validation using full length calculation
The main method by which the model and the computer programme MACROHOURS 
were validated, was by long hand calculation. The uncharged dextran F/P ratio and PVP 
L/P ratio parameters of best-fit for Model B were used to calculate the respective 
expressions and k n  for man (i.e. GFR = 125 ml/min, Vc = 5600 ml and
BFLR = 2ml/min) for a selected molecular radius value. The intercompartmental 
parameters k 2l, k u and k n were calculated for man whilst k m was set equal to zero i.e.
the case of no metabolism. The coefficients a3, a2, a t and a0 of the cubic equation 16 
given by equations , 17, 18, 19 and 19a respectively, were then calculated accordingly.
Equation 16 was then differentiated to give, 
df(x)  2
—-—  = 3n3x + 2a2x + a, 30
ax
d f { x )
which is a quadratic equation and which was then evaluated a t  = 0  for the
dx
selected molecular radius using the general equation for solving quadratic equations,
- B ± - J B 2 - 4 A C
x  = ------------------------  31
2 A
(where in this case A = 3a3 , B  = 2 a 2 and C  = n ,) to give two values of x, x n  and 
x T2 which represent the values of x  at which the two turning points of the curve given 
by equation 16 occur, i.e. the two turning points occur at (jcr , ,/(* > ,) )  and
i x T2 * f ( x T2 ))• To perform these calculations a small computer programme in BASIC 
was written called ’PAUL9* and which is presented in Appendix A4.1
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2.3.3 V alidation of the m odel and the com puter program m e
The physiological thrcc-compartment pharmacokinetic model and the computer 
programme MACROHOURS were validated in two ways which are described in parts (a) 
and (b) as follows:
(a) Validation using full length calculation
The main method by which the model and the computer programme MACROHOURS 
were validated, was by long hand calculation. The uncharged dextran F/P ratio and PVP 
L/P ratio parameters of best-fit for Model B were used to calculate the respective 
expressions k m  and k l2 for man (i.e. GFR =125 ml/min, Vc = 5600 ml and
BFLR -  2ml/min) for a selected molecular radius value. The intercompartmental 
parameters k 2], k n and k i} were calculated for man whilst k m was set equal to zero i.e.
the case of no metabolism. The coefficients a3, a2, a t and aQ of the cubic equation 16 
given by equations , 17, 18, 19 and 19a respectively, were then calculated accordingly.
Equation 16 was then differentiated to give, 
d f ( x )  ,
 = 3ct3x + 2  a 2x + a, 30
dx
d f ( x )which is a quadratic equation and which was then evaluated a t  = 0  for the
dx
selected molecular radius using the general equation for solving quadratic equations,
- B ± J b 2 - 4 A Cx  = ------------------------  31
2 A
(where in this case A = 3a l , B  = 2a 2 and C = c7 ,) to give two values of x,  x n  and 
x T2 which represent the values of x  at which the two turning points of the curve given 
by equation 16 occur, i.e. the two turning points occur at (x n , / ( x n )) and 
( XT2 > f ( x T2 ))• To Pcrform these calculations a small computer programme in BASIC
was written called ‘PAUL9' and which is presented in Appendix A4.1
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and so on, until eventually either f { x )  = 0 or more commonly | / M |  < I E - 14. When 
| / ( x ) |  < I E - 14 (the convergence limit), or indeed of course when f ( x )  = 0  then this
represents the first root of equation 16.
The first root was then removed from equation 16 using the process of long division so 
that equation 16 was reduced to a quadratic equation whose two roots could be 
calculated by hand using the general formula given by equation 31. The largest of these 
three roots is then assigned to be y the middle (next largest) root is assigned to be a, 
and the smallest root is assigned to be p.
This process was repeated for the uncharged macromolecules using the same baseline 
parameters and parameters of best-fit etc described above for man for molecular radii 
values of a = 20 A, 25 A, 30 A, 35 A and 40 A. The values of the three roots y, a and |J 
calculated in each case by this brute-force method were then compared to the 
corresponding respective roots y , a  and (} calculated by MACROHOURS for these 
selected uncharged molecular radii in the case of no metabolism. In each respective 
case the values of the roots agreed exactly, hence validating the numerical component 
of the programme MACROHOURS. For obvious reasons this time consuming validation
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method was only used for the afore-mentioned selected molecular radii and 
parameters.
(b) Validation using a collapsing method
The second way the model and the programme MACROHOURS were validated was to 
collapse the three-compartment pharmacokinetic model into a two-compartment 
pharmacokinetic model which had been developed at an earlier stage of the modelling 
process. The fractions of the dose predicted for a two-compartment model were 
calculated using Minsq [4411 in early studies and these could be compared with data 
calculated using MACROHOURS.
For example, the differential equations describing the physiological two-compartment 
pharmacokinetic model are as follows,
+ k excr)A P + k 2\A L 33.1
—j  ^= kl2Ap -k2]AL 33 2
which upon solving by the method of Laplace transforms (see appendix A5.2 for 
skeleton solution) gave,
A , {(*2, ~(k2l
Ap = ------------------7---------- t------------------  33.3
(* i - * 2)
D 0k n {e-” ‘ - e ' " ' ' )
A l = - 2 J t  \— '  3 3 '4(/r, - J t 2)
_  (^12 "*"^ 21 ^excr )  A l  ^tier )  ^ A 21Awhere K, =
1 2
(A,2 +  * 2, +  kacr)-yj(kn +k2l +kexJ2 -4k2ik, 
and 7T-, = -------------------------- -------------------------------------
33.5
33.6
with > k 2 > 0 33.7
so that A eum ~  A  — ~  33.8
, „  Da{ ( k n - K 2)e-*'’
and C P = -------------------- t---------- r----------------  33.9
V c i ^ - 7 1 , )
Hence in order to collapse the new physiological three-compartment pharmacokinetic 
model into equations 33.3, 33.4. 33.8 and 33.9 for the physiological two-compartment
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pharmacokinetic model, k u , k 3X and k m were entered in MACROHOURS as zero. The 
three roots then calculated by MACROHOURS would then have the largest root y being 
equivalent to the root Kx in the physiological two-compartment pharmacokinetic model, 
with the middle (next largest) root a  being equivalent to the root Jt2, and the smallest
(third) root would take a value of zero. The fractions of the dose predicted in the 
compartments AP, AL, AELIM and CP was then be compared in each case. This analysis was 
performed for uncharged macromolecules for the same molecular radii values, 
parameters of best-fit, and baseline parameters as used in validation (a), over a 
simulation time period from zero to 48 hours in 4 hour intervals. In each case the 
simulated results using MACROHOURS for the collapsed version of the new 
physiological three-compartment pharmacokinetic model agreed with the results 
calculated using Minsq [441] and the physiological two-compartment pharmacokinetic 
model.
A skeleton solution of both the physiological one and two compartment 
pharmacokinetic models which were developed as part of the modelling process is 
given in Appendix A5.1 and A5.2 respectively. A full solution and description is not 
given because; firstly, these two more simplified models of the body were not the main 
objectives of this study (although they were a necessary part of the modelling process 
for validation purposes), secondly, their solution by the method of Laplace transforms 
can in theory be extracted, by setting the appropriate parameters to zero, from the 
solution of the new physiological three-compartment pharmacokinetic model presented 
in Appendix A l. and thirdly, although they are physiological pharmacokinetic models, 
if the intercompartmental parameters are treated strictly as first-order rate constants 
rather than taking their assigned physiological values for each molecular radius value, 
then their solution follows the solution of classical one and two compartment 
pharmacokinetic models in the pharmacokinetic textbooks. The mathematical 
expressions developed for k ^ a n d  k ]2, and indeed k 2X, were first introduced and tested
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into these two more simple physiological pharmakokinetic models, as appropriate. 
Initial simulations were performed on Minsq [441].
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2.3.4 Conclusions
The novel physiological three-compartment pharmacokinetic model, with the associated 
computer programme MACROHOURS, represent the development of the model for 
macromolecular distribution, which was used in later experiments. The model was designed 
to predict via the simulation performed using MACROHOURS, the molecular radii which are 
most effective in getting the greatest fraction of a macromolecular drug into the target site, 
the lymph, and thus to any cancer micrometastases present there. In addition to predicting 
the fraction of the macromolecular drug dose present in the lymph, the new physiological 
three-compartment pharmacokinetic model will also predict for each molecular radius 
(within the range determined by the modelling process) the fractions of the dose present in 
the blood and the liver, and the fractions which have been excreted via the kidneys and 
metabolised by the liver, and the total fraction of the dose eliminated. The new 
physiological pharmacokinetic model is unique in that it predicts the fate of both protein 
and uncharged macromolecular drugs in the body, taking into account the different regional 
capillary permeability to different size macromolecules and the different physiology and 
flow rates. The model is also unique in that it enables calculation of the separate 
contributions of renal excretion and hepatic metabolism. The advantages and disadvantages 
of this new physiological three-compartment pharmacokinetic model over the key 
theoretical/predictive macromolecular anticancer drug and drug-targeting pharmacokinetic 
models in the literature are discussed in chapter 5.
115
Chapter 3




The aim of the simulations presented in this chapter was to examine the effect of 
molecular radius on the distribution of macromolecules in man, and hence to predict 
the molecular radii which are likely to be most effective in accessing the interstitial 
fluids. In addition to calculating the fraction of the macromolecular dose present in the 
lymph, the simulations were required to predict for each molecular radius, the fraction 
of the dose present in both the blood and the liver, and the fractions excreted 
unchanged via the kidneys, and metabolised (hepatically cleared) by the liver, as a 
function of time. This would allow the fate of a macromolecular drug dose in the body 
to be predicted for all molecular radii within the 20-70A range over any desired time 
period. Section 3.2 investigates the effect of molecular radius on the distribution of 
both protein and uncharged macromolecules in the absence of metabolism. In section 
3.3 the strategy for determining some realistic rates of metabolism is described, and 
these rates of metabolism are then used later in section 3.3 to investigate the effect of 
molecular radius on the distribution of macromolecules in the presence of metabolism. 
For these studies the lung was used as a model for tissues with continuous endothelia. 
In section 3.4 the data for L/P ratio in subcutaneous tissues was used to investigate the 
influence of more restrictive tissue endothelia on the predictions of pharmacokinetic 
distribution. Section 3.5 presents the main conclusions.
In each set of simulations the molecular radius was varied from 20A to 70A in intervals 
of 5A (and lA intervals in some cases) and distribution was simulated over 48 hours (4 
hour intervals), 240 hours (12 hour intervals), and in sections 3.2 and 3.4, 1008 hours 
(72 hour intervals). These time periods and intervals were found to be the most useful 
for examination of the overall trends. The raw datum generated from these simulations 
is given in Appendix B which is presented separately in lever-arch file form. The figures 
presented in this chapter have been selected to emphasize particular points. In some of 
these figures some early data time points (at 1 and 2 hours for the 48 hour simulations; 
at 1, 3 and 6 hours for the 240 hour simulations; and at 12, 24, 36 and 108 hours for
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the 1008 hour simulations) from other simulations performed in this study (given in 
Appendix B) have also been included to show the early profiles of disposition in more 
detail. The figures described in each of the subsections of this chapter are presented at 
the end of each subsection. All the simulations in this chapter are for a 70kg man and 
used the known or assigned physiological values which were presented in Chapter 2.
3,2 The effect of molecular radius on the distribution of protein and uncharged 
macromolecules in the absence of metabolism
3.2.1 Introduction
In this section the effect of molecular radius on the distribution of both protein and 
uncharged macromolecules in the absence of metabolism, i.e. km = 0 .0  m in 1, is studied. 
The simulations presented here can be thought of as representing the 'ideal case' for an 
inert macromolecular drug which is not metabolised by the liver such as 
polyoxyethylene. In practice proteins would be subject to metabolism in vivo, but it was 
useful to simulate their distribution in the hypothetical case of zero metabolism in 
preliminary studies. The respective protein and uncharged parameters of best-fit and 
the other baseline parameters used in this set of simulations are given in table 3.1. The 
simulated results are described and discussed in subsection 3.2.2, and a summary of 
the subsequent trends is presented in subsection 3.2.3.
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TABLE 3.1 The baseline param eters used in the simulations to investigate the effect of molecular radius on the distribution of protein 
and uncharged macromolecules in the absence of metabolism
D0 1 unit (dimensionless)
* excr <
GFR -  125 ml/ min 
Vc = 5600ml
and Model B withnfi]t -\,aofilt =17.486, kfiu =0.20941 for protein macromolecules
and/7^, = 2 =  17.612, =0.007333 for uncharged macromolecule
* 1 2 <
BLFR = 2 ml / min 
Vc = 5600 ml
and Model B with nfymph = 1 ,aol>wph = 13.558, klymph =0.010454 for protein macromolecules
and nfymph =\,aofymph =14.711, kfymph =0.019532 for uncharged macromolecules
*21
1.78571£-4min_1<
Plasma 4. . ,-------- filtration ratio = 1
Lymph
LFR = 2 ml/min 
VL = 11200ml
*13
2.57143£,- lm in '1
Liver_ j-1jtrat|on ratj0 _ j 
Plasma
Total blood flow rate to liver = 1440ml / min 
Vc = 5600ml
*31
2.57143 £0 min"1 <
Plasma _u 4. 4. .-------- filtration ratio = 1
Liver
Total blood flow rate from liver = 1440ml/ min 
VH = 560 ml
*„ 0.0 m in 1
3.2.2 Results and Discussion
The simulations for both the protein and uncharged macromolecules clearly predict the 
importance of molecular radius in determining the distribution of a macromolecular 
drug in the body. This is illustrated in figures 3.1 A.1 - 3.1 A.11 and 3.1 B.l - 3.1 B.4 for 
the protein macromolecules and figures 3.2 A.1 - 3.2A.11 and 3.2 B.l - 3.2 B.4 for the 
uncharged macromolecules. These figures show that although the absolute fractions of 
the dose in each of the blood, lymph and liver compartments and the fraction of the 
dose excreted are different for both macromolecule types (protein and uncharged), the 
common trend is that as the molecular radius increases there is a corresponding 
increase in the fraction of the dose accumulating in the lymph compartment, and a 
corresponding decreasing fraction of the dose being excreted. At high molecular radii 
the time taken for distribution to the lymph may be considerable, but as there is 
reduced excretion and no metabolism, the dose is predicted to accumulate in the 
interstitial fluids.
Figures 3.1A.1-3.1A.11 and 3.2A.l-3.2A.il each represent the fraction of dose in each 
compartment versus time for a particular molecular radius. The rapid plasma clearance 
of low molecular weight hydrophilic compounds (a=20-25A) is predicted due to 
extensive glomerular filtration, which is very much more rapid and dominant than 
lymphatic uptake for these smaller size macromolecules. The data are replotted to 
show the influence of molecular radius on the fraction of dose present in each 
compartment in figures 3.1B.1-3.1B.4 and 3.2B.1-3.2B.4. These plots are presented 
using an extended timescale in figures 3.3A-3.3D, 3.4A-3.4D, and 3.5A-3.5B.
In the absence of metabolism the largest macromolecule produced the greatest fraction 
of the dose in the blood and liver, and the smallest macromolecule produced the least 
fraction of the dose in these compartments, for the whole duration of the simulation 
period. Loss from these compartments can take place by excretion or uptake into the 
lymph, both of which are influenced by molecular radius. Since clearance by both
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mechanisms decreases as molacular radius increases, the overall plasma clearance 
must also decrease with increasing molecular radius. Consequently, as shown by 
figures 3.1B.4 and 3.2B.4 it is the smallest macromolecule which is also excreted most, 
and the largest macromolecule which is excreted least, for the whole duration of the 
simulation period. However, as shown by figures 3.1 B.2 and 3.2 B.2, although the 
ultimate fraction of the dose in the lymph does increase with increasing molecular 
radius, the accumulation of large molecules in the lymph can take a considerable time 
so that over the first few days the highest levels in the lymph are provided by 
intermediate molecular radii 45A-50A, rather than the macromolecule with the largest 
molecular radius.
Figures 3.1B.4 and 3.2B.4 emphasise the role of hydrodynamic radius in determining 
the rate of excretion of protein and uncharged molecules. At 25A, 90.2% of the dose for 
the protein macromolecules and 98.3% of the dose for the uncharged molecules is 
excreted within 1 2  hours, but when the radius is doubled to 40A, less than 11.3% and 
29% of the dose respectively is excreted in the same period.
The trends outlined above are due to the fact that as the molecular radius increases it 
becomes more difficult for the macromolecules to pass through the capillary 
membranes (extravasate) from the blood into the lymph, and from the blood into the 
kidney glomerulus (these rates of movement being modelled and controlled by the 
expressions for k n and k excr respectively, as described in Chapter 2). However there is a
differential effect, the glomeruli being less permeable to large molecules. At a 
molecular radius of 55A and greater (as shown by figures 3.1 A.7 and 3.1 B.4 for the 
protein macromolecules and figures 3.2 A.7 and 3.2 B.4 for the uncharged 
macromolecules), excretion becomes almost insignificant and uptake into the lymph 
becomes the only mechanism causing loss from the blood and liver compartments. 
(Most literature sources report the glomerular filtrate cut-off somewhere between radii 
45-60A radius [333-339]). The greater fractions of the dose observed in the lymph for 
the larger macromolecules can be explained by the greater fractions of the dose in the
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blood compartment for these sizes, since these macromolecules are either at or above 
the size of the renal threshold, and are therefore excreted very slowly or not at all, and 
so remain in the blood much longer than the rapidly excreted smaller macromolecules 
(the k 2] parameter models and controls the rate of return back to the blood from the
lymph, and is the same for all radii).
Figures 3.1 B.3 for the protein macromolecules and 3.2 B.3 for the uncharged 
macromolecules indicate that there is never greater than 1 0 % of the macromolecular 
dose in the liver at any one time. This is due to the greater size of k 3x in relation to k X3 
(k3x is ten times greater than k X3 since VH is one-tenth the size of Vc), so once the
macromolecule has equilibrated between the blood and the liver (rate determined by 
k x3), the overall mass transfer to and from the liver is equivalent. This can be explained
since the net blood flow rates, i.e. the total blood flow rates to and from the liver, are 
the same. This rapid distribution between the blood and the liver reflects the relative 
ease with which even the largest macromolecules pass out of the discontinuous 
capillary membranes from the blood into the liver sinusoids and back again, and is the 
reason why in most 'classical pharmacokinetic models' the liver is included as part of 
the central compartment. Since equilibration between the blood and liver is rapid, this 
explains why the peak fraction of the dose in the liver occurs at short times irrespective 
of molecular radius. Although the graphs do not show the period between 0 and 1 hour 
in detail, the peak fraction of the dose in the liver will in fact be 1 0 % of the dose very 
soon after intravenous injection because VH is one-tenth the size of Vc and k x3 is high.
Hence the peak time for the liver fraction will always be short and will always occur 
very soon after an i.v. bolus.
The net effect of the above distribution phenomena is that the larger macromolecules 
remain within the whole system much longer than smaller sized macromolecules. The 
smallest macromolecules (a < 2 5A) are transfered from blood to lymph much faster 
than the larger macromolecules but are lost from the system via excretion before they 
even have a chance to accumulate significant amounts in the lymph. Hence it is the
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radii within an intermediate size range of 45-50A which tend to produce the greatest 
fraction of the macromolecular dose in the lymph over the first few days. However in 
the absence of metabolism, as excretion is the only form of elimination, the larger 
macromolecules (i.e. >55A) are cleared very slowly and eventually accumulate in the 
lymph to high levels.
Figure 3.1 B.2 for the protein macromolecules shows that at the end of the 48 hour 
period significant amounts of the macromolecular drug dose have accumulated in the 
lymph for molecular radii 40A and greater. At 48 hours we see that between 30-37% of 
the dose is in the lymph for molecular radii 40A and greater, and that the fraction of 
the dose in the lymph is in fact still increasing for molecular radii 35A and greater. 
Figure 3.1 B.2  also shows that over about the first 40 hours a molecular radius of 45A 
produces the greatest fraction of the dose in the lymph, but from about 40 hours 
onwards to the end of the 48 hour simulation time it is molecules of 50A which do so. 
This trend is also shown in figure 3.2 B.2 to be similar for the uncharged 
macromolecules. Figure 3.2 B.2 shows that at the end of the 48 hour period significant 
amounts of the macromolecular drug dose have accumulated in the lymph for 
molecular radii 40A and greater (between about 20-30% of the dose for radii greater 
than 4 5A) and that the fraction of the dose in the lymph is still increasing for molecular 
radii 40A and greater. For uncharged molecules excretion of molecules with a < 35A is
considerable and at a = 35A the uncharged species would be expected to have different 
pharmacokinetics to negatively charged proteins (figs. 3.1 B.2 and 3.2B.2).
Both figures 3.1 B.2 and 3.2 B.2 show that there is a clear 'band of curves' of molecular 
radii 45A-70A producing significant fractions of the macromolecular dose in the lymph, 
with the intermediate radii sizes 45A - 50A producing the greatest fractions there at 
any one time. The figures also show that although a macromolecule of radius 40A is in 
amongst the most effective radii sizes, in the unlikely case of a total absence of 
metabolism and over longer time periods, 40A becomes less effective, being excreted 
more rapidly and thus cleared from the tissues after extended time periods. Figures 3.1
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B.2 and 3.2 B.2 also show that when comparing protein molecular radii with the same 
size uncharged molecular radii, the fraction of the dose present in the lymph is greater 
for the protein macromolecules than the uncharged macromolecules over the 48 hour 
period. This is mainly due to the effect of the dominant negative charge within the 
glomerular basement membrane of the kidney which repels negative or similarly 
charged molecules, i.e. proteins, thus reducing their rates of renal excretion and 
consequently increasing their blood circulation times so that they have a better chance 
of extravasating into the lymph than the relatively more quickly excreted uncharged 
molecules of the same size. Thus a macromolecular drug which is uncharged should be 
selected using different criteria. The figures also illustrate the fact that in the absence 
of metabolism the fraction of the dose present in the lymph over 48 hours has only 
reached a peak for the smaller macromolecules. Therefore simulations over longer time 
periods were performed (figures 3.3A-D and 3.4A-D).
Figure 3.3 B for the protein macromolecules shows that at the end of a 240 hour 
simulation period the fraction of the dose in the lymph was still increasing for 
molecular radii 60A and greater, and shows that over the first 40 hours a molecular 
radius of 45A produced the greatest fraction of the dose in the lymph. From about 40 
to 72 hours a molecular radius of 50A produced highest levels (as indicated by figure
3.1 B.2 over 48 hours), and from about 72-204 hours a molecular radius of 55A 
produced the greatest fraction of the dose in the lymph. At 240 hours the largest mass 
in the lymph (51.6% of the dose) was produced by a molecular radius of 60A. Thus in 
the extreme case of a totally inert molecule which is not subject to metabolism the 
largest molecules would ultimately have a moderate advantage over intermediate sized 
molecules. Figure 3.4B shows similar predictions for uncharged polymers where from 
about 204 hours onwards to the end of the 240 hour period, the highest mass in the 
lymph was provided by a molecular radius of 55A (44.6% of the dose in the lymph at 
240 hours).
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An interesting point suggested by the simulations over each of the chosen time periods 
which is worth noting (shown by figures 3.3 A-3.31) and 3.4 A- 3.4 D for example), is 
that in the absence of metabolism if proteins are compared with uncharged molecules 
of the same size, we see that for radii less than 4 5A, the fraction of the dose found in 
the blood and the liver compartments is greater for the protein macromolecules than 
the uncharged macromolecules over most times. However for molecular radii 45A and 
greater the fraction of the dose found in the blood and liver compartments is less for 
proteins than uncharged macromolecules. For molecular radii less than 50A 
(simulations over 48 hours in lA intervals found the exact radius to be 47A), the 
fraction of the dose excreted is greater for the uncharged molecules than proteins, but 
then for molecular radii 47A and greater the fraction of the dose excreted is less for the 
uncharged macromolecules than the proteins. Also at a molecular radius of about 45A 
(simulations over 48 hours found the exact radius to be 44A), in the absence of 
metabolism, the fractions of the dose in the blood and liver compartments are almost 
equal for both the protein and uncharged macromolecules at most times.
One possible explanation for the above pattern for macromolecules of molecular radius 
20A to 45-47A may be that since excretion via the kidneys is the only form of 
elimination, the influence of charge has a large effect on the plasma clearance, proteins 
being retained by the repulsive interactions with fenestrated endothelia of the 
glomerulus. But once the macromolecules have reached the size when excretion 
becomes less prevalent (most literature reports this as being somewhere between 45- 
60A [333-339]), the effect of the negative charge within the glomerular basement 
membrane is not so important and other factors begin to play a more dominant role. 
The simulations suggest that the larger uncharged macromolecules (>50A radius) are 
not excreted as quickly as the larger protein macromolecules of the same radius. These 
phenomena also play a part even in the presence of metabolism. The simulations in 
sections 3.3 and 3.4 will show that for each of the chosen rates of metabolism the 
above pattern is generally repeated over either all (in the case of the slowest rate of
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metabolism) or at least some of the simulation time period, and that when metabolism 
occurs the fraction of the dose metabolised is also greater for the protein 
macromolecules than the uncharged macromolecules for all radii less than 4 5A. This is 
presumably since there is a larger mass in the liver pool to be metabolised. For all radii 
45A and greater uncharged macromolecules are predicted to be metabolised most.
To conclude this section on the simulations in the absence of metabolism, figures 3.5 A 
and 3.5 B for the fraction of the macromolecular dose in the lymph for the protein and 
uncharged macromolecules respectively and which represent the simulations over the 
longest chosen time period (1008 hours), also illustrate the trends outlined earlier.
Figure 3.5 A shows that for proteins by the end of the 1008 hour period the fraction of 
the dose in the lymph had reached a peak and started to decline again for all radii 70A 
and less, and that the greatest mass in the lymph at any one time occurred at a 
molecular radius of 60A. Simulations in lA intervals found the optimum radius to be 
58A, producing 51.6% of the dose in the lymph at about 216 hours. At the end of the 
1008 hour period a molecular radius of 65A resulted in the most drug left in the 
lymph, i.e. about 50% of the dose (simulations in lA intervals found the exact radius to 
be 66A, giving 50.1% of the dose there at 1008 hours). Similarly figure 3.5 B for the 
uncharged macromolecules showed a similar picture. The optimum molecular radius 
was about 55A, i.e. about 45% of the dose in the lymph at 288 hours (simulations in lA 
intervals found the optimum radius to be 53A, giving 45.2% in the lymph at about 288 
hours). At 1008 hours a molecular radius of 55A gave the greatest fraction of the dose 
in the lymph, 44.2%.
Figures 3.5 A and 3.5 B predict that for uncharged molecules the intermediate size 
macromolecules (a = 55-60A) are the most effective in getting the greatest fraction of 
the dose to the lymph at all times. For proteins, 60-65A radii become more effective 
towards the end of this very long time period.
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The simulations over 1008 hours enabled the molecular radii which produced the 
greatest peak fraction of the dose at any one time in the lymph in the absence of 
metabolism to be discovered for both the protein and uncharged macromolecules, i.e. 
radii 58A and 53A respectively. In reality all macromolecular drugs are probably 
metabolised in some way and these cases are considered in section 3.3. However it is 
useful to understand the behaviour of hypothetical inert macromolecules so that the 
influence of metabolism can be appreciated when introduced.
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Figures 3.1 A. 1-3.1 A.11
The effect of m olecular radius on the d istribu tion  of protein m acromolecules in the body 
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Figures 3 .IB. 1-3.1 B.4
The effect of molecular radius on the distribution of protein macromolecules in the body 
over 48 hours in the absence of metabolism
3.1 B.l 3.1B.2
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The effect of molecular radius on the distribution of uncharged macromolecules in the 
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Figures 3.5A and 3.5B
The effect of molecular radius on the distribution of protein (figure 3.5A) and uncharged 
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This set of simulations investigated the effect of molecular radius on the distribution of 
both protein and uncharged macromolecules in the body in the absence of metabolism. 
This set of simulations therefore represented the best or 'ideal case' since a 
macromolecular drug which is not metabolised will remain in the body longer than a 
macromolecular drug which is metabolised, and will therefore be more likely to get a 
greater fraction of its dose into the lymph, the target. The simulations in the absence of 
metabolism illustrated the following trends over each of the chosen simulation time 
periods:
• Although the actual fractions of the dose in each of the blood, lymph and liver 
compartments and the fraction of the dose excreted are different for both the 
protein macromolecules and the uncharged macromolecules, the trend is that as the 
molecular radius increases there is a corresponding increasing fraction of the dose 
found in each of the blood, lymph and liver compartments, and a corresponding 
decreasing fraction of the dose being excreted. With regard to the blood and the 
liver compartments, the largest macromolecule produces the greatest fraction of the 
dose, and the smallest macromolecule produces the lowest fraction of the dose, in 
these compartments for the whole of each of the simulation time periods. In the 
case of the fraction of the dose excreted, the largest macromolecule is excreted 
slowest, and the smallest macromolecule is excreted most rapidly, for the whole of 
each of the simulation time periods.
• Although the fraction of the dose in the lymph does increase with increasing 
molecular radius for both the protein and uncharged macromolecules, the general 
tendency is that it is not the largest molecular radius which produces the greatest 
fraction of the dose in the lymph over the first few days, but generally the 
intermediate size molecular radii (a = 5 5A) that do so.
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• There is a clear group of macromolecules of radii 45A-70A producing significant 
fractions of the dose in the lymph for both the protein and uncharged 
macromolecules.
• The biological half-lives increase with increasing molecular radius for both classes 
of macromolecule.
• If proteins are compared with uncharged molecules of the same hydrodynamic 
radius then the proteins will almost always produce a greater fraction of the dose in 
the lymph than the uncharged macromolecules.
The simulations in the absence of metabolism therefore suggest that the best size 
candidates to deliver the greatest fraction of the dose to the lymph are macromolecules 
within the intermediate 45-55A molecular radii range, with the lower intermediate size 
molecular radii being the most effective over early times and the larger intermediate 
size molecular radii tending to be the more successful at the later times. In the case of 
protein macromolecules which are not subject to metabolism, significant tissue uptake 
will occur with sizes up to 65A radius over very long time periods. In the absence of 
metabolism the theoretical highest peak fractions possible occur at molecular radii 60A 
and 5 5A for the protein and uncharged macromolecules respectively.
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3.3 The effect of molecular radius on the distribution of protein and uncharged
macromolecules in the presence of metabolism
3.3.1 Introduction
In this section the effect of molecular radius on the distribution of both protein and 
uncharged macromolecules in the presence of metabolism (hepatic clearance) is 
studied. In subsection 3.3.2 the choice of some realistic rates of metabolism is 
discussed. These rates of metabolism are then used throughout the rest of subsection
3 .3 .2  to investigate the effect of molecular radius on the distribution of both protein 
and uncharged macromolecules, with particular attention on the fraction of the 
macromolecular dose present in the lymph. A summary of the subsequent trends and 
conclusions shown in subsection 3.3.2 is then given in subsection 3.3.3.
As outlined in Chapter 2, the physiological three compartment model presented here 
assumes that the first order rate of metabolism refers to the rate at which a
macromolecule is hepatically cleared (eliminated) by the liver and lost from the system 
altogether. In relation to a particular macromolecular prodrug this could be estimated 
from known experimental data, but in the absence of particular data the approach 
taken here was to study a range of k m values which is expected to span a realistic
range.
3.3.2 Results and Discussion
In an effort to determine some realistic rates of metabolism initial simulations were 
performed using the following choices of k m: 0.001 m in 1, 0.003 m in 1, 0.01 m in 1,
0.03 m in 1 and 0.1 m in 1, which represent the following half-life times of the
macromolecule in the liver; 11 hrs 33 mins, 3 hrs 51 mins, 1 hr 9.3 mins, 23.1 mins and
6.93 mins, where t x/ = 0-693  is the half-life of the macromolecule in the liver
/2 k m
compartment. Initial simulations were performed for molecular radii 40A and 60A for 
both the protein and uncharged macromolecules over 48 hours (4 hour intervals). 
Molecular radii 40A and 60A were chosen because as a result of the simulations over
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each time period in section 3.2, they appeared to represent the lower and upper limits 
of molecular radii between which the most interesting trends were observed. This was 
particularly true of the lymph, where at a molecular radius of about 40A and greater 
significant fractions of the dose were beginning to accumulate in the lymph, and by 
about 60A the fraction of the dose there had reached levels close to the maximum 
observed. A time period of 48 hours was chosen since it was one of the best time 
periods to depict the overall trends in pharmacokinetic distribution.
Initial simulations over 48 hours for both the protein and uncharged macromolecules at 
either radius (40A and 60A) revealed that the two faster rates of metabolism (0.03 m in 1 
and 0 .1  m in 1) were so fast that they were probably not relevant for use in future 
simulations since most of the macromolecular drug dose, even for the larger molecular 
radius of 60A, was eliminated before it even had a chance to distribute to the tissues. 
This is clearly illustrated by figures 3.6 A.l-3.6 A.5 and 3.6 B.l-3.6 B.5 for the protein 
macromolecules for each of the five values of k m. (The corresponding figures for the
uncharged macromolacules are not shown since they are very similar, as indicated by 
the raw simulated data presented in Appendix B.) Thus a macromolecular prodrug with 
k m > 0 .0 1  m in 1 would have very poor access to the interstitial fluids.
For future work three metabolic rates were chosen; 0.001 m in 1, 0.003 m in 1 and 0.01 
m in 1 , which spanned the range over which the significance of metabolism changed 
from low to high. Simulations were performed for both the protein and uncharged 
macromolecules over both 48 hours and 240 hours for each of the three rates of A: form
molecular radii 20-70A in 5A intervals.
Figures 3.7 A.l-3.7 A.6  and 3.7 B.l-3.7 B.6  for the protein macromolecules with k m 
equal to 0.003 m in 1 and 0.01 min ' 1 respectively for example, show that even in the 
presence of metabolism, the general trend over a considerable time span is that as the 
molecular radius increases there is a corresponding increasing fraction of the dose 
found in the blood, lymph and liver compartments, with a corresponding decreasing
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fraction of the dose being excreted, though now a significant fraction of the dose is also 
being metabolised.
Clearly, comparing molecular radii for the slower rate of k m (0.003 m in 1) with the 
corresponding molecular radii at the faster rate of k m (0 .0 1  m in 1), then the absolute
fractions of the dose in each respective compartment are different for each rate of 
metabolism. An increase in k m results in a corresponding decreasing fraction of the
dose in the body overall since the total elimination half life is decreased. However, as in 
the absence of metabolism, the general trend, which occurs in the presence of 
metabolism, is that the largest macromolecule produces the greatest fraction of the 
dose in the circulation, and the smallest macromolecule produces the least fraction of 
the dose in the blood and liver compartments. As a result, the fraction of the dose 
metabolised by the liver is highest for the largest macromolecule and lowest for the 
smallest macromolecule. Thus excretion is a major factor in pharmacokinetics of 
macromolecules when k m < 0.01 m in 1. The renal clearance is avoided by increasing
molecular radius until the molecules are too large to excrete in significant amounts. In 
summary, the larger macromolecules stay within the whole system much longer than 
the smaller macromolecules, though the fact that discontinuous capillaries are found in 
the liver allowing easy movement of large macromolecules from the blood to the liver, 
means that larger macromolecules are more available for metabolism. Distribution of 
the large macromolecules will be critically influenced by metabolic rate.
Most importantly, both figures 3.7 A.l-3.7 A.6  and 3.7 B.l-3.7 B.6  illustrate that the 
fraction of the dose reaching the lymph increases with molecular radius size, up to 
intermediate radii of about 50A. However in the presence of metabolism further 
increases in radius (a > 60A) reduce the effective fraction and duration of the dose 
reaching the lymph compartment. Thus in the presence of metabolism, in a realistic 
model, it can be anticipated that there will be an optimum molecular radius for uptake 
into the tissues. The optimum will be the intermediate size molecular radii (45-55A ),
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with the lower of these intermediate sizes being more successful over the shorter times 
(the exact radii for these observations are given later).
In summary, the general trends illustrated and described in section 3.2 appear to be 
well established even in the presence of metabolism. The corresponding figures in this 
set of simulations for uncharged macromolecules are not presented because the trend 
is well established for both macromolecule types (data are available in Appendix B).
To conclude this section on the simulations in the presence of metabolism, figures 
3.8A-3.8C and 3.9A-3.9C examine closely the fraction of the macromolecular drug dose 
in the lymph for both the protein and uncharged macromolecules for each of the 
respective three chosen k m rates. These sets of simulations over 240 hours are from a
practical point of view the most useful and emphasize the trends already indicated 
earlier.
Figures 3.8A-3.8C and figures 3.9A-3.9C show that as the rate of metabolism increases 
then the absolute fraction of the dose in the lymph at any time decreases for each 
molecular radius. For each rate of metabolism the fraction of the dose in the lymph has 
peaked for each radius within the 240 hour period, with the peaks occurring at 
increasingly earlier times as k m increases.
Figure 3.8A for the protein macromolecules with &m=0.001 m in 1 (the slowest of the 
three chosen rates of metabolism) shows that over about the first 42 hours a molecular 
radius of 45A produces the greatest fraction of the dose in the lymph, then from about 
42-96 hours a radius of 50A does so. From about 96 hours onwards to the end of the 
240 hour period a molecular radius of 55A is most effective. There is a clear 'band of 
curves' for molecular radii 45-70A producing significant fractions of the dose in the 
lymph, with time to peak fraction occurring at roughly the same time. Radii greater 
than 5 5 A peak at approximately 108 hours, radii 45A and 50A peak at 84 hours and 96 
hours respectively. Figure 3.8A shows that the greatest peak fraction of the dose in the 
lymph at £^=0.001 m in 1 occurs at a molecular radius of 55A (37.196 of the dose at 96
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hours), and that the greatest m ass of drug in the lymph after the 240 hour period also
occurs at a radius of 55A (29.1% of the dose).
Figure 3.8B for the protein macromolecules with &m=0.003 m in 1 shows a similar 'band 
of curves' for molecular radii 45-70A producing significant fractions of the dose in the 
lymph, with a molecular radius of 40A also achieving high levels at earlier times (over 
the first 60 hours). For this slightly faster rate of metabolism, over about the first 40 
hours a molecular radius of 45A gives the greatest fraction of the dose in the lymph, 
then from about 40-132 hours a molecular radius of 50A was most effective. From 132 
hours to the end of the 240 hour period a molecular radius of 55A was optimal. The 
molecular radius of 50A produces the greatest peak fraction of the dose in the lymph 
(26.4% of the dose at 60 hours). The largest fraction of drug in the lymph at the end of 
the 240 hour period was achieved at 55A (12.3% of the dose). Again the time to peak 
within this band of curves occurred at about the same time, 60 hours, with a radius of 
40A producing an earlier peak at about 48 hours. Simulations in lA intervals revealed 
the exact radius which produces the greatest fraction of the dose in the lymph to be 
49A (26.4% of the dose at 60 hours). The greatest fraction left in the lymph at 240 
hours occurred at a radius of 53A (12.3% of the dose). Therefore since the special case 
simulations in lA intervals in section 3.2 found the greatest fraction of the dose in the 
lymph in the ideal case (km=0.0 m in 1) to occur at a radius of 58A, then this suggests
that the greatest fraction of the dose in the lymph at any one time will not occur at 
exactly the same radius for each different rate of metabolism, but instead lies within 
this intermediate size band.
Figure 3.8C for the protein macromolecules with £m=0.01 m in 1 (the fastest of the three 
chosen k m rates) is perhaps the most interesting of the three figures because in addition 
to the trends outlined above, we now see that for this relatively fast rate of k m, even 
molecular radii as small as 35A are also becoming effective over early times in 
producing significant fractions of the macromolecular dose in the lymph. Though the 
absolute fractions reaching the lymph are substantially reduced at this metabolic rate.
143
Consequently for this faster rate of metabolism the 'band of curves' producing 
significant fractions of the dose in the lymph now corresponds to molecular radii 35- 
70A with a molecular radius of 35A being relatively successful over about the first 36 
hours and then falling away gradually over the rest of the time period. The peak 
fractions of the dose in the lymph for each radius within this 'band of curves' once 
again occur at about the same time, 32 hours, except for the radius of 35A which peaks 
earlier at about 28 hours. Figure 3.8C shows that over about the first 16 hours a 
molecular radius of 40A produces the most drug in the lymph, then from about 16-108 
hours it is a radius of 45A doing so, and from 108-240 hours there is little to choose 
between the radii 45A and 50A, although the molecular radius of 45A has the highest 
mass left in the lymph at the end of the 240 hour period (2.8% of the dose). The 
greatest peak fraction of the dose present in the lymph occurs at a molecular radius of 
45A (14.2% of the dose at 36 hours). Simulations in lA intervals in this case found the 
radius producing the greatest peak fraction of the dose in the lymph to be 4 5A, with 
47A having the greatest fraction left at the end of the 240 hour period.
The analysis shows that as the metabolic rate increases, the optimum radius for 
interstitial distribution decreases. This illustrates the complex relationship between 
distribution and molecular radius which is usefully modelled here.
Similar trends are illustrated in figures 3.9A-3.9C for the uncharged macromolecules 
for each of the three rates of metabolism. For almost all of the 240 hour period it is the 
intermediate size molecular radii 45A and 50A which produce the greatest fraction of 
the macromolecular drug dose in the lymph. In each figure the 'band of curves' 
producing the most significant fractions of the dose in the lymph once again occurs for 
molecular radii 45-70A with a molecular radius of 40A also in amongst this band in the 
case of the fastest k m rate (&m=0.01 m in 1). Also, once again, the peak fractions of the 
dose for the radii within this 'band of curves' for each respective k m rate appear to 
occur at approximately the same time, at about 108 hours for £m=0.001 m in 1 (with a 
radius of 45A peaking slightly earlier at about 84 hours), at about 72 hours for
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k m=0.003 m in 1 (with a radius of 45A again peaking slightly earlier at about 60 hours), 
and at about 36 hours for £m=0.001 m in 1 (with a radius of 40A peaking slightly earlier 
at about 28 hours). Interestingly, these times for each k m rate for the uncharged
macromolecules are very similar to the corresponding peak times for the protein 
macromolecules, especially in the cases of A:m=0.001 m in 1 and £m=0.01 m in 1. This
suggests that these are robust estimates of peak time, since the intercompartmental 
rate constants for proteins and uncharged polymers are quite different due to 
difference in molecular charge.
Figure 3.9A for the uncharged macromolecules with £m=0.001 min*1 shows that over 
about the first 40 hours a molecular radius of 45A gives the greatest fraction of the 
dose in the lymph, but from about 40 hours to the end of the 240 hour time period a 
molecular radius of 50A is most effective. Figure 3.9A also shows that a molecular 
radius of 50A produces the greatest peak fraction of the dose in the lymph (31.1% of 
the dose at 108 hours), and that the greatest fraction of the dose present in the lymph 
at the end of the 240 hour period also occurs for a radius of 50A (24.1% of the dose).
Similarly, figure 3.9B for the uncharged macromolecules with £m=0.003 m in 1 shows 
that over about the first 44 hours a molecular radius of 45A gives the greatest fraction 
of the dose in the lymph, but from about 44 hours to the end of the 240 hour period 
once again a molecular radius of 50A is optimal. Figure 3.9 B shows that once again a 
molecular radius of 50A produces the greatest peak fractions of the dose in the lymph 
(21.1% of the dose at 72 hours), and that the greatest fraction of the dose left in the 
lymph at the end of the 240 hour period occurred at a radius of 50A (9.5% of the dose).
Finally, figure 3.9 C for the uncharged macromolecules with £m=0.01 m in 1 shows that a 
molecular radius of 45A produces the greatest fraction of the dose in the lymph for 
almost all of the 240 hour period, except for about the first 4 hours, which sees a 
radius of 40A doing so. Correspondingly figure 3.9 C shows that a molecular radius of 
45A produces the greatest peak fraction of the dose in the lymph (1 1 .1% of the dose at
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36 hours), and that the greatest fraction of the dose left in the lymph at the end of the
240 hour period also occurs for a radius of 45A (2.1% of the dose).
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Figures 3.6A.1-3.6A.5 and 3.6B.1-3.6B.5
The effect of the five different k ni rates on the distribution of protein macromolecules of 
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Figures 3.7A.1-3.7A.6 and 3.7B.1-3.7B.6
The effect of molecular radius on the distribution of protein macromolecules in the body 
over 48 hours for k equal to 0.003 min 1 and 0.01 m in 1 respectively
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Figures 3.8A-3.8C
The effect of molecular radius on the distribution of protein macromolecules in the 
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Figures 9A-9C
The effect of molecular radius on the distribution of uncharged macromolecules in the 
lymph over 240 hours for each of the three chosen k m values.
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3.3.3 Conclusions
This set of simulations investigated the effect of molecular radius on the distribution of 
protein and uncharged macromolecules in the body in the presence of metabolism. The 
trends illustrated were as follows:
• Although the absolute fractions of the macromolecular drug in each of the blood, 
lymph and liver compartments and the fractions of the dose excreted and 
metabolised are different for each type of macromolecule and for each k m rate, 
some general trends are evident. Increase in k m results in a corresponding decrease
in the fraction of the dose in the body overall since more drug is being eliminated. 
For each k m rate as the molecular radius increases there is a corresponding
increasing fraction of the dose found in each of the blood and liver compartments, 
as a result of the decreasing fraction of the dose being excreted. The fraction of 
dose reaching the lymph is influenced by the balance between extravasation and 
elimination, with intermediate radii producing the highest levels of lymphatic 
distribution.
• Although the fraction of the dose in the lymph does increase with increasing 
molecular radius for both macromolecule types, with increasing k m rates resulting
in a corresponding decreasing fraction of the dose in the lymph, the general trend is 
that it is not the largest molecular radius which produces the greatest fraction of 
the dose in the lymph, but is in fact the more intermediate sizes 40/45-50/55A that 
do so, with the lower intermediate sizes being more successful over earlier times 
and at faster k m rates, and the larger intermediate size molecular tending to become 
more optimal over the later times and at slower k m rates. As the rate of metabolism
increases then the actual fraction of the dose found in the lymph decreases when 
comparing the same molecular radii at different k m rates. The peaks for each radius 
occur earlier as k m increases (all radii for each k m rate having reached a peak within 
the 240 hour period).
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• A distinct group of radii 40/45-70A produce significant fractions of the dose in the
lymph for both the protein and uncharged macromolecules at each k m rate.
• The blood half-lives increase with increasing molecular radius for both 
macromolecule types but decrease with each increasing k m rate, the smallest
macromolecule having the most rapid distribution and elimination phases 
(becoming faster as the k m increases), and the largest macromolecule having the 
slowest distribution and elimination phase (becoming faster as k m increases).
• If protein molecular radii are compared with uncharged molecular radii of the 
same size for each k m rate then the protein macromolecular drugs will always
produce a greater fraction of the dose in the lymph than the uncharged 
macromolecular drugs.
The simulations therefore show that the general trends outlined in section 3.2 also 
occur in the presence of metabolism as well. They predict that for a macromolecular 
drug which is metabolised then the best size candidates to produce the greatest 
fraction of the dose in the lymph appear to be macromolecules with radii within the 
intermediate 40/4 5-50/5 5A size band, with the 4 0 /4 5A sizes being more successful 
over earlier times, and faster k m rates, and the larger 50/5 5A sizes being the more 
successful over the later times and slower k m rates. The simulations suggest that for a 
macromolecular drug which is metabolised very quickly then molecular radii as small 
as 35A can also be effective in getting a significant fraction of the dose in the lymph at 
early times.
3.4 The effect of molecular radius on the distribution of the uncharged 
macromolecules, with and without metabolism, using the more restrictive 
subcutaneous skin L/P ratio parameters of best-fit.
3.4.1 Introduction
In this comparatively shorter but nevertheless important section, the effect of 
molecular radius on the distribution of the uncharged macromolecules using the more
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restrictive subcutaneous skin L/P ratio parameters of best-fit is discussed. The purpose 
of this work was to determine if the trends already observed in sections 3.2 and 3.3 are 
repeated, and what difference, if any, results from using L/P ratio data from this 
different (more restrictive) tissue type. This was expected to shed light on the likely 
accuracy of the simulations in 3.2 and 3.3 by deliberately varying distribution 
parameters. As outlined in Chapter 2 the uncharged subcutaneous skin L/P ratio data 
[372, 373, 410] was also used here because it represented the best of the rest of the 
available data. Consequently the simulations in this section are performed over the 
same time periods as those in sections 3.2 and 3.3, with and without metabolism, also 
using the same k m rates as before (0.0 m in 1, 0.001 m in 1, 0.003 min*1, 0.01 m in 1). The
parameters of best-fit and the other baseline parameters used in this section are given 
in table 3.2.
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TABLE 3.2 The baseline parameters used in the simulations to investigate the effect of molecular radius on the distribution of
uncharged macromolecules (in the absence and presence of metabolism) using the more restrictive L/P ratio parameters of 
best-fit.
A ) 1 unit (dimensionless)
k excr
GFR = 125 ml /  min 
Vc = 5600  ml
and Model B with nfllt = 2,aom = 17.612 ,fc„„  = 0 .0 0 7 3 3 3
kn
BLFR = 2ml /  min 
Vc = 5600ml
and Model B with nfymph = 1, aofymph = 13.092, = 0.05492
*21
1.78571.E '-4m in'l <
Plasma .
------------ filtration ratio =  1
Lymph
LFR =  2 ml /  min 
VL =  11200ml
*13
2 .5 7 1 4 3 E -lm in '1
- |jver filtration ratio = 1 
Plasma
Total blood flow rate to liver = 1440m l /  min 
Vc = 5600m l
*31
2.57143 £ 0  m in -1
Plasma f .lk .
-----------  filtration ratio = 1Liver
Total blood flow rate from liver = 1440 ml /  min 
VH = 560 ml
*m 0.0 m in 1 , 0.001 m in 1, 0.003 m in 1, 0.01 m in 1
3.4.2 Results and Discussion
The raw simulated data (presented in Appendix B) for each set of simulations for each 
k m rate over each time period once again showed (as in sections 3.2 and 3.3) that
although the actual fractions of the dose in each of the blood, lymph and liver 
compartments, and the fractions of the dose excreted and metabolised are different for 
each k m rate, with increasing k m rates resulting in a decreasing fraction of the dose in 
the body overall, the general trend for each k m rate was again that as the molecular 
radius increases there is a corresponding increasing fraction of the dose found in each 
of the blood, lymph and liver compartments, and a decreasing fraction of the dose 
being excreted. Excretion once again becomes almost insignificant at radii 55A and 
greater. The more restrictive subcutaneous skin L/P ratios mean that every 
macromolecule, including the smaller molecular radii, are taking comparatively longer 
to get out of the continuous blood capillaries into the lymph, and so are more likely to 
be excreted or transfered into the liver to be metabolised. Hence, if we compare 
molecular radii in this subcutaneous skin case for each k m rate with the corresponding 
same size uncharged molecular radii in sections 3.2 and 3.3 for each k m rate, we see 
that in the subcutaneous skin case the fractions of the dose in the blood (and therefore 
the blood half-lives) are greater, the fractions of the dose in the lymph are less, the 
fractions of the dose in the liver are greater, and the fractions of the dose excreted and 
metabolised are greater. This is clearly shown if figures 3.10A-3.10D for the 
subcutaneous skin uncharged macromolecules with k m=0 .0  min*1 are compared with
the corresponding figures 3.4A-3.4D in section 3.2.
Many of the features of the previous simulations were reflected here but the most 
important data on interstitial uptake are shown in figure 3.10 B and indeed figures 3.11 
A-3.11 C and 3.12 A-3.12 C. These figures show that although the fraction of the dose 
in the lymph increases with increasing molecular radius size, the general trend for each 
k m rate once again is that it is not the largest molecular radius which produces the
greatest fraction of the dose in the lymph, but is in fact the intermediate molecular
radii 40/45-55A. Lower intermediate sizes (including 35A at very early times and at 
fastest k  rates) are more successful over earlier times and at faster k m rates, with theW ' m 1
larger intermediate sizes tending to be the more successful over later times and at 
slower k m rates. The clearest difference between the data produced here and that
described earlier is that the access of molecules with radii greater than 55A to the 
lymph is clearly more restricted emphasising the existance of an optimum radius of 45- 
50A. Times to peak were similar to those generated using the lung L/P data but the 
absolute fractions gaining access to lymph, using skin L/P data, were considerably 
lower.
Figures 3.11A-3.11C in the absence of metabolism (A:m=0.0 m in 1) show that the fraction 
of the dose in the lymph has peaked for all radii less than 65A by the end of the longest 
simulation period (1008 hours), with the greatest peak fraction occurring at about 288 
hours for a molecular radius of 50A (17.0% of the dose), and a molecular radius of 55A 
giving the greatest fraction of the dose left there at the end of the longest time period 
(14.9% of the dose).
Figures 3.12A-3.12C for each k m rate show once again that the fraction of the dose in 
the lymph has now peaked for all radii within the 240 hour period and that most of the 
peaks for the radii within the 40-70A range (the exceptions being the 40/45A sizes 
which occur earlier) again occur at about the same time for each respective k m rate, i.e. 
at about 120 hours for A: =0.001 m in 1, at about 72 hours for A: =0.003 m in 1, and atm 1 m 1
about 36 hours for Am=0 .0 1  m in 1. Figure 3.12 A for A:m=0.001 m in 1 shows that the 
greatest peak fraction of the dose in the lymph occurs for a molecular radius of 45A at 
about 96 hours (1 0 .6 % of the dose) and that a molecular radius of 50A gives the 
greatest fraction of the dose left there at the end of the 240 hour period (about 7.9% of 
the dose). Similarly figure 3.12 B for A:w=0.003 m in 1 shows that the greatest peak
fraction of the dose in the lymph occurs for a molecular radius of 45A at about 60 
hours (7.4% of the dose) and that a molecular radius of 50A gives the greatest fraction 
of the dose there at the end of the 240 hour period (2.5% of the dose). Likewise, figure
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3.12 C for £m=0.01 m in 1 shows that the greatest peak fraction of the dose in the lymph 
at any one time occurs for a molecular radius of 45A at about 36 hours (3.8% of the 
dose) and that a molecular radius of 45A has the greatest fraction of the dose left in 
the lymph at the end of the 240 hour period (0.6% of the dose).
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Figures 3.10A-3.10D
The effect of molecular radius on the distribution of uncharged macromolecules in the 







1------ 1------ 1------ 1------ r




















0 24 48 72 96 120 144 168 192 2 1 6  240 0 24 48 72 96  120 144 168 192 216 240














The effect of molecular radius on the distribution of uncharged macromolecules in the 
lymph over 48 hours, 240 hours and 1008 hours respectively, in the absence of 









b. 0 .0 5
0.00
0 4 8 12 16 20 24  28  32  36  40  44  48







- i  * I I I  I  I— 1— i
144 288 432 5 7 6  7 2 0  864 1008
0.0
0
T im e  ( h o u r s )
3.1 IB
0 24 48 72 96 120 144 168 192 2 1 6  240
Time (h ours)













The effect of m olecular radius on the distribu tion  of uncharged macromolecules in the 
lym ph over 240 hours for each of the three k m values for the m ore restrictive L/P ratio 
param eter of best-fit.
3.12A
0.20









tou 0 .0 5tu
0 24 48 72 96  120 144 168 192 216  2 4 0
0.00












0 24  48 72 96 120 144 168 192 2 1 6  2 4 0
0.00
T im e (h o u r s)
3.12C
0 .0 4 0
k m = 0 .0 l
0 .0 3 5
e- o .o 3 o
c  0 .0 2 5
0.020
0.010
0 .0 0 5
0.000
0  2 4  4 8  72  9 6  1 2 0  144  1 6 8  1 92  2 1 6  2 4 0




















T i m e  ( h o u r s )
1G2
3.4.3 Conclusions
The more restrictive L/P ratios such as those from the subcutaneous skin clearly result 
in comparatively less of the macromolecular drug dose reaching the lymph compared 
with the less restrictive (more permeable) L/P ratios from the lung as used in sections
3.2 and 3.3. However, all the same trends as outlined in sections 3.2 and 3.3 are once 
again also repeated in this the more restrictive L/P ratio case, with the simulations once 
again predicting that it is the intermediate size molecular radii 40/45-55A (including 
3 5 A at very early times and fast k m rates) which will produce the greatest fraction of
the macromolecular drug dose in the lymph. Once again the lower intermediate size 
molecular radii appear to be the more successful over earlier times and at faster k m
rates, with the larger intermediate size molecular radii tending to become more 
successful over later times and at slower A. rates.nt
3.5 Conclusions
The best size macromolecular drugs to produce the greatest fraction of the dose in the 
lymph are macromolecules with radii within the 40/45-50/55A intermediate size range, 
with the lower intermediate sizes appearing to be the more successful over earlier 
times and at faster k m rates, and the larger intermediate sizes appearing to be the more 
successful over later times and at slower k m rates. For a macromolecular drug which is 
metabolised very quickly, even molecular radii as small as 35A can be relatively 
effective at early times. Protein macromolecular drugs are better than uncharged 
macromolecular drugs. In the case of protein macromolecules which are not subject to 
metabolism significant tissue uptake will occur with sizes up to 65A radius over very 
long time periods. Hence, if you are lucky enough to know roughly how quickly a 
particular macromolecular carrier or macromolecular drug system is metabolised, then 
the choice of size may depend upon whether you want a macromolecular carrier or 
macromolecular drug system within this intermediate size range which gets into the 
lymph relatively quickly but does not produce the greatest fraction of the dose there
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possible and does not stay there so long, or one that takes a bit longer to get there, but 
once there produces a greater fraction of the dose there and stays there longer.
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Chapter 4




The aim of this chapter is to illustrate how the model presented in this study can be 
used for fitting purposes. It shows how the model can be used to generate or predict 
the tissue distribution of macromolecules and the role of the two major elimination 
processes (renal excretion and hepatic clearance), following the fitting of experimental 
data on plasma clearance of macromolecules. In so doing, this chapter therefore also 
serves as another justification and validation of the work presented in this study.
The selection of the data used to illustrate this application of the model is described in 
section 4.2. The selection of appropriate scaled baseline parameters and the methods 
used* to perform the fitting of the model to the selected data are also discussed in that 
section. In section 4.3 the results from fitting experiments are presented. Section 4.4 
then presents some general remarks.
4.2 Methods
4.2.1 Selection of data to be used
Before any fitting could be performed, the first task was to select appropriate 
macromolecular drug distribution data from the literature. The desired data to which 
the model could be fitted would ideally consist of many plasma concentration versus 
time data points for several different size macromolecules for man. It would also be 
very useful if other disposition data were also available for other key compartments of 
the body such as the lymph or the liver, or for the two major elimination processes, 
(renal excretion and hepatic clearance), so that other comparisons between observed 
and predicted data could also be made. Preferably the data would also be expressed in 
terms of the fraction of the dose or percent of the dose in each tissue or eliminated as 
well. However, most of the macromolecular drug disposition data currently available is 
for animals rather than humans, and often consists of only a few plasma concentration 
versus time data points or a plasma concentration versus time plot without any 
published data. Little data are available on tissue distribution to each compartment
(blood, lymph and liver) or the two major elimination processes (renal excretion and 
hepatic clearance). The situation is not helped by the comparative novelty of the use of 
targeted macromolecular drug systems in chemotherapy, particularly with regard to 
passively-targeted macromolecular systems, since many of these have not reached full 
clinical trial stages yet. Consequently, for the fitting experiments described in this 
chapter it was decided to use (with permission) data for intravenous administration 
into male wistar rats, of five radiolabelled Bovine Serum Albumin-Methotrexate (BSA- 
MTX) conjugates recently described in a colleague’s thesis [442]. These data comprise 
of many plasma concentration versus time data points, is in a usable form, and is more 
complete than most of the data currently available in the other literature. The five BSA- 
MTX conjugates selected were designated as BSA-MTX (5.1 % w/w), BSA-MTX (11.74% 
w/w), BSA-MTX (11.76% w/w), BSA-MTX (13.63% w/w) and BSA-MTX (13.64% w/w), 
where the figures in parentheses refer to the weight concentration of MTX. It was 
decided to pool the data for the BSA-MTX (11.74% w/w) conjugate with the data for the 
BSA-MTX (11.76% w/w) conjugate since these conjugates were virtually the same. 
Similarly, the plasma concentration versus time data for the BSA-MTX (13.63% w/w) and 
BSA-MTX (13.64% w/w) conjugates were pooled. Data from the same thesis [442] on i.v. 
administration of other radiolabelled proteins into male wister rats was also used; 
namely free bovine serum albumin, lactalbumin, carbonic anhydrase and chicken egg 
albumin. The data for the BSA-MTX (5.1% w/w) conjugate, the pooled BSA-MTX (11.74% 
w/w) and BSA-MTX (11.76% w/w) conjugates, and the pooled BSA-MTX (13.63% w/w) 
and BSA-MTX (13.64% w/w) conjugates , is presented in tables 4.1 - 4.3 respectively.
The data for the free bovine serum albumin, lactalbumin, carbonic anhydrase and 
chicken egg albumin is presented in tables 4.4 - 4.7 respectively. Each data set has been 
transformed into the form most useful for this study. Consequently plasma 
concentration is expressed as the fraction of dose per ml of plasma.
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Table 4.2 Pooled BSA-MTX (11.74% w/w) and BSA-MTX (11.76% w /w) conjugate
plasma concentration versus time data
BSA-MTX (11.74% w/w) BSA-MTX (11.76% w/w)
Time (hours) i.v. Plasma 
Concentration 
(fraction of dose/ml)
Time (hours) i.v. Plasma 
Concentration 
(fraction of dose/ml)
1 2.955E-2 1 6.266E-2
1 2.089E-2 1 6.389E-2
3 0.584E-2 2 2.906E-2
3 0.498E-2 2 3.311E-2
6.75 0.329E-2 4 1.472E-2
6.75 0.297E-2 4 0.888E-2
19 0.116E-2 7 0.531E-2
19 0.108E-2 7 1.099E-2
24 0.082 IE-2 24.5 0.449E-2
24 0.0924E-2 24.5 0.308E-2
30.5 0.121E-2 30.75 0.295E-2
30.5 0.129E-2 30.75 0.324E-2
48 0.0506E-2 48 0.187E-2
48 0.0713E-2 48 0.187E-2
54.5 0.0494E-2 52.5 0.176E-2
54.5 0.0303E-2 52.5 0.164E-2
71.75 0.0319E-2 71.5 0.107E-2
71.75 0.0215E-2 71.5 0.111E-2
76 0.0331E-2 79 0.103E-2
76 0.0182E-2 79 0.110E-2
96 0.0402E-2 96 0.074 IE-2




Table 4.3 Pooled BSA-MTX (13.63% w /w) and BSA-MTX (13.64% w/w) conjugate
plasma concentration versus time data
BSA-MTX (13.63% w/w) BSA-MTX (13.64% w/w)
Time (hours) i.v. Plasma 
Concentration 
(fraction of dose/ml)
Time (hours) i.v. Plasma 
Concentration 
(fraction of dose/ml)
0.75 6.92 IE-2 1 2.558E-2
0.75 5.919E-2 1 1.614E-2
3 5.998E-2 3 0.668E-2
3 5.784E-2 3 0.634E-2
4.75 1.351E-2 5 0.552E-2
4.75 1.730E-2 5 0.535E-2
7.5 0.499E-2 8 0.424E-2
7.5 0.562E-2 8 0.436E-2
18.5 0.198E-2 23 0.160E-2
18.5 0.184E-2 23 0.177E-2
19 0.173E-2 26.5 0.154E-2
29 0.117E-2 26.5 0.183E-2
29 0.106E-2 31.75 0.124E-2
43 0.073 5E-2 31.75 0.197E-2
43 0.0637E-2 48 0.0791E-2
48 0.072 5E-2 48 0.0959E-2
48 0.0541E-2 49.5 0.0712E-2
67.5 0.0471E-2 49.5 0.0793E-2
67.5 0.062 5E-2 54 0.0899E-2
78.75 0.0443E-2 54 0.102E-2
78.75 0.0532E-2 71 0.0508E-2
94 0.0362E-2 71 0.0564E-2
94 0.0283E-2 79.5 0.0558E-2
96 0.0446E-2 79.5 0.0692E-2
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Table 4.6 Carbonic anhydrase 
plasma concentration 
versus time data
Table 4.7 Chicken egg albumin 
plasma concentration 
versus time data









































Having selected the data, the next step was to decide upon a strategy to perform the 
fitting, and to scale the physiological parameters from humans to values representing 
rats.
4.2.2. The fitting strategy
One of the most logical and sensible ways to fit the model to any experimental data 
would be to fit the equation describing plasma concentration versus time (equation 2 0  
given in chapter 2 ) to the selected plasma clearance data, varying k m to establish the
most appropriate rate of hepatic clearance whilst keeping all the other parameters 
fixed. However, to use Minsq [441] or similar curve-fitting programmes to perform this 
operation would be inappropriate. This is due to the form of the model, i.e. the number 
of compartments and the number of compartmental processes, and also because the 
roots y, a, p> describing the solution to the model depend upon the relationship between 
k n , k 2X, k X3, k 3], k ^  and k m, with each of these in turn depending upon their assigned 
baseline values. In addition k n and k ^  also depend upon the particular molecular 
radius of the macromolecule. To use regression with only k m entered as a varying 
parameter in equation 2 0  with y, a  and p kept at fixed values, or indeed to use 
regression with k m and/or any of the baseline parameters entered as varying 
parameters whilst keeping y, a  and at fixed values, would be inappropriate because 
then y, a  and p would be taking one independent fixed value each instead of taking 
values which depended upon the relationship between k ]2, *21. *13. *3.. k ^cr and k„, or 
upon the designated physiological baseline parameter values. Similarly, to enter y, a  
and p as varying parameters themselves either instead of, or as well as k m and/or any 
baseline parameters would be inappropriate, because y, a  and p would then be taking 
values which were independent of the relationship between k n , k 2X, k l3, k 3l, k ^  and 
k m, and of the designated physiological baseline parameter values. The way forward 
was therefore to simulate plasma concentration using MACROHOURS for different k m 
rates whilst keeping all other baseline parameters fixed at their assigned values. The 
predicted data were then printed out or imported into a plotting programme such as
Sigmaplot and observed in plot form on screen, or both, to establish the best choice of 
k m to fit the selected plasma concentration versus time data. Once this k m rate was
established, it was then re-entered into MACROHOURS with the other baseline 
parameters, and simulations were performed over any desired time interval to predict 
the fraction of the dose expected to be found in each of the blood, lymph and liver, and 
also the fractions of the dose renally excreted and hepatically cleared (and the total 
fraction of the dose eliminated).
4.2.3. Selection of scaled baseline parameters
Before any fitting to equation 20 could be performed, baseline parameters first had to 
be scaled from their human values to values appropriate to the animal species of 
interest. Before describing which baseline parameters were used for the rat, it is 
appropriate to make some general comments about animal scaling.
There are many similarities in the anatomy and physiology of mammalian species. A 
general belief in this similarity has been the cornerstone of most biomedical research. 
All mammals share a remarkable geometric similarity. One general blood flow diagram 
for example could be used for several mammals, many organs and tissues are similar 
fractions of the body weight, and many volumes of distribution tend to be proportional 
to weight across species [443]. Indeed, it has been shown that some anatomical and 
physiological properties can in fact be correlated among mammals as exponential 
functions of body weight [444]. Some physiological processes vary as the 0.7 - 0.8 
power of body weight; anatomic variables show a near first-degree dependence on 
body-weight [444]. Hence the physiological function per unit of organ weight or per unit 
of animal weight generally decreases as body size increases [443], (though several 
exceptions to this trend no doubt also exist as well). Consequently for results from any 
study involving scaling to be realistic, appropriate time scaling also needs to be taken 
into account, and this is usually done automatically when various model parameters 
are assigned the appropriate scaled baseline values. Major qualitative differences such
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as the absence of a gallbladder in some species are the exception [443]. The two 
processes which influence scale among animal species are physical processes and 
chemical processes [443, 445]. The physical processes such as blood flows, organ 
volumes, tissue binding, kidney clearance etc, often vary 'comparatively' predictably 
among mammalian species [443, 445], and some information independent of any 
biochemical reactions is often available from experimental studies in the literature 
about these. In some very general situations it has in fact been reported that purely 
physical interactions of exogenous chemicals with biological tissues and fluids are 
expected not to show a great variation among species [443], and there is often better 
than order magnitude in many tissues, with the liver exhibiting the greatest 
discrepancy. Chemical processes on the other hand, such as metabolic reactions, vary 
greatly and unpredictably among species [443, 445]. Indeed, the most significant 
species differences that may confound pharmacokinetic predictability are in the 
qualitative pathways and kinetic characteristics of metabolism [443], and over the years 
several studies have been conducted in simple systems to investigate the effect of 
metabolism of molecules (usually small molecules) on inter-species scaling (reviewed by 
references [443, 445]). The unpredictability is because, in reality, foreign organic 
compounds actually tend to be metabolised in two phases [443, 446]. Phase I reactions 
leading to oxidation, reduction and hydrolysis products, whilst phase II reactions 
leading to synthetic or conjugation products that are relatively polar and thus more 
easily excreted by the kidneys in the urine, and in some cases by the liver in the bile. 
Within this general framework there are also large species variations, and it has in fact 
been observed that Phase I reactions are relatively common and often very 
unpredictable [446], whilst Phase II reactions are more limited in number than Phase I 
reactions but it may be possible to identify some patterns of these [446]. Humans are 
believed to usually metabolise drugs less rapidly than other smaller animals [447,448]. 
Each of these factors therefore plays an influencing role, although to try and model or 
predict the two phases of metabolism as processes in their own right is obviously an 
extremely difficult task to accomplish. Most models are necessarily forced to either
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include metabolism within one single general elimination process (occurring from the 
plasma), not represent it at all, or at best, represent it as an individual first-order loss 
process occurring somewhere from the model. The situation when considering any 
scaling is further complicated by the fact the physical and chemical processes interact 
so that the relationship of the pharmacokinetics of any given drug between one species 
and another may be relatively straightforward, or alternatively it may be rather obscure 
[445]. The relationship is more straightforward for drugs which are not metabolised 
since then all interactions are physical and there are no chemical processes involved. 
There are several good reviews in the literature describing most of the different studies 
and approaches which have been used in investigations of interspecies scaling [443, 
445]. To date however more work is necessary before the problem of inter-species 
scaling can be fully understood, and there is no standard rule or method to be used or 
to say how it should be done. Recent allometric techniques are interesting [449], 
although these are generally more appropriate for small molecules eliminated soley by 
physical processes. More work is therefore needed in the area, before the similarities 
and differences underlying the distribution and elimination of molecules in different 
species can be fully appreciated. It appears that the clearances and distributions of 
molecules, particularly macromolecules, follow well-defined, size-related physiological 
relationships, (as illustrated by the F/P ratio and L/P ratio data described and discussed 
in chapter 2 and the associated models developed in this study to model this data), and 
that preclinical pharmacokinetic data are a good indicator of human pharmacokinetics.
For the fitting demonstrations described in this chapter the following scaled baseline 
parameters were used for the rat (250g male wistar rat):
(i) Volume of blood (Vc) = 12ml
This value was available in the literature [450].
(ii) Volume of lymph (Vl) = 40ml
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This value represents 16% of 250g, i.e. the same percentage of body weight of 
total interstitial fluid (lymph) as for humans is assumed.
Volume of blood in the liver (Vh) = 1.2ml
This value represents 10% of 12ml, i.e. the blood volume of the liver is assumed 
to be the same percentage of the total blood volume as it is for humans.
Blood to lymph flow rate (BLFR) = Lymph to blood flow rate (LFR) = 0.00714 
ml/min
These values are assumed to be the same fraction of lymph flow rate per 
volume of total interstitial fluid (lymph) as for humans, i.e. 1.785 x 10' 4 per min
Blood flow rate from the liver = Blood flow rate to the liver = 8.0 ml/min 
This value was estimated from Knaak et al 1451].
Glomerular Filtration Rate (GFR)
For this parameter it was difficult to assign a value since values quoted in the 
literature varied quite considerably between rats with different and similar body 
weights, e.g [326]. Therefore, it was decided to obtain the most realistic rate of 
GFR by fitting the equation describing plasma concentration versus time 
(equation 20) with k m=0.0 min ' 1 (i.e. no hepatic clearance) to the free BSA
plasma concentration versus time data, presented in table 4.4. For this fit, the 
scaled baseline parameters given in parts (i) - (v) were used along with the usual 
model baseline parameters which did not require scaling, ie Model B with nfiit=l, 
aofiit= 17.486, kfi]t=0.20941, niymph=l, aoiymph=13.558 and ^ ^ ^ = 0 .0 1 0 4 5 4  for 
protein macromolecules, the dose Do set to unity, and the plasma/lymph 
filtration ratio, the liver/plasma filtration ratio, and the plasma/liver filtration 
ratio each also set equal to unity (free-filtration). The molecular radius of BSA is
well quoted in the literature as being 37A  [442], so this radius was used. The 
free BSA plasma concentration versus time data were chosen to establish the 
most appropriate rate for the GFR parameter because the main fitting 
demonstrations described in this chapter were to the BSA-methotrexate 
conjugates, and also the size of this protein macromolecule (radius of 37A  ) 
meant it was less likely to be renally excreted so quickly or bind to any plasma 
proteins in vivo so easily as the other selected smaller free protein 
macromolecules, i.e. the lactalbumin, carbonic anhydrase and the chicken egg 
albumin. Figures 4.1 A and 4.IB show the fit of equation 20 to the free BSA data 
using these baseline parameters with &m=0.0 m in 1 and GFR varying between
0.3-0.6 ml/min.
Figures 4.1 A and 4 .IB show that the best choice of value for the GFR appears to be 
GFR=0.5 ml/min and consequently this value was selected to be used for the fitting 
demonstrations described in section 4.3.
The set of baseline parameters to be used for the rat data are now complete, and these 
are summarised in table 4.8.
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Figures 4.1A and 4 .IB Fit to the BSA plasma concentration versus time data with km = 
O.Omin-1 and varying rates of glomerular filtration
Figure 4.1 A (linear scale)
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Table 4.8 Baseline parameters used in the fitting of the model to rat protein macromolecules and BSA-MTX conjugate data.
Do 1 unit (dimensionless)
kexcr
GFR = 0.5 m l /  m in  
Vc = 12 ml
and Model B with Hpjt = 1 , aoplt = 1 7 .4 8 6 , kp{t = 0 .2 0 9 4 1  for protein m acrom olecules
k ]2
BLFR = 0 .00714 m l / m i n  
Vc =1 2  ml
and Model B with n^ph  = = 13.558, = 0 .010454 for protein m acrom olecules
*21 1 .785£-4m in -'<
filtration ratio - 1  
LFR = 0.00714 ml / min 
VL = 40ml
*13 6 .67E -1  min *•
)iver filtration ratio = 1plasm a
Total blood flow rate to liver = 8.0 ml /  min 
Vc =12 ml
*31 6.67E0 min"1'
pl,asma filtration ratio = 1liver
Total blood flow rate from liver = 8.0 ml /  min 
VH = 1.2 ml
What remains to be specified is the molecular radius of the macromolecule of interest. 
For some macromolecular drugs or macromolecular drug corrugate systems, the 
molecular size of the particular macromolecule or macromolecular conjugate system 
will already be known in terms of its molecular radius. For other macromolecular 
systems however, the molecular size may only be given or known in terms of its 
molecular weight. For these latter systems the molecular radius needs to be calculated 
or estimated from the known molecular weight. This can generally be achieved by using 
one of the following two methods:
Method A
4
By using the formulae for the volume of a sphere, i.e. V =  —/z^3, and the well known
, .  ^  . Mass (m w ) , . ,relationship Density ( p )  = --------   - ,  to obtain the expression ,
Volume
m o le c u la r  ra d iu s  *  ^ j 'd m w /A 7 rp  4.1
Therefore by using a macromolecular drug whose mass (molecular weight, mw) and 
molecular radius are well known in the literature, e.g. free BSA (mw  66296Da, radius 
37A), an approximate general value for the density can be estimated (e.g. 
density ( p ) * 0 .3 g  / cm3 for free BSA), and this general density value along with the
mass of the particular macromolecular drug or macromolecular drug conjugate system 
can then be entered into equation 4.1 to give an approximate molecular radius size for 
a set of related molecules. For the free lactalbumin, carbonic anhydrase and chicken egg 
albumin used for some of the fitting demonstrations described in this chapter, each 
had an unknown molecular radius which was estimated using this method, with the 
density assumed to be equal to 0.3 g/cm 3. The estimated molecular radius using this 
method for the lactalbumin (mw 14200Da) was found to be approximately 2 2 A , the 
estimated molecular radius for the carbonic anhydrase (mw 29000Da) was found to be 
approximately 28A , and the molecular radius for the chicken egg albumin (mw 
45000Da) was found to be approximately 33A .
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Method B
Estimates of radius were also obtained by extrapolating the molecular radius from a 
relatively well known figure in the literature 13261, which plots molecular radius in 
relation to molecular weight for some substance used to investigate glomerular 
filtration. Figure 4.2 illustrates this figure.
Figure 4.2 Molecular radius size in relation to molecular weight for some substances 
used to investigate glomerular filtration (taken from the literature [326])
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Using this figure, the molecular radius for the lactalbumin was estimated to be 
approximately 2 lA , the molecular radius for the carbonic anhydrase was estimated to 
be approximately 27A  , and the molecular radius for the chicken egg albumin was 
estimated to be approximately 32A .
Each BSA-MTX conjugate was assumed to have a molecular radius the same size as free 
BSA, i.e. a=37A. This is an approximation which was considered reasonable since the 
major effects of MTX conjugation on BSA distribution were increased rates of 
metabolism.
4.3 Results
4.3.1. Fits of the model to the three BSA-MTX conjugates.
Using the fitting strategy described in subsection 4.2.2, the baseline parameters given in 
table 4.8 , and a molecular radius of 37A, the plasma concentration was simulated 
using equation 20 with MACROHOURS. These results are presented in parts 4.3.1.1-
4.3.1.3 (the raw simulated data is given in Appendix B).
4.3.1.1. The fit to the BSA-MTX (5.1% w/w) conjugate
For the BSA-MTX (5.1% w/w) conjugate, rates of hepatic clearance £m=0.005-0.01 m in 1 
appeared to fit the data well, as shown by figures 4.3A.1 and 4.3A.2.
The best choice of rate of hepatic clearance to fit the data appeared to be £m=0.008 
m in 1. This k m rate was re-entered into MACROHOURS with the other baseline 
parameters, and simulations were performed over the appropriate time interval ( 1 0 0  
hours in this case) to predict the fraction of the dose which can be expected to be found 
in each of the blood, lymph and liver, and also the fractions of the dose renally excreted 
and hepatically cleared (and the total fraction of the dose eliminated). Figures 4.3B and
4.3.C illustrate the predicted results in plot form.
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Comparisons between observed and predicted data could additionally also be used to 
support the choice of best k m rate, e.g. by simulating MACROHOURS using the best 
choice of k m and comparing the observed plasma concentration versus time data with 
the model predicted plasma concentration versus time data. For a good fit, there should 
be a random spread of small positive and negative differences between observed and 
predicted data. Table 4.9 indicates a satisfactory fit for the BSA-MTX (5.1% w/w) 
conjugate with k n=0.008 m in 1. Both the distribution and elimination phases of the
plasma concentration versus time profile are well represented.
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Figures 4.3A.1 and 4.3A.2 Fit to the BSA-MTX (5.1% w/w) conjugate plasma concentration 
versus time data for varying rates of km.
Figure 4.3A.1 (linear scale)
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Figures 4.3B and 4.3C Predicted fraction of dose disposition data for the BSA-MTX (5.1%
w ./w) conjugate w ith km = 0.008m in‘l.
Figure 4.3B (linear scale)
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Table 4.9 Observed and predicted plasm a concentration versus time data for 
BSA-MTX (5.1%w/w) conjugate.
Time (hours) Observed (O) i.v. 
plasm a concentration 
(fraction of dose/m l)
Predicted (E) i.v. 
plasm a concentration 
(fraction of dose/m l)
Difference (O - E)
1 6.933E-2 6.80786E-2 1.2514E-3
1 9.007E-2 6.80786E-2 2.19914E-2
3 5.899E-2 5.50093E-2 3.9807E-3
3 4.129E-2 5.50093E-2 -1.37193E-2
5 4.757E-2 4.45137E-2 3.0563E-3
5 3.775E-2 4.45137E-2 -6.7637E-3
7 2.934E-2 3.608 38E-2 -6.7438E-3
7 3.335E-2 3.60838E-2 -2.7338E-3
23.5 0.678E-2 0.725859E-2 -4.7859E-4
23.5 0.737E-2 0.725859E-2 1.1141E-4
30.5 0.572E-2 0.417797E-2 1.54203E-3
30.5 0.590E-2 0.417797E-2 1.72203E-3
48 0.230E-2 0.17671E-2 5.329E-4
48 0.275E-2 0.17671E-2 9.829E-4
52.5 0.234E-2 0.15711E-2 7.689E-4
52.5 0.236E-2 0.1571 IE-2 7.889E-4
55 0.179E-2 0.148944E-2 3.0056E-4
55 0.174E-2 0.148944E-2 2.5056E-4
71.75 0.0989E-2 0.11783E-2 -1.893E-4
71.75 0.126E-2 0.11783E-2 8.17E-5
97.5 0.0604E-2 0.093882 7E-2 -3.3482E-4
97.5 0.0824E-2 0.0938827E-2 -1.1482E-4
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4.3.1.2. The fits to the BSA-MTX conjugates with high MTX content.
For the pooled BSA-MTX (11.74% w/w) and BSA-MTX (11.76% w/w) conjugates, and the 
pooled BSA-MTX (13.63% w/w) and BSA-MTX (13.64% w/w) conjugates, rates of hepatic 
clearance £m=0.01-0.05 min ' 1 and Arm=0.01-0.04 min ' 1 respectively appeared to fit the
data well, as shown by figures 4.4A.1 and 4.4A.2 and 4.4B.1 and 4.4B.2 respectively.
The best choice of rate of hepatic clearance to fit the plasma concentration versus time 
data for both sets of these pooled BSA-MTX conjugate data appeared to be k m-  
0.02 m in 1. This k m rate was therefore re-entered into MACROHOURS and simulations 
were performed over an appropriate time interval ( 1 0 0  hours again for both pooled 
sets). Figures 4.4C and 4.4D illustrate the predicted results in plot form. The figures 
represent the predicted results for both sets of pooled BSA-MTX conjugates since the 
best k m rate for each was found to be the same.tn
Table 4.10 for the pooled BSA-MTX (11.74% w/w) and BSA-MTX (11.76% w/w) 
conjugates, and table 4.11 for the pooled BSA-MTX (13.63% w/w) and BSA-MTX (13.64% 
w/w) conjugates show the observed and predicted plasma concentration versus time 
data for each set of these pooled BSA-MTX conjugates. As already indicated by figures 
4.4A. 1 and 4.4A.2 and figures 4.4B and 4.4B.2 respectively, these tables show that both 
the distribution and elimination phases of the plasma concentration versus time 
profiles for both sets of pooled data are relatively well represented.
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Figures 4.4A.1 and 4.4A.2 Fit to the pooled BSA-MTX (11.74% w /w ) and BSA-MTX (11.76%
w /w ) conjugates plasm a concentration versus time data for varying rates of km-
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Figures 4.4B.1 and 4.4B.2 Fit to the pooled BSA-MTX (13.63% w /w ) and BSA-MTX (13.64%
w /w ) conjugates plasm a concentration versus time data for varying rates of km .
Figure 4.4B.1 (linear scale)
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Figures 4.4C and 4.4D Prediction fraction of dose disposition data  for the pooled BSA-
MTX (11.74% w /w ) and BSA-MTX (11.76% w /w ) conjugates and the pooled BSA-MTX
(13.63% w /w ) and BSA-MTX (13.64% w /w ) conjugates w ith km  = 0.02m in'^.
Figure 4.4C (linear scale)
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Table 4.10 Observed and predicted plasma concentration versus time data for the
pooled BSA-MTX (11.74% w/w) and BSA-MTX (11.76 w /w) conjugates.
Time (hours) Observed (O) i.v. 
plasma concentration 
(fraction of dose/ml)
Predicted (E) i.v. 
plasma concentration 
(fraction of dose/ml)
Difference (O - E)
1 2.955E-2 6.37976E-2 -3.42476E-2
1 2.089E-2 6.37976E-2 -4.29076E-2
1 6.266E-2 6.37976E-2 -1.1376E-3
1 6.389E-2 6.37976E-2 9.24E-5
2 2.906E-2 5.3718E-2 -2.4658E-2
2 3.311E-2 5.3718E-2 -2.0608E-2
3 0.584E-2 4.52479E-2 -3.94079E-2
3 0.498E-2 4.52479E-2 -4.02679E-2
4 1.472E-2 3.81302E-2 -2.34102E-2
4 0.888E-2 3.81302E-2 -2.92502E-2
6.75 0.329E-2 2.38859E-2 -2.05959E-2
6.75 0.297E-2 2.38859E-2 -2.09159E-2
7 0.531E-2 2.28976E-2 -1.75876E-2
7 1.099E-2 2.28976E-2 -1.19076E-2
19 0.116E-2 0.338979E-2 -2.2297E-3
19 0.108E-2 0.338979E-2 -2.3097E-3
24 0.082 IE-2 0.176543E-2 -9.4443E-4
24 0.0924E-2 0.176543E-2 -8.4143E-4
24.5 0.449E-2 0.16668E-2 2.8232E-3
24.5 0.308E-2 0.16668E-2 1.4132E-3
30.5 0.121E-2 0.09513 53E-2 2.58647E-4
30.5 0.129E-2 0.09513 53E-2 3.38647E-4
30.75 0.295E-2 0.0934249E-2 2.01575E-3
30.75 0.324E-2 0.0934249E-2 2.30575E-3
48 0.0506E-2 0.05132E-2 -7.2E-6
48 0.0713E-2 0.05132E-2 1.998E-4
48 0.187E-2 0.05132E-2 1.3568E-3
48 0.187E-2 0.05132E-2 1.3568E-3
52.5 0.176E-2 0.0483866E-2 1.27413E-3
52.5 0.164E-2 0.0483866E-2 1.15613E-3
54.5 0.0494E-2 0.047297E-2 2.103E-5
54.5 0.0303E-2 0.047297E-2 -1.6997E-4
71.5 0.107E-2 0.0400987E-2 6.69013E-4
71.5 0.111E-2 0.0400987E-2 7.09013E-4
71.75 0.0319E-2 0.040007E-2 -8.107E-3
71.75 0.0215E-2 0.040007E-2 -1.8507E-4
76 0.033 IE-2 0.03848E-2 -5.38E-3
76 0.0182E-2 0.0384847E-2 -2.0284E-4
79 0.103E-2 0.0374495E-2 6.55505E-4
79 0.110E-2 0.0374495E-2 7.25505E-4
96 0.0402E-2 0.0321059E-2 8.0941E-5
96 0.0142E-2 0.0321059E-2 -1.7905E-4
96 0.0741E-2 0.0321059E-2 4.19941E-4
96 0.0579E-2 0.0321059E-2 2.57941E-4
100 0.0801E-2 0.030965E-2 4.9135E-4
100 0.0667E-2 0.030965E-2 3.5735E-4
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Table 4.11 Observed and predicted plasma concentration versus time data for the
pooled BSA-MTX (13.63% w/w) and BSA-MTX (13.64% w /w ) conjugates.
Time (hours) Observed (O) Lv. 
plasma concentration 
(fraction of dose/ml)
Predicted (E) Lv. 
plasma concentration 
(fraction of dose/ml)
Difference (O - E)
0.75 6.92 IE-2 6.66036E-2 2.6064E-3
0.75 5.919E-2 6.66036E-2 -7.4136E-3
1 2.558E-2 6.37976E-2 -3.82176E-2
1 1.614E-2 6.37976E-2 -4.765 76E-2
3 0.668E-2 4.52479E-2 -3.85679E-2
3 0.634E-2 4.52479E-2 -3.89079E-2
3 5.998E-2 4.52479E-2 1.47321E-2
3 5.784E-2 4.52479E-2 1.2 5921 E-2
4.75 1.351E-2 3.35481E-2 -2.00381 E-2
4.75 1.73E-2 3.35481E-2 -1.62481E-2
5 0.552E-2 3.21488E-2 -2.66288E-2
5 0.535E-2 3.21488E-2 -2.67988E-2
7.5 0.499E-2 2.10453E-2 -1.60553E-2
7.5 0.562E-2 2.10453E-2 -1.54253E-2
8 0.424E-2 1.93472E-2 -1.51072E-2
8 0.436E-2 1.934 72 E-2 -1.49872E-2
18.5 0.198E-2 0.364242E-2 -1.6624E-3
18.5 0.184E-2 0.364242E-2 -1.8024E-3
19 0.173E-2 0.338979E-2 -1.6597E-3
23 0.160E-2 0.198966E-2 -3.8966E-4
23 0.177E-2 0.198966E-2 -2.1966E-4
26.5 0.154E-2 0.134 594E-2 1.9406E-4
26.5 0.183E-2 0.134594E-2 4.8406E-4
29 0.117E-2 0.106993E-2 1.0007E-4
29 0.106E-2 0.106993E-2 -9.93 E-6
31.75 0.124E-2 0.0872311 E-2 3.67689E-4
31.75 0.197E-2 0.087231 IE-2 1.09768E-3
43 0.0735E-2 0.056058E-2 1.7442E-4
43 0.063 7E-2 0.056058E-2 7.642E-5
48 0.0725E-2 0.05132E-2 2.118E-4
48 0.054 IE-2 0.05132E-2 2.78E-5
48 0.0791 E-2 0.05132E-2 2.778E-4
48 0.0959E-2 0.05132E-2 4.458E-4
49.5 0.0712E-2 0.05024 73E-2 2.09527E-4
49.5 0.0793E-2 0.0502473E-2 2.90527E-4
54 0.0899E-2 0.0475605E-2 4.23395E-4
54 0.102E-2 0.04 75605 E-2 5.44395E-4
67.5 0.04 71 E-2 0.0416045E-2 5.4955E-5
67.5 0.062 5 E-2 0.0416045E-2 2.08955E-4
71 0.0508E-2 0.040283E-2 1.0517E-4
71 0.0564E-2 0.040283E-2 1.6117E-4
78.5 0.0443E-2 0.0375346E-2 6.7654E-5
78.5 0.0532E-2 0.0375346E-2 1.56654E-4
79.5 0.0558E-2 0.0372799E-2 1.85201 E-4
79.5 0.0692E-2 0.0372799E-2 3.19201E-4
94 0.0362E-2 0.0326921 E-2 3.5079E-5
94 0.0283E-2 0.0326921E-2 -4.392 IE-5
96 0.0446E-2 0.0321059E-2 1.24941 E-4
96 0.0397E-2 0.0321059E-2 7.5941 E-5
96 0.0375E-2 0.0321059E-2 5.3941E-5
96 0.0353E-2 0.0321059E-2 3.1941E-5
97 0.0416E-2 0.0318168E-2 9.7832E-5
97 0.0374E-2 0.0318168E-2 5.5832E-5
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4.3.2. Fits of the model to i.v. dosage of lactalbumin, carbonic anhydrase and 
chicken egg albumin
In order to highlight some of the problems which can be encountered in modelling 
proteins and in animal scaling as well, equation 2 0  was also fitted to the plasma 
concentration versus time data of the lactalbumin, carbonic anhydrase and chicken egg 
albumin macromolecules, which was presented in tables 4.5-4.7 respectively. For these 
experiments, the same fitting strategy described in subsection 4.2.2. was used, along 
with the same baseline parameters given in table 4.8. The estimated molecular radii 
obtained using both Methods A and B described in section 4.2.3. were used for each 
macromolecule, and simulations were performed on MACROHOURS using a value of 
hepatic clearance k m=0.0 m in 1. The results from these simulations are presented in
plot form in figures 4.5A - 4.5C respectively (the raw simulated data are presented in 
Appendix B).
Figures 4.5A-4.5C show that these fits were poor. One might expect that equation 20 
should fit the plasma concentration versus time data of these three free proteins as 
well as it fitted the free BSA shown in figure 4.1, since the same baseline parameters 
and rate of hepatic clearance (i.e. k m=0.0 m in 1) were used. However, as shown by
figures 4.5A-4.5C for these three macromolecules, neither the distribution or the 
elimination phases of the data were adequately modelled. There are several possible 
explanations for this. One possible explanation could be that some of the values 
assigned to the rat baseline parameters given in table 4.8. were not typical for the rats 
used in these three particular experiments, and consequently some baseline parameters 
may be slightly over- or under-estimated for these particular rats. For instance, the 
elimination phases of the predicted plasma concentration versus time profiles for the 
lactalbumin and carbonic anhydrase macromolecules could be improved by decreasing 
the value of GFR, whilst the elimination phase of the profile for the chicken egg 
albumin could be improved by increasing the value of GFR. Similarly, the distribution 
phase of the predicted plasma concentration versus time profile for the chicken egg
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albumin, and at early times for the predicted plasma concentration versus time profiles 
for the lactalbumin and carbonic anhydrase macromolecules, could be improved by 
increasing the BLFR and LFR values, and/or by increasing the blood to liver and liver to 
blood flow rates, whilst the later distribution phase (after about the first 5 hours) could 
be improved for the latter two macromolecules by decreasing the value of BLFR and 
LFR and/or decreasing the blood to liver and liver to blood flow rates. An alternative 
and perhaps more likely explanation may be that since these three macromolecular 
drugs are comparatively small (i.e. smaller than the renal threshold) and are in a non­
conjugated form, they may be binding to some plasma proteins in vivo, and this could 
alternatively account for most of the differences between observed and predicted 
plasma concentration versus time data in the cases of the lactalbumin and carbonic 
anhydrase, and some of the differences in the case of the chicken egg albumin data. 
Indeed, the fairly unusual plasma concentration versus time profiles of the observed 
data for the lactalbumin and carbonic anhydrase protein macromolecules does in fact 
appear to indicate that this may be the case, since by observing the data visually, it 
appears that some binding must be happening since for such comparatively small 
macromolecules one would normally expect a smaller amount of each drug to be left in 
the body with respect to time than is actually observed experimentally. Macromolecules 
of this dimension should generally be renally excreted relatively quickly, which from 
the observed experimental data, does not appear to be the case. Also, in the case of the 
chicken egg albumin data, there are relatively few plasma concentration time data 
points anyway, and due to the size of this macromolecule (radius 32-33A ), one would 
perhaps not normally expect it to be eliminated quite so quickly as the observed 
experimental data suggests. Consequently, any difference between observed and 
predicted plasma concentration versus time data or profiles in these fits, may in fact be 
due to unpredictable or unusual anomalies or processes, such as binding to plasma 
proteins, in the observed rat plasma concentration versus time experimental data itself. 
Other possible causes for the difference between observed and predicted plasma
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concentration versus time profiles could also include unpredictable chemical processes, 
or they may simply be due to a combination of these explanations.
These three fits therefore illustrate some of the classic problems associated both with 
animal scaling, and the fitting of a theoretical model to actual experimental data. The 
fits show that in some situations, probably for macromolecules below the size of the 
renal threshold or macromolecular drugs not in a conjugated form, and in situations 
when any animal scaling is involved, other appropriate baseline parameters in addition 
to k m may also sometimes be needed to be varied via simulations on MACROHOURS
when performing any fitting of the equation describing plasma concentration versus 
time (equation 20) to experimental plasma concentration versus time data. The 
additional baseline parameters which will be needed to be varied in order to obtain the 
best fit, will be those about which very little is known either experimentally or in the 
literature. These three fits also show how unpredictable processes such as the binding 
of smaller macromolecules to plasma proteins in vivo can confound predictability as 
well.
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Figures 4.5A.1 and 4.5A.2 Fit to the lactalbum in plasm a concentration versus time data
w ith km = O.Omin*1-
Figure 4.5A. 1 (linear scale) 
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Figures 4.5B.1 and 4.5B.2 Fit to the carbonic anhydrase plasm a concentration versus time
data with km = O.Omin*1
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Figures 4.5C.1 and 4.5C.2 Fit to the chicken egg album in plasm a concentration versus
time data w ith km = O.Omin'1
Figure 4.5C.1 (linear scale)
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4.3.3 Visual fit of the model to an i.v. plasm a clearance plot of a polyethyleneglycol 
interleukin-2 (PEG IL-2) conjugate
A further fit performed in this study was the visual comparison of a plasma clearance 
plot for an intravenously administered polyethyleneglycol intrleukin-2 (PEG IL-2) 
conjugate, approximate molecular radius 55A, in man [132], with the model predicted 
plasma clearance plot for an uncharged macromolecule of radius 55A in man for 
varying rates of hepatic clearance. For this fit the uncharged baseline parameters 
presented in table 3.1 (given in chapter 3) and the rates of hepatic clearance selected in 
that chapter, i.e. k m = 0.0 m in 1, 0.001 m in 1, 0.003 m in 1, and 0.01 m in 1, were used.
Although no data were published for this PEG IL-2 conjugate [132], the plasma 
concentration versus time plot presented in the literature was useful, since it was in a 
normalised form and was over an appropriate time scale. Figure 4.6A shows this plot, 
whilst figure 4.6B shows the predicted fraction of dose in the plasma for the different 
k m rates (the raw simulated data for figure 4.6B are presented in Appendix B).
Visual comparison of figure 4.6B for k m= 0.01 m in 1 with figure 4.6A shows that at 48 
hours the plasma levels in each figure have decreased by two log-cycles, and that at 96 
hours they have either decreased, or are on the verge of decreasing, by a further log- 
cycle. Consequently on this basis, the predicted fraction of dose in the plasma for an 
uncharged molecule of radius 55A with k m = 0 .0 1  m in 1 appears to fit reasonably well
the plasma clearance of the PEG IL-2 conjugate. Other tissue distribution data can now 
be obtained by re-entering this k m rate into MACROHOURS and simulating; it is not
presented in this subsection since the most important tissue distribution, i.e. 
distribution to the lymph, was already represented in chapter 3.
This fitting demonstration was useful since it illustrated how the model can be used for 
fitting purposes when a plasma clearance plot and not any plasma concentration versus 
time data are presented. However, further visual fitting experiments of this kind were 
not performed, since most of the other plasma concentration versus time plots in the
2 0 0
literature were either in an unusable form, or were over an inappropriate time scale, or 
both.
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Figures 4.6B Predicted serum  clearance data for vary ing  rates of k m for a macromolecule 
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4.4 Conclusions
This chapter demonstrated how the model presented in this study can be used for 
fitting purposes. It showed how the model can be used to generate or predict 
disposition data for the key tissues of the body (blood, lymph and liver) and the two 
major elimination processes (renal excretion and hepatic clearance) which are important 
in both macromolecular drug distribution and the targeting of anticancer agents to the 
lymph, following the fitting of the equation describing plasma concentration versus 
time (equation 20) to plasma concentration versus time data in the literature. The fits 
demonstrated in this chapter illustrated some of the common problems encountered 
with animal scaling, and the fitting of a theoretical model to real experimental data. The 
fits of the model to the plasma concentration versus time data of the selected BSA-MTX 
(5.1% w/w) conjugate, the pooled BSA-MTX (11.74% w/w) and BSA-MTX (11.76% w/w) 
conjugates, the pooled BSA-MTX (13.63% w/w) and BSA-MTX (13.64% w/w) conjugates, 
and to the free BSA, were found to be relatively successful, as was the fit to the 
clearance plot of the PEG IL-2 conjugate. In contrast, however, the fits of the model to 
the plasma concentration versus time data of the three selected protein 
macromolecules, i.e. the lactalbumin, carbonic anhydrase and chicken egg albumin, 
were not so successful. Possible reasons for this have already been discussed, The fits 
demonstrated here suggest that in some situations, probably for macromolecules below 
the size of the renal threshold or macromolecular drugs not in a conjugated form, and 
in situations when any animal scaling is involved, other appropriate baseline 
parameters in addition to k m may also sometimes need to be varied via simulations on
MACROHOURS when performing any fitting of the models equation describing plasma 
concentration versus time (equation 2 0 ) to experimental plasma concentration versus 
time data. How well the model actually fits experimental data may only be known in the 
future, when more human and better animal macromolecular drug disposition data 
from pharmacokinetic studies involving targeted macromolecular systems in the field 
of cancer chemotherapy, or from non-chemotherapy macromolecular drug
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pharmacokinetic studies as well, becomes available, for key compartments of the body 
(blood, lymph, liver) and the two major elimination processes (renal excretion and 
hepatic clearance). The data selected to be used in the fitting demonstrations described 
in this chapter were as good as any that is available, and better than most, and the fits 





In this study a new physiological pharmacokinetic model was developed to investigate 
the fate of macromolecular drugs in the body. The model was based on the movement 
of macromolecules under normal vascular conditions between three important 
compartments (tissues) of the body (blood, extracellular fluid or lymph, and liver) and 
modelling the two major elimination processes (renal excretion from the blood 
compartment and hepatic metabolism from the liver compartment). These aspects of 
distribution were considered important in macromolecular drug disposition and the 
targeting of anticancer agents to malignant micrometastases located in the 
extravascular space (lymph). The model was required to take into account that for 
macromolecules renal excretion and hepatic metabolism were effectively occurring 
from separate compartments. The purpose of the model was to examine the effect of 
molecular radius on the distribution of both negatively charged protein and uncharged 
macromolecular drugs in man, both in the absence and presence of hepatic metabolism. 
This was achieved by taking into account the regional capillary permeabilities to 
different size macromolecules, and the physiology and flow rates within each 
compartment. Mathematical models of capillary permeability were developed to allow 
fitting of appropriate physiological experimental data from the literature. The latter 
models were used to model intercompartmental rate constants used in the 
physiological three-compartment pharmacokinetic model. The major objective was to 
predict via simulations the molecular radii which are likely to be most effective in 
delivering, following an intravenous bolus injection, the greatest fraction of a 
macromolecular drug dose to the extravascular fluids (lymph), and hence to any cancer 
micrometastases present there. In addition to predicting the fraction of the 
macromolecular drug present in the lymph, the proposed model also allows calculation, 
for each molecular radius within the range determined by the modelling process ( 2 0  < 
a < 7 0  A), the fraction of the dose that is present in the blood and the liver, the 
fractions of the dose which have been excreted via the kidneys and metabolised by the 
liver, and the total fraction of the dose eliminated, as a function of time. The model can 
also be used for fitting purposes. A necessary objective of the study was the
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development of the computer programme 'MACROHOURS' which had two main 
purposes; firstly to aid in the solution of cubic functions within the physiological three- 
compartment pharmacokinetic model equations, and secondly to perform simulations 
once the solutions to the model equations had been established. Simulations suggested 
that the best dimensions which produce the greatest fraction of a macromolecular drug 
dose in the lymph are macromolecules within the intermediate radii range of 40/45 - 
50/55 A , with lower sizes within this range being more successful over earlier times 
and at faster rates of hepatic metabolism, and upper sizes being more successful over 
later times and at slower rates of hepatic metabolism. It was shown that for a 
macromolecular drug which is metabolised very quickly, then molecular radii as small 
as 35A can also be as effective at early times. Protein macromolecules (i.e. negatively 
charged species) were found to be better candidates than uncharged macromolecules 
for delivering the greatest fraction of the dose to the target, the lymph, and hence to 
any cancer micrometastases located there. In the case of the protein macromolecules in 
the absence of hepatic metabolism or when the metabolic rate was low, the upper size 
range could be extended to 65A radius to give high concentrations in the tissues over 
very long time periods.
The model presented here differs in several important respects from the key 
theoretical/predictive macromolecular anticancer drug and drug-targeting 
pharmacokinetic models in the literature. As indicated in chapter 1 (section 1.2), 
actively-targeted and passively -targeted macromolecular drug conjugate systems are a 
relatively new innovation in the field of cancer chemotherapy. Consequently there are 
comparatively few of these theoretical/predictive physiological pharmacokinetic models 
in the literature. Most of the models which are available in the literature are concerned 
with examining monoclonal antibody (or immunotoxin) distribution and uptake in solid 
tumours. These have taken the form of geometrical membrane-limited models [86, 87, 
89-98, 262], although there are also some important compartmental blood flow rate- 
limited models [252, 253]. There are also two important general drug-targeting models
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[254, 255], and a paper containing a set of general models investigating the influence of 
transport limitation on the amount of macromolecular drug taken up by a general 
target [256]. The major features of each of these models is described in more detail in 
the appropriate category below. The advantages and disadvantages between the model 
presented in this study and each of these models is also discussed at the end of each 
category. The general strengths and weaknesses of the model presented in this study 
are then summarized at the end of this chapter, together with some suggestions for 
future work.
General drug-targeting models.
The model presented here differs in several important respects from two important 
general theoretical/predictive drug-targeting pharmacokinetic models in the literature 
[254, 255]. These differences are discussed below.
In the earlier of the general drug-targeting models in the literature, the model by Hunt 
et al. [254], a physiologically based four-compartment blood flow-rate limited 
pharmacokinetic model was used to aid prediction of the pharmacological benefits to 
be derived from the administration of a drug as a targeted drug-cairier combination. 
This was achieved by modelling the distribution of free drug which would be released 
from a carrier. The distribution of the drug carrier conjugate itself was not modelled. 
The compartments in the model represented response, toxicity and elimination tissues, 
and the blood, with the blood or central compartment also representing all other tissues 
not accounted for by the other three compartments. Each compartment had its own 
volume of distribution. Effective blood-flow rates were represented as occurring 
between the blood and the response compartments, the blood and toxicity 
compartment, and between the blood and elimination compartments. Drug delivery 
was designated by one of two different input functions, either an intravenous input 
function to the blood compartment in the case of free-drug administration, or release 
rates (and also input functions) of free drug from the carrier into each of the four
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compartments in the case when the drug is administered as a drug-carrier combination 
(these release rates are in fact later combined and rewritten in terms of an average in 
vivo drug release rate from the total carrier dose, and the fractions of drug release 
occurring in each of the four compartments). First-order elimination of free drug either 
in its original form or once it had been released from the carrier was designated as 
occurring from the response, toxicity and elimination compartments. The model is a 
simplified version of several earlier anatomic tissue perfusion models [240-243J, and 
builds on a model presented in some earlier work [452]. Two sets of differential mass 
balance equations describing the model were presented for the effective concentrations 
of drug at each site (compartment); one set representing the case for the intravenous 
administration of free-drug, and the other set representing the case for the intravenous 
administration of the drug-carrier combination. The authors expressed elimination 
from the compartments in terms of known blood flows and estimable tissue extraction 
ratios, defined two relative blood-flow parameters, and then solved analytically both 
sets of differential mass balance equations at steady-state, and in terms of the area 
under the site-concentration time curve (AUC). The solutions to these equations, i.e. the 
steady-state free-drug and drug-carrier equations for each compartment, were then 
used to generate two new parameters: therapeutic availability (TA) and drug targeting 
index (DTI), which allowed predictions of the magnitude of the improved therapeutic 
efficacy or increased apparent potency that would result when the drug is administered 
as a drug-carrier combination. The DTI was defined as the expected ratio of drug 
delivered to response and toxicity sites when the drug-carrier combination is used, 
divided by the same ratio when free drug is administered intravenously. TA was 
defined as the ratio of the dose fraction reaching target sites when the dose is 
administered parenterally as a drug-carrier combination to the amount reaching the 
same sites when an equal dose of free-drug is administered intravenously. An 
improvement in the therapeutic index (TI), a statistical measurement defined as the 
ratio of the median toxic dose to the median effective dose, and an increase in the TA 
were the primary benefits sought by the authors. A measure of the former was obtained
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from the value of the DTI, and this together with the TA were directly calculable 
following the solutions of the differential mass balance equations either at steady-state 
or in terms of AUC. Having obtained expressions for these parameters the authors 
performed various investigations for an average 70kg man using these expressions for 
the case of an ideal carrier (drug release confined to the response compartment only) by 
varying various parameters in turn. The major assumptions the authors made were; 
that all metabolites are inactive; the effective concentration at the action site is a 
function of the measurable concentration in the venous blood leaving the tissue; as long 
as drug remains associated with carrier it is inactive; the carrier without drug attached 
has no significant pharmacological or toxic properties of its own and is 
pharmacologically inert; and the species of interest is man.
The main results from the investigations of these authors are that drugs with high 
total-body clearance, that are known to act at target tissues having effective blood flows 
that are small relative to the blood flow to the normal eliminating organs, will benefit 
most from combination with an efficient, targeted carrier. Direct elimination of the 
drug at the target site or at the tissues where toxicity originates dramatically improves 
the DTI. Also, the fraction of the drug actually released from the carrier at both target 
and non-target sites can radically affect index values (a 1% change in the fraction of the 
dose delivered to the target can result in a 50% change in DTI).
In the second of the two major drug-targeting models in the literature, the model by 
Boddy et al. [2551, a similar physiologically based blood flow rate-limited 
pharmacokinetic model is presented to investigate some aspects of drug targeting, 
including the pharmacodynamics of therapeutic and toxic effects. The authors 
compared conventional administration and drug targeting at steady state for the same 
degree of therapeutic effect in man. The model consisted of three compartments: 
central, response, and toxicity, each with their own volumes. Blood flow was 
represented as occurring between the central and response compartments, and the 
central and toxicity compartments. Free drug elimination was represented as occurring
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from any of the compartments by first-order processes, whilst the drug-carrier on the 
other hand was represented as being eliminated from the central compartment only, 
also by a first-order rate process. Either free drug or drug-carrier was administered into 
the central compartment at a constant rate. The rate of free drug release in each of the 
three compartments was assumed to be a first-order rate process. Rates of elimination 
and of release of free drug depended on the product of the rate constant and the 
volume of the compartment. (The carrier without drug attached, and the drug-carrier 
conjugate are assumed to be pharmacologically inert). The authors then solved 
analytically at steady-state the differential mass balance equations describing the 
concentrations of both free drug and drug-carrier in the model to produce steady-state 
concentration expressions of free drug, drug-carrier, and free drug released from drug- 
carrier, for each of the three compartments. Two simple pharmacodynamic model 
equations [453], which relate therapeutic effect or toxic effect caused by free drug to 
concentrations in the response or toxicity compartments, were then introduced into 
some of these expressions, as appropriate, to produce alternative expressions for the 
parameters TA and TI. TA was defined as the ratio of the rate of input of free drug to 
that of drug-carrier for the same degree of maximal therapeutic effect. Also, using the 
definition for DTI given in the previous model, when the concentrations in the response 
compartment are identical, DTI was found to be equal to the ratio of concentration in 
the toxicity compartment. Hence, the authors of this model defined a similar targeting 
index (TI) by substituting toxic effect for concentrations in the toxicity compartment. 
Having obtained the alternative expressions for these parameters the authors then 
performed various simulations using these expressions for the ideal case (release of 
free drug confined to response compartment) for an average 70kg man, by changing 
parameters in turn, to compare conventional administration and drug targeting at 
different fractions of the maximum therapeutic response.
The main conclusions from the second of these two general drug-targeting models were 
that TI and DTI are maximized by a drug which is rapidly eliminated from the central
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compartment and targeted to a site with low blood flow. Both TI and DTI increase as 
the rate of elimination from the target site increases. The influence of these 
characteristics on the advantage of drug-targeting, prodrugs, or regional administration 
over conventional administration has also been noted previously [243, 254, 453, 454]. 
The effect of increasing the rate of elimination from the response and central 
compartments on DTI and TI changes if free drug is released from the drug-carrier 
outside of the response compartment. The kinetic characteristics of the drug-carrier 
complex, rate of elimination, and rate of free drug release, influence TA but not DTI or 
TI. The pharmacodynamics of the free drug in both the target and toxicity 
compartments have an important influence on TI but not on TA or DTI. As the 
pharmacological selectivity of the drug increases, so does TI, although a drug with good 
pharmacological selectivity may not gain an advantage from drug targeting. TI is very 
dependent on the shape of the effect-concentration curves, particularly that for toxicity. 
Also, while TA increases as the rate of elimination of free drug from either central or 
target compartments increases, TI may actually be reduced if release of free drug is not 
confined to the target compartment.
These two general drug-targeting models described above [254, 255] have several 
important disadvantages compared with the model presented in this study: The two 
general drug-targeting models [254, 255] do not consider the effect of molecular size or 
any other important physicochemical properties such as charge on distribution, since 
there are no parameters or expressions built into their structure to do this.
Consequently they do not take into account any physiological membranes or account 
for different regional capillary permeabilities to different size molecules, and hence 
assume rapid (free) distribution for all molecules, which although may be true for very 
small molecules such as the free-drug, is certainly not the case for larger molecules 
such as the macromolecular carrier or drug-carrier system. Thus these models are 
valuable to the understanding of low molecular weight prodrug action. Macromolecular 
drug-carrier systems are inappropriately assumed to move within each compartment of
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each model as easily and freely as the free-drug. First order release rates and the blood 
flow rates (which can only be assigned general values), are the only factors controlling 
how much drug is presented to and released from the drug-carrier into each 
compartment. The compartments of both the models [254, 255] do not represent 
specific organs or tissues such as the blood, lymph or liver, but instead represent 
general central, response, toxicity and elimination compartments (as appropriate), each 
with their own volumes, blood flow rates, and where appropriate first-order elimination 
rates. The values assigned to these parameters represent values which are not really 
appropriate to macromolecules. Also, the two major elimination processes, renal 
excretion and hepatic metabolism, are not specifically modelled for, since there is 
nothing in these two models [254, 255] which distinguishes renal excretion from 
hepatic metabolism, and no consideration is given to different rates of glomerular 
filtration (or liver sinusoidal extravasation) to different size molecules. There are no 
parameters or expressions built into these two models to take these processes into 
account. Additionally, the sets of differential mass balance equations describing both 
free-drug and drug-carrier in these two general models [254, 255] are solved at steady- 
state which means that equations to describe the concentration, mass, or fraction of 
drug in each compartment as a function of time are not obtainable, and consequently 
predictions as a function of time are not possible. The models can not therefore be 
used for any fitting purposes. Numerical methods would have been necessary if the 
models, certainly the four-compartment model [254], had been solved at non steady- 
state, and hence equations as a function of time for each compartment would still be 
unobtainable. This method of solution at steady-state is perhaps only really appropriate 
for low molecular weight prodrugs, since it is relatively easy to achieve infused steady- 
state for small rapidly distributing molecules, whereas for macromolecules this is much 
more difficult to achieve since their distribution will be much slower.
As a consequence of these points, and since the spirit behind the development of the 
above general drug-targeting models [254, 255] was geared towards aiding prediction
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of the pharmacological benefits to be derived from the administration of a drug as a 
targeted drug-carrier combination, these two models tend to represent a more general 
(non-specific) and simplified situation which although may be true for small molecules 
such as the free-drug, is certainly not the case for large molecules such as the carrier 
or drug-carrier conjugate. They are therefore both essentially concerned with small 
molecules such as the free-drug, and are generally inappropriate for macromolecules.
The main advantage of these two general drug-targeting models [254, 2551 compared 
with the model presented in this study is that they allow prediction of the 
pharmacological benefits to be derived from the administration of a drug-carrier 
combination, by presenting, and solving at steady-state, differential mass balance 
equations describing the concentrations of drug provided from a carrier. However, for 
the reasons already outlined, these models [254, 255], their method of solution, and 
predictions, may indeed be appropriate to low molecular weight prodrugs or indeed any 
drug with a molecular radius less than about 13 A say in this more general situation, 
but are however generally inappropriate for macromolecular drug disposition and the 
targeting of macromolecular prodrugs to the lymph, or indeed for any molecules larger 
than the size at which free extravasation no longer occurs (i.e. greater than about 13 A 
radius).
A general transport limitation model
The model presented in this study differs in several important respects from the set of 
general models presented in a recent publication by Aubree-Lecat et al. [256], to 
investigate the influence of transport limitation on the amount of macromolecular drug 
taken up by a general target. These differences are discussed below.
To demonstrate the influence of transport limitation on the amount of macromolecular 
drug taken up by a target, four general compartmental pharmacokinetic models have 
been discussed [256]. Two of these models were one compartment models, whilst the 
other two consisted of a central and a peripheral compartment. In the latter cases the
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two compartments modelled the transport limitation due to the presence of two 
intercompartmental transfer rate constants in both models. Two uptakes, one 
undesired, i.e. elimination, and one desired, i.e. representing uptake by a target, were 
also included in each model. These uptakes were represented by two general exiting 
parameters and were designated to be either both linear or both saturable. The first 
model therefore consisted of two linear elimination processes acting from a central 
compartment (the site where the initial drug dose is introduced). The second model 
consisted of two linear elimination pathways, each of them working from different 
compartments, i.e. central and peripheral. The third model consisted of a central 
compartment (with the same general volume as the first model) and two saturable 
uptake mechanisms. Finally the fourth model consisted of a central and peripheral 
compartment (each with the same respective general volume as those in the second 
model) with one nonlinear elimination mechanism in each. For each individual model 
the authors then solved the respective differential equation(s) for the concentration of 
drug in each compartment with respect to time and put these solutions into respective 
differential expressions for the amount of undesired (elimination) and desired (uptake 
by target) uptake in each model. These differential uptake equations for each individual 
model were then integrated to give the amount of desired and undesired uptake for 
each model. This was done algebraically for the first three models and numerically for 
the fourth. Having obtained equations for the amount of desired and undesired uptake 
for each model, each of these equations was then converted to infinite time. Having 
obtained these infinite time equations for each model the authors then investigated via 
simulations and plots, the fraction of the injected dose taken up by a general target at 
infinite time after injection as a function of different parameters of interest. The 
authors first compared the behaviour of the two models whose uptakes were both 
linear, i.e. the first two models, by investigating the fraction of the injected dose taken 
up by the target at an infinite time after injection as a function of: (a) the uptake rate by 
the target for different values of the rate constant of undesired elimination, (b) the ratio 
of the volume of the peripheral compartment over the volume of the central
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compartment, and (c) the transfer rate from the first to the second compartment. The 
authors then compared the effect of transport limitations on the fraction of the injected 
dose taken up by the target at infinite time after injection when both uptakes were 
nonlinear, i.e. comparing the third and fourth models, investigating this as a function 
of: (a) the normalised maximum velocity of the undesired elimination, (b) the rate 
constant of the transfer from the first to the second compartment, and (c) the 
normalised uptake of the undesired elimination. In each case the numerical values used 
for these investigations were taken from the literature, and in general were for mice.
The main results from these general investigations by Aubree-Lecat et al. [2561, include 
the fpllowing somewhat obvious conclusions: (a) it is of little use to increase the affinity 
of a macromolecular drug for its target when a transport limitation and an undesired 
elimination from the plasma are both present, (b) an increase of the uptake (rate of 
uptake or maximal velocity) by the target is not very productive because permeability of 
the capillary wall is the factor limiting access of macromolecules to tissues, and (c) 
maximal efficiency of therapeutic macromolecules could be achieved by increasing, 
where feasible, the transport across the barrier between the plasma and the target, and 
by preventing the undesired elimination as much as possible.
As with the two drug-targeting models [254, 255] described earlier, these general 
transport limitation models [256], also have several important disadvantages compared 
with the model presented in this study. They do not consider the effect of molecular 
size or indeed charge on distribution since each of the models parameters are assigned 
only general values from the literature, with the two transfer rates between the 
compartments taking values appropriate for macromolecules the size of 150kDa and 
420kDa only, and the two uptake rates being varied to cover a range of general values. 
The models therefore do not really take into account any physiological membranes or 
account for any different regional capillary permeabilities to different size 
macromolecules, since there are no parameters or expressions built into their structure 
to model or control this, and are subsequently therefore only really appropriate for
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macromolecules the size of either 150kDa or 420kDa. A macromolecule of 420kDa is 
probably too big to be of much use in drug-targeting anyway. Similarly the 
compartments of each model do not represent specific key tissues (i.e. blood, lymph 
and liver), but instead represent general central or central and peripheral 
compartments. Likewise, when the term uptake by its target is used in each of these 
models, it is used only in a general sense to refer to some general values assigned to a 
unidirectional exiting parameter from the model, rather than actually modelling the 
movement between the blood and a specific key target such as the lymph. The two 
major elimination processes, renal excretion and hepatic metabolism, are not 
specifically modelled for, but are instead inappropriately combined together as one 
general elimination process from the central compartment, which is assigned values 
appropriate for only two macromolecule sizes (150 kDa and 420kDa). The 
investigations performed with these models are done so at infinite time which means 
that the equation(s) for the amount of drug with respect to time are not used for any 
other purpose than obtaining these infinite time equations). Investigations at infinite 
time may only be appropriate for extremely large, inert macromolecules such as 
420kDa, since this size macromolecule may perhaps still be within the body after long 
periods of time, whereas smaller macromolecules, even the size of 150kDa, would 
almost certainly have been distributed around the body and been either partially or 
entirely eliminated by then.
As a consequence of the above points, the four general models presented in this recent 
publication [256], do not possess any major advantages over the model presented in 
this study.
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Models concerned with antibody distribution and uptake into solid tumours.
Evidence in the literature indicates that monoclonal antibodies (MAbs) and their 
fragments do not distribute homogeneously and in adequate quantities in tumours [81- 
102]. Indeed, it had become apparent that pharmacokinetic issues at the whole-body 
(global) and microscopic levels must be considered to analyse the distribution of MAbs 
(and immunotoxins) in tumours [47, 57, 59, 70-72, 8 6 , 96, 99, 245, 252, 253, 391]. 
Consequently several physiological pharmacokinetic models have been developed that 
integrate or involve various aspects of these global and microscopic issues [8 6 , 87, 89- 
98, 252, 253, 262]. Although the assumptions made in each of these models varies, 
they can however typically be categorised either geometrically as follows:
(a) General cases of planar (cartesian) geometry [8 6 , 96];
(b) A cylindrical geometry in which the centre of the cylinder is a tum our capillary 
which is surrounded by tumour interstitium [90, 95, 98];
(c) Varying cases of spherical geometries: (i) a tumour nodule uniformly surrounded by 
identical capillaries [91]; (ii) small avascular tumours surrounded by a fluid medium 
[262]; (iii) a macroscopic tumour nodule of densely packed tumour cells [87]; (iv) a 
prevascular tumour nodule embedded in normal tissue treated as a well-mixed 
compartment with the surrounding one blood and one lymphatic capillaries [97]; and 
(v) a homogeneously [89, 92] or nonuniformly [93, 94] perfused tumour surrounded by 
normal tissue;
or,
as compartmental models [252, 253].
Each of the geometrical models uses input parameters from a variety of sources 
(experimental studies in vitro, in animals, and occasionally clinical trials) and explores 
the sensitivity of MAb localisation in a tumour to variations in parameters the authors 
consider to be important. These parameters typically being any of either plasma
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pharmacokinetics [8 6 , 87, 90, 91, 96-98], vascular permeability [94, 98], transcapillary 
transport influx [87, 89-91, 97] and lymphatic efflux [93, 97] rates, diffusion coefficient 
[8 6 , 87, 89-98, 262], convective transport [89, 90, 92-95], antibody dose [90, 93, 94], 
antibody binding affinity [8 6 , 87, 90, 91, 94-98, 262], antigen density [94, 97], MAb size 
[90, 91, 94, 98], antibody metabolism [90, 94, 95, 98], necrosis [93, 94], or tum our 
interstitial pressure and fluid velocity [89, 92, 93, 95]. Each geometric model essentially 
consists of either one, two, or all three of the following matfor aspects, ((I), (II), (III)), each 
of which is embodied in one or more equations. The systems of equations in each 
model are solved numerically, often on very powerful computers such as a Cray 
supercomputer, and simulations are then performed to test the sensitivity of those 
parameters which the authors consider to be most influential in determining MAb 
distribution in tumours as a function of position and time (the simulations are also 
performed on very powerful computers). The major aspects of each of these 
geometrical models are as follows:
(I) The authors of several of the models, [8 6 , 87, 90, 91, 96-98], incorporate an equation 
for the global plasma kinetics by presenting a biexponential or triexponential 
expression based upon experimental data (e.g. typically [251, 455, 456] in the former 
case and [457, 458] in the latter) to describe the time (temporal) decay of MAbs and 
their fragments in the plasma.
(II) In some of the models, [89-91, 97], movement of MAbs and their fragments across 
capillary membranes into the interstitium (normal tissue interstitium or tum our 
interstitium, as appropriate, depending upon the particular geometry of the model) is 
also represented. This movement is generally represented by the Kedem and Katchalsky 
flux equations [264, 265] either in their original form or an adapted form, or similar 
flux equations for the diffusive and convective transport of molecules across 
membranes. These flux equations are adapted in various ways, usually by balancing the 
mass transported across the interface between a capillary (blood, or where appropriate, 
lymphatic) and the interstitial space (tumour or normal interstitial space, depending
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upon the geometry of the model), to give a first-order differential equation. The 
particular adaptations the authors make depends upon whether they are considering 
diffusion, convection, or both, to be the dominant transport mode (despite a very large 
literature on the subject it is still unclear how macromolecules cross capillary walls, 
although convection is commonly believed to account for most movement [460]). In 
some of these models both diffusive and convective flux of MAb through the capillary 
wall is assumed [89, 90], whereas in the others it is assumed to be either by diffusion 
only [91], or by convection only [97].
(Ill) In each of the models, [8 6 , 87, 89-98, 262], a convection-diffusion-reaction partial 
differential equation (the general form of which depends upon the type of geometry 
being considered), and where appropriate (if binding of MAb to tumour antigen 
molecules, e.g. [8 6 , 87, 90, 91, 94-98, 262], or MAb metabolism, e.g. [90, 94, 95, 98], is 
also being considered) a first order rate equation, are used to describe the spatial and 
temporal movement and distribution of free MAb and MAb-antigen bound 
concentration respectively in the tumour interstitium. Each convection-diffusion- 
reaction equation appears with a diffusion term, and either with [89, 90, 92-95] or 
without [8 6 , 87, 91, 96-98, 262] a convection term, with [89, 92-95] or without [8 6 , 87, 
90, 91, 96-98, 262] a distributed solute source term (which when present is represented 
by the classical pore model for transcapillary exchange [461]), with [8 6 , 87, 90, 91, 94- 
98, 262] or without [89, 92, 93] an extravascular binding term, and with [90, 94, 95, 98] 
or without [8 6 , 87, 89, 91-93, 96, 97, 262] a metabolism term, as appropriate, 
depending upon the authors assumptions, i.e. whether these processes are being 
represented as occurring or not occurring. When MAb metabolism is being considered, 
[90, 94, 95, 98], it is assumed to occur only when MAb is bound to tumour antigen, and 
is usually represented in the accompanying first-order rate equation. Each convection- 
diffusion-reaction equation focuses on radial diffusion only, and has initial and 
boundary conditions defined when they are appropriate, i.e. either at the interface 
between the tum our and the surrounding normal tissue in which it is embedded in [89,
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92-94, 97, 262], or at the interface between the tumour and the blood capillary wall [8 6 , 
87, 90, 91, 95, 96, 981. The authors concentrate on either diffusive or convective 
transport, or both, for the percolation of MAb and MAb fragments through the tum our 
because as in the case of movement across capillaries, it is uncertain which is the 
dominant process (convection has also been considered the most important process in 
transport of macromolecules over macroscopic distances in tumours [462], although 
the basis for movement across microscopic distances into densely packed cellular areas 
is not at all clear, the pattern of penetration suggests diffusion [8 6 , 96]).
To date, probably the most interesting and important result from these predictive 
geometrical models has been the concept of a "binding site barrier” to antibody 
percolation [8 6 , 87, 90, 91, 94-98, 262], where the very fact of antibody binding to the 
tumour cell surface antigen inhibits the uniform distribution of antibody throughout 
the tumour. This is because percolating antibody tends to bind to tissue in the vicinity 
of the capillaries from which it extravasates. The binding site barrier is a function of 
binding affinity, antigen concentration, and the antibody transport coefficients, 
although these parameters can play a double-edged role [8 6 , 87, 90, 91, 94-98, 262].
For example, increasing the diffusion coefficient of the antibody enhances its 
penetration of the tum our at early times and more antibody is bound more uniformly 
throughout the tumour, however, at longer times a higher diffusion coefficient also 
accelerates the loss of antibody from the tumour. Also, although increasing the binding 
affinity results at early times in a more heterogeneous distribution of antibody (more 
antibody is bound in the outer regions of the tumour, but far less penetrates to the 
tumour centre), at later times the distribution is less heterogeneous and more antibody 
is retained throughout the tumour. The implications of the binding site barrier have 
important implications for tumour therapy since depending upon the purpose one may 
often want to maximize particular characteristics of the antibody distribution. For 
diagnostic imaging for example, highly specific binding of antibody to antigen may be 
optimal, and microscopic homogeneity of the binding throughout the tumour is not
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important. Alternatively if the aim of therapy is to incapacitate the tumour vasculature, 
then poor antibody percolation may be advantageous. However, if it is necessary to 
reach all viable cells within the tumour, good percolation may be essential. Other 
results from these predictive geometrical models can generally be summarised as 
showing that the poor penetration and heterogeneous distribution of MAb in tumours 
may result from high antibody affinity [8 6 , 90, 96], high MAb molecular weight [90, 98], 
increased rates of antibody metabolism [90, 94, 98], slow rates of transcapillary influx 
[89-91, 97] and/or fast rates of lymphatic efflux [93, 97], high antigen concentration 
[97], and the elevated tumour interstitial pressure [89, 92, 93, 95]. Each of these factors 
therefore also plays an influential role.
These geometrical models [8 6 , 87, 89-98, 262] have several important disadvantages 
compared with the physiological pharmacokinetic model presented in this study. The 
geometrical models are essentially concerned with exploring the sensitivity of MAb or 
MAb fragments (or immunotoxin) distribution and uptake in solid tumours and are 
consequently generally primarily concerned with issues at the local microscopic level in 
solid tumours (which as outlined in Chapter 1 are known to possess their own peculiar 
vascular properties) rather than specifically addressing the more regional problem of 
modelling (under normal vascular conditions) the movement of macromolecular drugs 
between the three major compartments of the body (blood, lymph, and liver), and the 
two major elimination processes (renal excretion and hepatic metabolism), which are 
important in macromolecular drug distribution and the targeting of anticancer agents 
to the lymph, and hence to any cancer micrometastases located there. Indeed, only one 
of the geometrical models considers the case of a prevascular tumour nodule, i.e. one 
of the models presented by Weinstein and co-workers [97], and only a few of the 
models also incorporate other important aspects of MAb pharmacology such as issues 
at the global (whole body) pharmacokinetic level [8 6 , 87, 90, 91, 96-98]. Consequently, 
apart from one of the models, [97], no allowance is made for an interstitial fluid or 
lymph compartment, although some of the models, [93, 97], do incorporate lymphatic
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efflux parameters. The two main elimination processes, renal excretion and hepatic 
metabolism are also not represented. Also, any transcapillary transport, is where given, 
generally represented in the form of flux equations, which are only really relevant for 
the particular MAb being studied, as indeed are any global pharmacokinetic issues or 
lymphatic efflux parameters where given. This is because many of the parameters used 
in each of the respective model equations (bi- or tri-exponential expression, first-order 
differential equation, convection-diffusion-reaction partial differential equation, and 
first-order rate equation, as appropriate, depending upon the particular geometrical 
situation being considered and the authors assumptions) are only appropriate for that 
particular size MAb or MAb fragment being considered (typically IgG (mw 150kD) [87, 
89-95, 97, 262], F(ab')2 (mw lOOkD) [89, 90, 92, 98], or Fab (mw 50kD) [8 6 , 89, 90, 92- 
96]) and not any other. Hence, if any other size macromolecule was to be considered, 
many new values for these parameters (typically these include as appropriate, the 
plasma concentration bi- or tri-exponential temporal decay parameters, the plasma-to- 
tissue transport coefficient, the lymphatic efflux parameter, the diffusion constant, 
convective transport terms, rate constants associated with binding and metabolism, and 
various parameters associated with distributed solute source terms) or indeed entirely 
different parameters, would be needed for each different size macromolecule. This data 
either does not exist (for either animals or man), or is extremely difficult to calculate 
experimentally. The fact that these authors use common diffusion and convection 
terms, parameters or expressions to describe any movement is perhaps a disadvantage 
in itself, because not only is it still not entirely clear which is the dominant process for 
either transcapillary transport, movement through the interstitium, or percolation into 
and through tumours, but also the inclusion of these processes means that the models 
require such a large number of input parameters that the equations correspondingly 
become extremely bulky and complex. A model which is based upon or incorporates 
extravasation data, blood-tissue/tissue-blood flow rates and organ volumes, as the 
model presented in this study does, overcomes these problems since it will 
automatically be representing any diffusion or convection as well, as it is real data
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(extravasation data). The geometrical models therefore do not consider the effect of 
molecular size or indeed charge on distribution in the body, nor do they take account 
for any different regional capillary permeabilities to different size macromolecules 
since there are no parameters or expressions within the various models equations to 
model or control these processes. The only effects of molecular size or charge 
considered by these models are therefore those for the particular MAb or MAb 
fragment being studied, and are for the distribution either inside a solid tumour, or in 
one case only [97], a prevascular tumour nodule, and are therefore generally at a 
microscopic level only. Another important disadvantage with the geometrical models is 
that due to the large number of parameters required, most of the resulting complex and 
bulky equations describing the models, and indeed the subsequent simulations, can 
generally only be solved and performed respectively on powerful mainframe computers 
such as a Cray super-computer. This numerical method of solution usually involves the 
use of very powerful specifically written computer programme packages or algorithms, 
and often incorporates collocation finite element processes. Consequently exact 
analytical solutions as a function of time for these models are not usually obtainable 
and the models become so complex that they can not really be used for fitting purposes 
of any kind. They are also extremely difficult to validate either analytically, numerically, 
or experimentally. In brief, as a consequence of these points, these geometrical models 
therefore do not specifically model or allow prediction of, as a function of size or time, 
the movement of macromolecules (either proteins or uncharged polymers) in man.
The main advantage of these geometrical models [8 6 , 87, 89-98, 262] compared with 
the model presented in this study is that they do allow insight at a microscopic level 
into the sensitivity of MAb or MAb fragment distribution and uptake in solid tumours, 
or in one case [97], a prevascular tumour nodule. This is desirable from a predictive 
point of view and it would be interesting to extend the studies presented here to 
include models of tumour uptake. Never the less it was felt that the emphasis placed by 
the above models on vascular tumours was not the prime concern and that attention
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should be focused on delivery to the lymph compartment and hence to any cancer 
micrometastases located there, so that they can destroy or neutralize these malignant 
cells before they have a chance to become vascularized or spread. For the model 
presented in this study it was decided not to have an additional compartment, i.e. a 
fourth compartment, representing a cancer micrometastases cell. There were several 
reasons for this: Firstly, the inclusion of such an additional compartment and any 
associated input parameters or expressions would result in a model of such complexity 
that one would then be faced with many of the disadvantages of the geometrical 
models outlined above, i.e. they have too many parameters, are only solvable 
numerically on powerful mainframe computers etc. Such a model could not be solved 
to give exact analytical solutions and specific equations for each compartment and 
hence could not practically be used for fitting purposes. Also the complexity and 
amount of work required to do this as well would perhaps be beyond the time and 
facilities of a single Ph.D. study. Secondly, assigning appropriate realistic values to this 
additional compartment or any associated or additional parameters would be very 
difficult, particularly if the movement between the lymph compartment and the cancer 
micrometastases cell was represented by anything other than a first-order rate process. 
Thirdly, the interstitial fluid or lymph compartment is in any case the target tissue/site 
the macromolecular drug system must reach in order to deliver the therapeutic 
anticancer agent to the cancer micrometastases cells, and once in this compartment, it 
is reasonable to assume the various specifically engineered built-in processes found in 
most macromolecular drug conjugate systems will allow the movement, uptake, or 
release of a proportion of the dose of attached therapeutic agent into cancer 
micrometastases cells located there at the appropriate time. Finally, and perhaps most 
importantly of all, this study was primarily concerned with the somewhat different 
problem of modelling the movement of macromolecules (either proteins or uncharged 
polymers) under normal vascular conditions between the blood circulation and tissues 
and modelling the two major elimination processes (renal excretion and hepatic 
metabolism). The study was not immediately concerned with either solid tumours or
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indeed any uptake, binding and distribution in solid tumours or prevascular tumour 
(cancer micromestastases) cells. Rather the objective was to develop models of the 
movement of macromolecules between the blood, lymph and liver, and to model the 
two major elimination processes, in order to obtain the optimum size candidate 
macromolecule for distribution to tissues.
Some authors have provided a simpler approach, compared to the geometrical models, 
of exploring MAb (or immunotoxin) uptake and distribution in tumours by considering 
a compartmental model, although there are comparatively few examples of these 
models in the literature. Typically the best of these compartmental models are the 
models presented by Sung et al [252, 253] since they can be regarded as representing 
simplified versions of the earlier compartmental models [244-250]. The models of 
Sung et all [252, 253] avoid the use of a large number of adjustable parameters, and 
hence they avoid the complexity of the equations used in earlier models which has 
made earlier models too cumbersome for data analysis. The simplified models [252, 
253] consist of a plasma compartment and tumour tissue interstitium compartment, 
both of uniform concentration, with the latter compartment being further divided into 
two compartments containing cell-bound and free interstitial MAb [253] or 
immunotoxin [252]. In these models it is assumed that: (a) after a bolus i.v. injection 
the plasma MAb [253] or immunotoxin [252] concentration decreases biexponentially; 
(b) MAb [253] or immunotoxin [252] is transported from the plasma into the tum our 
unidirectionally at a rate equal to the product of the plasma-to-tissue transport 
constant (a first-order rate constant) and the plasma concentration; (c) MAb [253] or 
immunotoxin [252] in the tumour interstitium rapidly equilibrates between free and 
bound forms according to either the Langmuir adsorption isotherm [253], an equation 
where the binding affinity constant and the interstitial concentration of binding sites 
can be treated as separate parameters [253], or as a single constant [252], equal to the 
product of these two parameters; and (d) loss of free MAb [253] or immunotoxin [252] 
from the tumour occurs at a rate equal to the convective flow of interstitial fluid in
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tumours, multiplied by the coexisting interstitial unbound MAb [2531 or immunotoxin
[252] concentration. The equations used to describe these two models, and which are 
necessarily solved either partially [252] or entirely [253] numerically, are therefore a 
biexponential expression for assumption (a), the appropriate respective Langmuir or 
single constant (as described above) for the rapid equilibration between free and bound 
forms in the tumour interstitium for assumption (c), a mass balance equation which 
states that the sum of the bound and free tumour interstitial concentrations is equal to 
the total tumour interstitial concentration, and finally a first-order differential equation 
which is for assumptions (b) and (d) combined and describes the overall rate of change 
of MAb [253] or immunotoxin [252] concentration in the tumour interstitium.
The strategy behind the development of these two compartmental models presented by 
Sung et al [252, 253] was to develop a simpler model of macromolecular transport, 
employing parameters that correlate with physiological processes, which could capture 
the predominant features of transport events, yet be parsimonious enough to be 
amenable to data fitting. Hence their purposes of development was 2-fold; (a) to 
examine theoretically via simulations (using appropriate model parameter estimates 
from the tumour physiology literature) the effects on MAb [253] or immunotoxin [252] 
uptake in solid tum ours produced by changing the value of the parameters believed by 
the authors to play an important role in transport and binding (these model-predictions 
are then tested experimentally); and (b) to be capable of being applied to the analysis of 
animal experimental data in order to obtain quantitative estimates of MAb [253] or 
immunotoxin [252] transport and binding constants in in-vivo systems. The earlier of 
the two models [252] was used to describe the special case of doses being low enough 
so that binding sites in a tumour are far from being saturated (the low dose allowing 
the ratio of free and bound drug in the interstitium to be represented as a constant). In 
contrast, the later of the two models [253] was used to describe the more common case 
of doses being sufficiently high so that binding sites approach saturation. The latter of 
the two models was hence used to extend the work of the earlier model over a wider
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dose range (by representing binding with the Langmuir adsorption isotherm for 
reversible, saturable binding). The main results from these two compartmental models 
are; (a) at low doses an increase in binding affinity may lead to an increase in MAb 
uptake [252, 253]; (b) at doses approaching saturation of antigen or when uptake is 
permeation limited an increase in the binding affinity from moderate to high affinity 
will have only a small effect on increasing MAb uptake [253]; (c) an increase in antigen 
density will greatly increase MAb uptake when uptake is not permeation limited [253], 
and (d) for high dose applications, efforts to increase MAb uptake in a tumour should 
emphasise the identification of an abundantly expressed antigen on tumour cells more 
than the selection of a very high affinity MAb [253]. These simulations will clearly be 
useful in design of antibody-based delivery systems, though they do not consider the 
intracellular fate of the molecules following binding.
As with the geometrical models, these two compartmental models development by 
Sung et al [252, 253], also have several restrictions compared with the model presented 
in this study, and these are as follows: They are both concerned with the uptake and 
binding of MAbs or immunotoxins in solid tumours and were consequently developed 
to be used solely in both the description of this process and in the analysis of 
associated tumour experimental data, rather than being developed to address the 
general issue of modelling the movement of macromolecular drugs (under normal 
vascular conditions) between the major compartments of the body. They are 
consequently both concerned with issues in solid tumours (which are known to posses 
their own peculiar vascular properties) rather than the extravasation of macromolecular 
drug systems under normal vascular conditions. They do not have any compartments 
representing the liver or the normal total interstitial fluid (lymph), nor do they model or 
represent the two main elimination processes (renal excretion and hepatic metabolism). 
The only elimination catered for in these two models [252, 253] is that which occurs 
either via interstitial fluid flow from the tumour or that which occurs with the temporal 
decay of the biexponential plasma concentration equation, both of which, for the
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reasons explained later, are only appropriate for the particular MAb or immunotoxin 
being studied. They do not consider the effect of molecular size or any other important 
physicochemical properties such as charge on distribution, nor do they take into 
account the different regional capillary permeabilities or extravasation rates to different 
size molecules. Indeed, the only transcapillary movement represented in these two 
models [252, 253] is a first-order unidirectional process from the plasma to the tumour 
tissue which is governed by the product of a plasma-to-tissue transport constant and 
the coexisting plasma concentration, and which is also only relevant for the particular 
MAb or immunotoxin being studied. Macromolecules the size of the particular MAb or 
immunotoxin were considered by the authors (these being toxins of molecular weight
t
60KD and 210KD in one case [252], and an IgG monoclonal antibody of approximate 
molecular weight 150KD in the other [253]). The parameters used in each of the 
respective equations to describe each model are appropriate for that particular size 
MAb or immunotoxin macromolecule only, and are generally inappropriate for 
macromolecules of any other size. Hence, if any other size macromolecule was to be 
considered, many new values for these parameters (these parameters mainly being the 
plasma concentration biexponential temporal decay parameters, the plasma-to-tissue 
transport constant, the convective flow of interstitial fluid in tumours, the fractional 
interstitial volume of the tumour, the MAb binding affinity constant and the interstitial 
concentration binding sites), would need to be determined for each different size 
macromolecule. This datum either does not exist for animals or man, or is extremely 
difficult to determine experimentally. The later of these two compartmental models
[253], also has the added important disadvantage in that the system of equations 
describing the model does not have an exact analytical solution, but m ust be solved 
entirely numerically using a complex algorithm (in this case a fourth-order Runge-Kutta 
algorithm from Mathematical which can only be run on a powerful computer. 
Consequently any fitting of experimental data to these compartmental models [252, 
253] can only be carried out using finite difference processes via computer 
programmes constructed from subroutines or algorithms from various statistical and
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mathematical libraries. This is a disadvantage due to both the difficulty in constructing 
such a 'hybrid' programme and the requirement of a powerful computer to perform this 
operation on, and of course also the sheer complexity of the process itself by using 
such finite element processes. The main advantage with these two compartmental 
models [252, 253] is that they allow both a description and investigation of the uptake 
and binding of Mabs and immunotoxins in solid tumours, since they were developed 
for that purpose.
The afore mentioned theoretical/predictive pharmacokinetic models [8 6 , 87, 89-98, 
252-256, 262] are of considerable interest in relation to the work presented here but do 
not address the main objectives of this study. The model presented in this study 
models and allows prediction of, as a function of size and time, the movement of 
macromolecules (either protein or uncharged polymers) under normal vascular 
conditions between three important compartments of the body (blood, lymph, and 
liver), and models the two major elimination processes (renal excretion and hepatic 
metabolism). The model presented here takes account of varying molecular radius size 
and charge, and enables renal excretion and hepatic metabolism to occur from separate 
compartments. It is also able to some extent to take account of the different regional 
capillary permeabilities to different size macromolecules and the different physiology 
and flow rates within each compartment (tissue). The model and accompanying 
computer programme presented in this study is able to predict for any desired 
molecular radius within the 2 0  - 70 A radius range and for any desired interval of time, 
the fraction of an intravenously administered macromolecular drug dose that is present 
in the blood, the lymph and the liver, and also the fractions of the dose which have 
been excreted by the kidney and hepatically cleared by the liver (the total fraction of the 
dose eliminated is also given). This is a vitally important issue, since from a drug- 
targeting point of view it is extremely important to know and be able to predict, the fate 
of a macromolecular drug in the body for each of these key tissues and elimination 
processes, and which macromolecule or macromolecular carrier or drug conjugate
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system is most likely to produce the greatest fraction of the dose in the tissue fluids 
and lymph. Each of these issues is essentially determined by molecular size and charge, 
which the model presented in this study directly considers and the other 
theoretical/predictive models in the literature do not. The existing models in the 
literature are either inappropriate for macromolecules since they assume rapid 
biodistribution or are appropriate for one size of macromolecule only but are too 
theoretical and are mainly concerned with issues in solid tumours.
In addition to the above outlined advantages and strengths, the model presented in this 
study can also, as has already been described and discussed, be solved to give exact 
analytical equations and solutions for each compartment, and can be used to generate 
macromolecule distribution data following the fitting of the models equation 
describing plasma concentration versus time to plasma concentration versus time data 
by finding the appropriate k m rate. Indeed, the modelling process presented in this
study was developed so that these important criteria were satisfied. This was achieved 
by restricting the model to only the three compartments of the body (blood, lymph, and 
liver), the two major elimination processes (renal excretion, i.e. k excr, and hepatic 
metabolism, i.e. k m), and the other key inter-compartmental processes (k l2, k 2X, k u , 
k 3X). Additional compartments, namely a compartment representing a cancer 
micrometastases cell, and/or additional tissue compartments could have been added to 
the model, but then the mathematical equations describing the model would then have 
become too complicated and complex to be solved analytically and would therefore 
have had to be solved entirely by numerical methods (probably on a very powerful 
computer and using various subroutines and algorithms imported from a variety of 
sources). This in turn would have meant that specific equations for each compartment 
as a function of time would not have been obtainable, and the model could not easily 
be used for a fitting purpose of any kind, without employing more cumbersome 
numerical methods, such as finite-difference algorithms. Any simulations or fits of the 
model presented in this study were therefore by comparison much easier to perform.
The fitting of experimental protein and BSA - methotrexate data described in chapter 4 
illustrated the usefulness of the model. In this case it was possible to vary the k m
parameter whilst keeping all the other parameters fixed until the clearance fitted the 
selected plasma concentration versus time data. Having obtained the appropriate k m
rate, it was then possible to use MACROHOURS to calculate the fractions of the dose 
expected to be found in each of the blood, lymph, and liver, and also the fractions of 
the dose which would be expected to be excreted and hepatically cleared over the 
desired time interval.
Another key advantage of the model presented here which should also be emphasised, 
is the separation of the elimination process renal excretion and hepatic metabolism, so 
that they each can occur as individual processes in their own right from the appropriate 
compartment (i.e. renal excretion from the blood compartment and hepatic metabolism 
from the liver compartment). The model was indeed developed so that this important 
criterion was satisfied as there is a need to use this information in the design of 
macromolecular prodrugs. In each of the key theoretical/predictive macromolecular 
anticancer drug and drug-targeting models in the literature these processes are, as has 
already been outlined, either not represented at all, or are combined together as a single 
elimination process occurring from the plasma, often in the form of biexponential or 
occasionally a triexponential temporal decay equation, and appropriate only to the 
particular size macromolecule being considered by the author (usually IgG).
Since the model presented here is based on physiological parameters, by altering the 
value of the appropriate parameters), it can be used to make predictions for other 
animal species (e.g. as in chapter 4) and for different disease states (e.g. decreasing or 
increasing the value of GFR to investigate renal disease in man whilst keeping all the 
other parameter at their human values).
The major weakness of the model used in this study is the need to specify the nature of 
the capillary endothelium as a single model for the whole body. Thus, data for
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continuous endothelia, which are present in the bulk of tissues, were used. However, 
clearly in practice there would be a different uptake into tissue, with fenestrated 
capillaries. The number of tissue compartments could have been increased to allow 
simultaneous modelling of various endothelia but at present there is not enough 
physiological data to make this worthwhile. Indeed a weakness of the modelling study 
presented here lies in the lack of useful human F/P ratio and L/P ratio data available 
from the experimental literature, and in the lack of abundant F/P ratio and L/P ratio 
data available for the same animal species. The lack of any reliable F/P ratio and L/P 
ratio data beyond a molecular radius of 70 A was one of the principal reasons why the 
model was not used for predictions for any macromolecules with a molecular radius
t
greater than 70 A. However, as already discussed in chapter 2 the F/P ratio and L/P 
ratio data used in this modelling study was probably a good representation of the likely 
situation for man with respect to tissues with continuous endothelia. Ideally 
extravasation concentration ratio data regarding the movement of macromolecules 
from the sinusoidal blood capillaries into the extravascular spaces of the liver (i.e. the 
liver/plasma ratio), the corresponding concentration ratio of the movement back again 
(i.e. the plasma/liver ratio), and the movement of macromolecules from the lymph to 
the blood (i.e. plasma/lymph ratio), would have been available to confirm the 
assumptions made in this modelling study that these ratios, particularly the 
liver/plasma ratio, are close to unity. As discussed in the appropriate subsection of 
chapter 2 , the evidence in the literature, and indeed the absence of this datum itself, 
suggests that this is indeed generally the case for all macromolecules, except possibly 
the extremely large macromolecules or particles with which this study is not concerned. 
In the cases of the liver/plasma and plasma/liver ratios there might possibly be some 
constraints on movement which may lead to concentration ratios very slightly, and 
hence probably insignificantly less than unity, but there is insufficient data available at 
present to illustrate this. However, the model was designed to allow estimates of these 
ratios to be built into the model should reliable data become available in the future.
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There are also no anionic or cationic L/P ratio data available to go with the selected 
anionic and cationic F/P ratio data. This meant that any simulations could not be 
performed for either anionic or cationic macromolecules. However, protein and 
uncharged macromolecules are the two main types of macromolecule used in drug 
targeting and these are modelled for by the model. The anionic results would be very 
similar to the protein simulations in any case, as illustrated by the F/P ratio fits and 
parameters of best-fit described in chapter 2. The model is however also designed to 
allow estimates of these anionic or cationic ratios or indeed similar mathematical 
models to those developed to model the selected F/P ratio and L/P ratio data, to be 
built into the model should these data become available in the future (an additional
i
advantage of the model).
Some of the other parameters used in the model did not have well quoted values in the 
literature. These were principally the BLFR and the total blood flow rate from the liver. 
The reasoning behind the choice of values assigned to each of these parameters has 
already been discussed in the appropriate subsection of chapter 2. In each case the 
most appropriate, logical and sensible choices of value were made in light of all the 
information available, i.e. in man 2ml/min for BLFR and 1440ml/min for the total blood 
flow rate from the liver. However, as with any parameters in the model, the model is 
designed to allow the values of these parameters to be adjusted should better data 
become available in the future. A lack of known or well quoted values in the literature 
for some model parameters is a common weakness which befalls almost all 
physiological pharmacokinetic models. Often, this is because the experiments required 
to establish values for these parameters are extremely difficult or sometimes even 
impossible to perform. The BLFR parameter is probably such a parameter.
The rates of metabolism used in this study refer to first-order rates of loss from the 
macromolecules within the liver and hence from the system altogether. In reality some 
macromolecules will in fact be converted to other active moieties during hepatic 
metabolism and not lost from the system, though to try and model this would be
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inappropriate as it will be a unique property of each macromolecule. Ideally more 
information would have been available in the literature to confirm that the three 
selected rates of metabolism (hepatic clearance) used in this study were reasonable 
choices for macromolecules. For the reasons discussed in chapter 3 they do appear to 
be good choices, although all the general trends described in that chapter would still be 
the same even if they were slightly too fast or too slow.
It was hoped that the fits of the model to the selected macromolecular animal plasma 
concentration versus time data described in chapter 4 would have been more 
successful. This exercise emphasised that proteins do not behave as inert, non 
interacting species in the blood circulation. Where some of the fits described in that 
chapter were not so successful as the others, it may have reflected both the difficulty in 
scaling between species (a common feature of almost all physiological pharmacokinetic 
models) and the unpredictability of some of the experimental data (some of the selected 
protein macromolecule plasma data from the literature showed anomalies in it before 
any fitting was even attempted). Indeed, in this respect the fits of the model to the 
plasma concentration versus time data of the selected BSA-methotrexate conjugates 
from the literature were relatively good, whilst the fits to the plasma concentration 
versus time data of the selected protein macromolecules from the literature were not 
quite so successful. Possible reasons for this have already been discussed in chapter 4. 
Also as discussed in chapter 4, it was not possible to use nonlinear regression directly 
for fitting data. This was due to the form of the model, i.e. the number of 
compartments and the number of compartmental processes, and also because the roots 
y, a, (5 depend upon the relationships between k n , k 2l, k ]3, k 3], k ^  and k m, with each 
of these in turn depending upon their assigned baseline values, with k n  and k ^  also 
depending upon the particular molecular radius of the macromolecule as well. The best 
and most logical way of trying to fit the model to the macromolecular plasma clearance 
data was to vary k m whilst keeping all the other parameters fixed, so that the most
appropriate rate of hepatic clearance is established. However, to use Miniq [441] with
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only k m entered as a varying parameter would be inappropriate because then y, a  and |3
would take independent values instead of each being dependent upon the relationship 
between k n , k 2l, k n , k 3x, k ^  and k m. The way forward was therefore to simulate 
MACROHOURS for different k m rates whilst keeping all other baseline parameters fixed, 
to establish the best choice of k  . Once this had been established, this k„ rate was re-m ’ m
entered into MACROHOURS and simulations performed over the desired time interval 
to predict the fraction of the dose expected to be found in each of the blood, lymph, 
and liver, and also the fractions of the dose renally excreted and hepatically cleared 
(and the total fraction of the dose eliminated).
Another weakness of the model is the assumption that each drug molecule is uniformly 
spherical. To have assumed otherwise would have meant that the structure of each 
macromolecule would have had to be considered individually, and this would have been 
extremely unpractical and virtually impossible to do.
For simplicity the model does not consider the fate of the free-drug/therapeutic agent 
once it has been released from the carrier macromolecule, since this was not the prime 
objective of this study. To have included any additional compartments or 
compartmental processes would only have distracted from this objective. For similar 
reasons the model also does not consider any binding of macromolecules to plasma 
proteins whilst in the blood since this is generally an unpredictable process anyway and 
is therefore very difficult to model, and generally , if at all, occurs with the small 
macromolecules which are not so important to this study.
The value of the work presented in this study may only be known when more human 
data are available. A lack of useful human (and indeed animal) macromolecular drug 
disposition data currently available from pharmacokinetic studies involving targeted 
macromolecular systems in the field of cancer chemotherapy (due to the relative 
newness of this approach), or indeed from the non-chemotherapy macromolecular drug 
pharmacokinetic literature as well, for key compartments of the body (blood, lymph,
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liver) and two major elimination processes (renal excretion and hepatic clearance) 
makes it difficult to conclude whether the model and modelling study presented in this 
thesis is an accurate representation of what is actually happening in vivo, or if the 
problem has been oversimplified. Most of the tissue distribution data which is currently 
available in the literature is for animals rather than humans, often consists of only a 
few data points or plots without any published data, and is usually clearance data or 
tumour accumulation data rather than distribution data for other important tissues. 
However, as with any predictive model, the model presented here proposes what is 
believed to be a likely situation and can be used as a guidance for the direction of 
future investigations and experiments. In this respect it is hoped that this work will be 
of some value to the high degree of interest which is currently being shown towards 
drug-targeting in the field of cancer chemotherapy, particularly the use of passively 
targeted macromolecular conjugate systems, or indeed to the field of macromolecular 
drug disposition in general. To date, it is not clear where macromolecules are going 
once they have been administered into the body, be it humans or animals (the fits of the 
model to the animal data presented in chapter 4 illustrated the latter). The key 
macromolecular anticancer drug system and drug-targeting theoretical/predictive 
pharmacokinetic models currently available in the literature are either inappropriate for 
any size of macromolecule since they assume rapid biodistribution, or are appropriate 
for one size of macromolecule only but are mainly concerned with issues in solid 
tumours and are too theoretical. The aim of this study was therefore to try and throw 
some light on the subject of macromolecule biodistribution by investigating the effect 
of molecular radius on distribution by developing a model which would try to predict 
the fate of either protein or uncharged macromolecular drugs in the body as a function 
of time (under normal vascular conditions) for the key compartments of the body 
(blood, lymph, and liver) and the two main elimination processes (renal excretion and 
hepatic metabolism) which are important to both macromolecular drug distribution and 
the targeting of anticancer agents to the lymph and hence to any cancer 
micrometastases located there (and which can also be used for fitting purposes if
237
desired as well). The success of any macromolecular drug system depends upon such
predictive models as the one presented in this study.
Suggestions for Future Work
1. To perform more simulations should better animal or any human F/P ratio and 
L/P ratio data become available in the future.
2. To perform more simulations should any data become available in the future 
which differs significantly from any of the values assigned to the unknown 
parameters.
3. To fit the model to more data should better or more useful animal or any 
human macromolecular drug disposition data from pharmacokinetic studies 
involving targeted macromolecular anticancer drug conjugate systems become 
available in the future.
4. Use a specific animal model to determine physiological parameters i.e. rat 
(mouse).
5. This study showed that the best choice of size macromolecule, macromolecular 
carrier or macromolecular drug conjugate system to produce the greatest 
fraction of a macromolecular drug dose in the lymph following an intravenous 
bolus dose are macromolecules within the intermediate radii range of 40/45 - 
50/55 A, with the lower intermediate sizes being the more successful over 
earlier times and at faster rates of hepatic metabolism (hepatic clearance), and 
the upper intermediate sizes being the more successful over later times and at 
slower rates of hepatic metabolism (hepatic clearance). It was shown that for a 
macromolecular drug or macromolecular drug conjugate system which in 
hepatically metabolised (hepatically cleared) very quickly, then even molecular
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radii as small as 35A can also be relatively effective at early times in getting a 
significant fraction of the does into the lymph. Protein macromolecules were 
found to be better candidates than uncharged macromolecules for delivering the 
greatest fraction of the dose of the target, the lymph, and hence to any cancer 
micrometastases located there. In the case of the protein macromolecules in the 
absence of hepatic metabolism (hepatic clearance), the upper intermediate size 
range could in fact be extended to 65A radius over very long time periods. 
Experiments should therefore be performed in man using different size 
macromolecular drug systems (preferably for each size macromolecule within 
35 - 65A range) and measuring at appropriate time intervals (e.g. 240 hours at 4 
hour intervals) the fractions of the dose in the blood, the lymph, and the liver, 
and also the fractions which have been renally excreted and hepatically cleared, 
to test these findings, although this is of course very difficult to do (other 
animals e.g. rats or mice could alternatively be used but then other problems 
such as inter-species variations in addition to the difficulty in performing the 
experiments themselves in animals as well also come into operation).
6 . Any experiments in the field of cancer chemotherapy involving the targeting of 
macromolecular anticancer drug systems to the lymph and hence to any cancer 
micrometastases located there should be performed using a macromolecular 
carrier or macromolecular drug conjugate system (preferably proteins) within 
the intermediate 40/45 - 50/5 5A size ranges (with macromolecular drugs with 
radii as small as 35A radius or as large as 65A radius also being useful in 
certain situations). If the rate at which the particular macromolecular drug 
system is hepatically metabolised (hepatically cleared) is known, then the choice 
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Appendix Al
Solution of the new physiological three compartment pharmacokinetic model
From 2.3.2.1 the set of differential equations which describe the new physiological 




— (  ^12 ^13 ^excr  )  ^ P  ^21 +  ^ 3 1  ^ H
dt
dA
— kn Ap k2]AL
r  = ~ (k l l + k j A H + k n Al
dt
where all notation is as defined in section 2.3.2.
Using the Laplace transform rules for constants, linearity and first-derivatives (as 
defined in 2.3.2.3) the Laplace transforms of equations A l.l, A1.2 and A1.3 can be 
taken to give equations A1.4, A1.5, and A1.6 respectively as follows:-
For equation A l.l, 
dA
dt
— L[ (k n  + k l3 + k ^  )A P + k2] A l + k 3XAff j
therefore,
sL [A p ] — A p 11=0 — ~ {k n  + k ]3 + k excr>)L [A p ] + k 2\L [A L\ + k 3]L [A H ]
hence,






Similarly for equation A1.2, 
dAL
dt
~~ l \ k n A p k 2]A l \
therefore,
hence,
I f=0“  ^12 ] ^21 ^ [ ^ l ]
sci2 -  0  = k u a x ~ k 2la 7
Similarly for equation A1.3, 
dA
dt
— Z/[ (# 3, + km)AH + k ^ A p ]
therefore,
hence,
s L [ A „ ] - A „ \ M = - { k ^ + k „ ) L [ A H] + k n L [ A p }
s a , - 0  = - ( k 3l+ k „ ) a , +  k ua t
Re-arranging equations A1.4, A1.5 and A1.6 gives equations A1.7, A1.8 and A1.9 
respectively as follows:-
(For equation A1.4) (s  + k ]2 + k n -I- k excr )a] -  k 2la 2 -  k 3Xa 3 -  D0
(For equation A 1.5) ~ k n a x + ( s  + k 2l)a2 = 0
(For equation A l.6 ) ~ k u a x + ($  + £ 3, + k m)a3 = 0
The determinant A of the system of equations A1.7, A1.8 and A1.9 is therefore,
- k .
A  =













= ( s + f c ]2 +*13 +ktxcr){(s+k2i ) ( s  + *3, + * « ) - ( o ) ( 0 ) } - ( - * 21 ) { ( - ^ 1 2 ) ( 5 + ^31 )“ (o)(—^ ,3 )}
+  ( “ *31 ) { ( - * 1 2  ) ( 0 ) “ ( - ^ 1 3  ) U  +  *21 )}
= (s+kn + kX3 +kexcr)(s2 +k3Xs+kms+k2Xs+k2Xk3X + k2X km)
~{kX2k2Xs +kX2k2Xk3X +kx2k2xkm)—(kx3k3xs+kx3k3xk2x)
= s 3 + k 3X s 2 + k ms 2 + k 2] s 2 + k 2X k 3x s  + k 2X k ms 
+ k X2s 2 + k x2k 3xs  + k x2k ms + k x2k 2xs + k x2k 2lk 3x + k X2k 2Xk m 
+k l3s  + k X3k 3Xs + k X3k ms + k x3k 2Xs + k x3k 2xk 3x + k X3k 2Xk m
+  k eXc r s 2  + k eXc r k  31* +  k excr k m ^  k excr k 2 \^  k excr k 2l k 3l k excr k 2 \ k m
- k X2k 2Xs - k X2k 2Xk 3X- k x2k 2xk m ~ k X3k 3Xs — k X3k 3Xk 2X 
= s 3 + (k 3X + k m + k 2X + k X2 + k X3 + k m  ) s2
+{k2]k 3X + k 2Xk m + k X2k 3X + k X2k m + k X3k m + k X3k 2X + k excrk 3] + k excrk m ^  k excrk 2X')s
+{kX3k 2Xk m + k excrk 2Xk 3X k  excrk 2Xk  J)
A1.10
Now equation A1.10 can be thought of as tracing the same general form as a cubic 
equation with roots y , a  and £ say as follows,
(s  + T'Xs + orX s+j#) A l . l l
which when expanded out gives, 
s 3 + s 2 ( a  + P  + y )  + s ( a p  + a y  + p y )  + a p y  A1.12
since a polynomial of degree n has n roots (i.e. n = 3 in this case).
Therefore by comparing the coefficients of the s 3 , s 2 , s  and constant terms in equation 
A1.10 with the corresponding terms in equation A1.12, it is readily apparent that the 
roots of equation A1.10 can be expressed in terms of the inter-compartmental 
parameters (first order rate constants) as follows,
CX + P  + y  = k 3X + k m + k 2X + k X2 + k X3 + k ^  A l.l 3
a p  + a y  + p y =  k 2Xk 3X + k 2Xk m + k X2k 3X + k X2k m+ k X3k m
+ k ]3k 2] *1" k excrk 3\ “^ excr^m «^*cr^ 21 A1.14
(*PY= k\3k 2Xk m Jr k excrk 2Xk 3x + k excrk 2]k m A1.15
A4
So defining the roots of equation A1.10 to be a, y and |3, the system of equations A1.13, 
A1.14 and A l . l5 can therefore be solved for either y, a  or [3 to give the three roots of 
equation A1.10. In each case, and for the reasons explained below, this calculation 
produces another cubic equation in terms of whichever root y, a or (3 is being solved 
for, and whose roots will actually represent the roots of equation A1.10. This is because 
regardless of whether y, a or (3 is selected to perform this calculation, the coefficients of 
the resulting cubic equation in each case will be exactly the same for each of y, a and (3, 
hence the roots of each resulting cubic equation will be exactly the same in each case as 
well, and as shown below will actually represent the three roots of equation A1.10. This 
is illustrated as follows by obtaining the cubic equation in terms of y,
Multiplying equation A1.14 by y gives,
& P Y  +  P Y  + & Y  =  Y { ^ 2 \ k 3\ k 2l k m k \ 2 k 3\ k l 2 k m ~ ^ k \ 3 k m k \3 k 2\ k  excrk 31
+ *«*r*„+*.«r*2l) A1.16
Now putting equation A l . l5 into equation A1.16 gives,
k n k 2Xk m +  k e x c r  k 2 \ k 3\ k excrk 2 \ k m Y  P )
~  21^31 ^ ’ k 2 \ k m ' ^ k \ 2 k 3\ k \ 2 k m "* "^1 3 k m +  k \ 3 k 2\ k excrk 3 1
excr k m k excr k 2l )  A 1 . 1 7
But from equation A 1.13 a  + p  = {kn + k 2x + k n 4- k 3l + k txcr + k m) — Y A1.18
So putting equation A1.18 into equation A l . l7 and re-arranging gives,
Y l  ~ Y 2 ( k \2 +  k 2\ + k U  +  ^ 3 1  + k excr + k m )
~*~Y(.k 2 \ k 3\ k 2 \ k m k \ 2 k 3\ ^r k \ 2 k m k \ 3 k m ^  k \ 3 k 2\ " ^ k excrk 3\ k excrk m k excrk 2 \ )  
— { k ] 3 k 2 \ k m k excrk 2 \ k 3\ k  excrk 2 \ k m )  =  ^
A1.19
Equation A l .l9 is therefore a cubic equation in terms of the root y and the inter- 
compartmental parameters, with the inter-compartmental parameters representing the 
coefficients of the cubic. By Descartes rule of sign all three roots of equation A1.19 are 
positive, and by the nature of the inter-compartmental parameters and the fact that the 
physiological pharmacokinetic model consists of three compartments, these roots are
A5
also obviously distinct and greater than zero. So for equation A1.19, letting the largest 
root be y 3 say, the middle (next largest) root be y 2 say, and the smallest root be y , 
say, then y 3 > y 2 > y x > 0. Similarly, if the system of equations A1.13, A1.14 and 
A l . l5 were solved for either a  or p as well, the resulting cubic equation in each case in 
terms of a  or p would have exactly the same coefficients as those in equation A l .l9, 
and due to Descartes rule and the reasons outlined above, the three roots of each of 
these equations would be real, distinct and greater than zero. Hence for the resulting 
cubic equation in terms of a, letting the largest root be a 3 say, the middle (next 
largest) root be a 2 say, and the smallest root be a ,  say, then a 3 > (X2 > a ] > 0. 
Likewise for the resulting cubic equation in terms of p, letting the largest root be p3, 
say, the middle (next largest) root be p2 say, and the smallest root be pi say, then 
A  >  A  >  A  >  0 *  However, because the coefficients of the resulting cubic equations 
are exactly the same in each case regardless of whether y, a  or p has been selected to 
solve the system of equations A1.13, A1.14 and A l . l5, then this also means that the 
roots in each case will be exactly the same (having the same respective values) in each 
case as well,
hence r  = y ,  = a , = f i , ,  a  = y 2 = a 2 =  P 2 ,and  P  = y, = « 1  = P v
Therefore since a polynomial of degree n has n roots, then the cubic equation of 
general form given by f(x) say as follows,
f ( x )  = a 3x 3 + a 2x 2 + a ]x  + a 0 = 0 A1.20
with 
a 3 = 1
Cl2 —  ~ { tk n  + & 2 1  "**^13 " ^ A x c r  ^ A i )
a \ = ( A l A l  + A l A  ^ ' k n k 3 \ ^ k \ 2 k m +  A 3 A i  A 3 A i  **" A x w A l  "*” A w c r A i  ^ « r c r  A l )  
a 0 =  ” ( A 3 A l A r  ^e x c r  A l  A l  A x e r A l A i )
gives the three roots y, a  and p with y  > a  >
A6
Equation A1.20 can then be solved numerically using the Newton-Raphson and 
synthetic division techniques described in subsection 2.3.2.3 to find the roots y, a  and (3 
. (The root y was selected purely arbitrarily to illustrate the calculation described 
above.) The roots y, a  and (3 therefore can be thought of also as being hybrid 
physiological parameters.
Before progressing to the next stage, it is important to note that if £ , is defined to be
the sum of all exit inter-compartmental parameters (first-order rate constants) out of 
physiological compartment /, then for the sake of convenience of notation the bulky 
expressions above are simplified as follows,






and equations A1.7, A1.8 and A1.9 become equation A1.24, A1.25 and A1.26
respectively as follows:
(equation A1.7 becomes) — E 2a 2 — k 3]a 3 = D 0 A1.24
(equation A1.8 becomes) A1.25
(equation A1.9 becomes) - k ua x + ( s + £ 3 )a 3 = 0 A1.26
so the determinant A of the system of equations A1.24, A1.25 and A1.26 is,
s  + E^ E 2 k 3l 
A =  - k n s + E 2 0
—k ]3 0  s + E 3
= ( s + E , ) { { s  + E 2)(S + E , ) - ( 0 ) ( 0 ) } - { - E 2) { ( - k n ) ( s + E 3) - ( 0 ) ( - k n )}  
+ ( - k » ) { { - k l2) ( 0 ) - ( - k n )(S + E 2)}
A 7
= (s  + E x)(s + E 2)(s  + E 3) -  k X2E 2 (s  + £ 3) - * 31*,3 (s  + £ 2)
= ( 5  + E x )(s + E 2s  + E 3s + E 2E 3) — k X2E 2s — k X2E 2E 3 — k 3Xk x3s  — k 3xk X3E 2 
= s 3 + E 2s 2 + E 3s 2 + E 2E 3s + E xs 2 + E xE 2s  + E xE 3s  + E xE 2E 3 - k u E 2s
= s 3 + s2(Ex + E 2 + E3) + s( E xE 2 -\-E2E3 + E xE3 - k X2E2 - k 3XkX3) 
+ ( E xE 2E3 - k nE2E3 - k 3XkX3E2)
where equations A1.10 and A1.27 are identical.
A1.27
Similarly, equations A1.13, A1.14 and A1.15 can also be expressed as equations A1.28, 
A1.29 and A1.30 respectively as follows,
(equation A l. 13 becomes) CX +  +  y  — E x + E2 + E 3 A 1 .2 8
(equation A l. 14 becomes) Oifi + (Xy +  fiy =  E XE 2 +  E2E3 + E XE3
- k l2E2 - k , A1.29
(equation A1.15 becomes) a/3y=  E ,£ 2£ 3 - k n E 2E,  - k JlkuE2 A1.30
where equation A1.28 is identical to equation A l . l3, equation A1.29 is identical to 
equation A1.14, and equation A1.30 is identical to equation A l . l5.
For a ,
Applying Cramers rule gives,
a, =
A> - e2 -k3X
0 s + E 2 0
0 0 s + E 3
A
£>„{(*+£, )(s +£3 )-(o)(o)} - ( -£ 2 K(o)(*+£3 +(-** ){(o)(om<>)(*+£2)}
( i+ y )(s + a )(s + )9)
A('? + -E2)(5+£3)
( 5 + y ) ( s + . a ) ( s + ^ )
A1.31
Therefore to get A p the inverse Laplace transform of this function m ust be taken, but 
first the function must be separted by the method of partial fractions as follows,
A8
4
D0(s + E 2){s  + E , )  G  , H  , /
let------------ 7 --------w-------- w-------i t  =   r +
(s+ T 'X s+ aX s + Z?) (5 + 7 ) (s + or) (5 + pi)
therefore , D0(5 + £ 2)(5 + £ 3) = G(s + a)(.s+ J3) + H(s + y)(s + J3) + l(s + y)(s + a) 
so when s = - y  ,
D0{E2 -  y)(E, -  y) = G ( « -  y)(/3- y)
hence,
^  _ A ( £ 3 ~ r ) ( £ 3 - r )  _ -Pq(^2 - r ) ( s 3 - r )
( a - r ) ( p - r )  (7 - a ) { r - P ) A1'32
Similarly when 5 = - a
D0{E2 -  a ) (£ 3 -  a ) = H ( y -  a)(/3 - a)
hence,
_  Dq{E2 — &){E3 — &) _ Dq(E2 — a){a-  E3)
( y - a ) ( 0 - « )  ( y - a ) ( a - /3 )
Similarly when 5 = —/3,
A, ( £ 2 -  £ ) (£ , - f l )  = l ( r -  P)(a -  p)
hence,
( r - P t a - P ) A 1 3 4
Therefore,
D0(s + E2){s  + E3) D0(E2 -  y) (E3 -  y) D0{E2 -  a ) {a  -  £ 3) D0(E2 -  p ) ( E 3 -  p )
n ,  = - : ------------ w  w  r  =   w  w  r  +  ■; w -------------- w -------------r  +
1 (* + r)(s + tf)(s + yff) (r -a r ) (r -y 0 ) (^  + r) (r  -  <*)(<* -  y3)(s + or) (y  -  p)(oc -  p) (s  + p )
so taking the inverse Laplace transform gives
A9
r ' h ]  = £-1
D0(E2 - y ) ( E 3- y )  D0(E2 - a ) ( a - E 3) + D0(E2 -  p) (E3 -  P)
(y - a ) ( y - / 3 ) ( s + y ) ( y - a ) ( a - P ) ( s + a )  ( y - P ) ( a - P ) ( s + P )
D0(E2 - y ) ( E 3- y )  
(y - a ) ( y - / 3 )
1 D0(E2 - a ) ( a - E 3) 1 : d o(e 2 - 0 ) ( e , - P ) 1
s+y (y - a ) ( a - p ) . s + a . J+ p
therefore,
AP =
Da(E2 - r ) ( E 2- y ) e ^  D0(E2 -a) (a-E, )e -<* D0(E2 - 0 ) ( E 2- p p r *
(r - a ) ( r - P )
-+
( y - a ) ( a - P )
+ -
( y - P ) ( o c - p )
i.e. AP = G<r* + He-°*+Ie
A1.35
A1.36
hence in terms of the original notation
AP =
E>o(k2i ~ y ) ( k3 \ +k m- y ) e  7t D0(k2l- a ) ( a - ( k 3]+km))e at D0(fc2] -  P)(k3l +km -  P)e pt
( y - a ) ( y - p ) ( y - a ) ( a - p )
+ ■
( y - P ) ( a - p )
A1.37
Also, since at time t the concentration of the drug in the blood compartment is given by
A DCP = —■£-, with CP | (=0 = C0 =— , then equation A l.35, A1.36, and A1.37 can also be
Ec Vc
expressed in concentration terms as follows as well,
Cp= Vc{ r - a ) ( y - p ) Vc( y - a ) ( a - p )
i.e. CP =y-(Ge~rt +He~ca +Ie~P) = Gle~yt +Hxe~ca + / ,e_/*
where
K ( r - P ) { o c - P ) A1.38
 1 ^ A1.39






hence in terms of the original notation,
A) (*21 -r)(*3i A  (*21 - a ) ( a - ( k31 +*«))e-£* A(*21 ->0)(*31 +km-P)e'




Applying Cramers rule gives,
s + £j Dq ^31
- k n 0 0
- k n 0 s+E3
a,  =




Therefore to get A L the inverse Laplace transform of this function m ust be taken, but 
first the function m ust be separated by the method of partial fractions as follows,
-^0^12 ^3 ) A B C+  r  +
( s + j ' X s  +  arXs +  y#) ( ‘S +  T') ( s  +  or) ( s + f i )
therefore,
D0kn {s + E3) = / 4 ( s + a ) ( s  +  J3) + B ( s + y ) ( s +  ]3) + C(s  + y ) ( s  + a )
so when s =  - y  ,
D„kn ( E3 -  y)  = A ( a  -  y ) { p  - y)
hence,
A _  D<,kn(E} - r )  _  >^0kn ( E i - y )  
{ a - r ) { p - y )  (Y - a ) { y - P )
Similarly when s  =  - a  ,
D0kn ( E , - a )  = B ( y - a ) ( p - a )
hence,
3 =  ^ 1 2 ( ^ 3 - ^ )  _  D ok n  (<* - E 3) 





Similarly when s  = -J3
Dakn(E, - f i )  = C ( r - P ) ( a - p )
hence,
C =
D0k u ( E , - f i )  
(;r - P ) { a ~ P )
Therefore,
A) ^ 12 {s + Ei  ) D0k]2(E3 y) D0kn (a E$) Z)0&]2(l
(s+r)(s+a)(s+j3) ( y - a ) ( y - P ) ( s + y )  ( y - a ) ( a - p ) { s + a )  ( y ~ p ) (a ~
so taking the inverse Laplace transform gives,
L~] [a2 ] = ZT1 Eo)k\2 (E^ y) ^  D0ki2{(X E3) ^ D^k^iE^ P)
( y - a ) ( y - f i ) ( s + y )  ( y - a ) ( a - P ) ( s + a )  ( r ~ P) ( a~ P) ( s+P)
A) ^ 12 1
( y - a ) ( y - P ) s+y
. EQkn j —i
( y - a ) ( a - p ) s+a
D0k ]2 r - 1
(y - p ) ( a - p )
therefore,
D0ku (E} - r ) e -» , Dakn { a - E i )e-C‘ _ D0k j E z -
L ( r - a ) i r - f i )  l r - a ) { a - P ) (y - P ) { a - P )
i.e. = yle -^  + B e '"  + C e '^
hence in terms of the original notation,
D A i { k » + k „ - y ) e - *  , A , * . 2 ( « ~ ( * 3 , + * „ ) > - ' ”  . D 0 k n ( k » + k m











Applying Cramers rule gives,
s+Ex - E 2 






( j + g 1) { ( j + g 2) ( 0 ) - ( 0 ) ( 0 ) } - ( - g 2){(-^ 12)(0)-(0)(-A:13)} + D0{ ( -^ 12)(0 )-( - fe i3 )( j+ g 2)}
(.y+r)(j+ar)(j+y0)
D0kXi (s+E2 ) 
(s+y)(s+ar)(.s+y0) A1.51
Therefore to get A ff the inverse Laplace transform of this function m ust be taken, but
first the function m ust be separated by the method of partial fractions as follows,
D0ku ( s + E 2) _  p  Q R
( s + y ) ( s + a ) ( s + / ) )  ( s + y )  ( s + a )  ( s+j3)
therefore,
D0ku ( s + E 2) = / >( s + a ) ( s + fi) + Q(s  + y ) { s + f i )  + R(s  + y ) ( s  + a )  
so when s  =  —y  ,
d oK M i - r )  = P ( a - r ) ( P - r )
hence,
D0kn ( E2 - y )  _  D0ku ( E2 - y )
( a - r ) ( P - r )  ( r - a ) ( r - f i )
Similarly when S = - a ,
D0ku (E2 - a )  = Q ( y - a ) { f i - a )
A13
hence,
D0ku {E2- a )  _ P0k]3( a - E2) 
(y - a ) ( p - a ) ( y - a ) ( a - p )
Similarly when s — - f 5 y
D0k„{E2- p )  = R { y - p ) { a - p )
hence,
D0kn (E2 - P)
( y - p ) { a - p )
Therefore,
_ A)^ 13 (,s + ^ 2 ) _ ^0^13 ( ^ 2~Y)  A)^ 13 ^ 2 ) A) ^ 13 (
*3 (s+r)(s+or)(s+/3) (r-ar)(r-y3)(5+7') + (/-ar)(ar-y0)(5+ar) + (r->0)(ar
so taking the inverse Laplace transform gives,
A)^i3(^2 ~ y ) E)0k]3( a - E 2)L-'[a3] = L~'
D0k]3(E2 -/3)
( r - a ) ( r - f i ) ( s + r )  ( r - a ) ( a - p ) ( s + a )  (y -P)(<x - P ) ( s+P)
D0k]3(E2 y) ,
(y -<*)(y -P) s+y
Dpku (a  E2) j 
( y - a ) ( a ~ P )
1
s+ar
D0k]3 (E2 P) ,
( r - f l X a - f i )
therefore,
D0k j E 2- y ) e -» ^ ( t - ^   ^ D0k„(E2 -  f i ) e ^  
" ( r - a ) ( y ~ P )  \ y - a ) ( a - p )  (y ~ p ) { a ~ p )
i.e. 4 ,  =  ■Pe- '1 +  0<T“' + R e_/,r
hence in terms of the original notation,
. D0k»(k2X-y)e'* D0kn( a - k2])e~* P0ku(k2i - P)e'^
" (7 - a ) ( y - P ) ( y - a ) ( a - P )  ( y - p ) { a ~ p )
A1.53
A1.54









Calculation of the equations for AEXCR and AM
In this appendix, calculation of the equations to describe the fractions of the dose 
which have been excreted by the kidneys and metabolised (hepatically cleared) by the 
liver with respect to time in the new physiological three-compartment pharmacokinetic 
model are presented:
From 2.3.2.3 the rate of change in the mass (amount) of drug excreted by the kidneys is 
represented by the equation,
Now the equation for A p has been calculated in part 2.3.2.3 and Appendix A1 to be,
A»(*2 ] - r ) ( * 3i + * „ - r ) e  *  | £>0(*2| - g ) ( a - ( t 3| + O ) e  m  ^ P o (k2 l - 0 ) ( k , l + k „ - 0 ) e  *  












Ae YTB —EXCR e^xcr
f=0
=  k^excr
Dp(Kl -r)(fe31 +fcm -r ) g -rf A>(*21 -g )(tt-( fc 3l +fem))e"at DpiKl -  P)(Kl + K ~ p y *  ■ .
ir-a)ir-P) + (Y - a ) { a - p ) {Y - p ) { a - p )
D o  U21 -  r X ^ i  +  k «  -  r ) e _7t D 0 (^21 -  <*)(<* -  (^ 3 1  +  ) ) e '<n D 0 ( k 21 -  p){k31 + -  y0 ) e - /”
- r ( r - a ) ( r - P )  - a ( r ~ a ) ( a - p )  - p { y - p ) { a ~ p )
Vexcr
D0{k2 1 -  y)(fc3i + K  -  r)e-yt D0(k2l -  « )(« -  {k3l + fcm ))e-°rf D0(&21 -  j3)(fc31 + km -  p)e'pt
- r i r - a ) { r - p )  - a { y - a ) { a ~ p )  - p { y ~ p ) { a - p )
Po{k2l -  y){k3l +km - y )  t D0{k21 -< *)(« -(fe31 + fc j)  > P0(fc21 ~P){k3 l +km ~p)  
- y { y - a ) { y - p )  + - a { y - a ) { a - p )  + - p ( y ~ p ) ( a - p )
Therefore,
(^ 21 ~ r) ( ^ 3 1  + ~ 7 ) (^ 21 -  a)(a -  (^ 3 1  + )) (^ 21 ~ P){k31 + -  p)A excr -  kexcr DQ y ( y - a ) { y - p )  a(y -  <x)(a -  p) p{y-p) (oc~p)
(*21 -  r)(*3i + km -y)e~* (*tji - « ) ( « - (*si +km))e~“ (k2l -0)(fc„ +fcm -/3)e^
yiy-a)(y-fi) a( y-aXa- l 3) P(y-P)(a-P) j
A2.5
i.e. ^  *  + /  + Z -  .KT* -  K; } A2.6
 ^_ (*21 -  r)(^ 3i + - r)
A r - a X r - P )  A 2 J
y  _  (^ 2! —**)(^~(^31 . 0  „
/ =  a ( r - a ) { a - f i )
A2.9
z _ { k n - P ) { k i x + k m - P )  
p { y - p ) { a - p )
Similarly, from 2.3.2.3 the rate of change in the mass (amount) of drug metabolised 
(hepatically cleared) by the liver is represented by the equation,
_ 7 A




C^ M  ~ A 2.ll
i=i i=i
Am ~  J kmAffdt — km J AHdt A2.12
t= 0
Now the equation for AH has been calculated in part 2.3.2.3 and Appendix A1 to be,
_ P 0k]3(k2] - y ) e D 0kn ( a  - k2l )e~at D0kn (kn
H ( r - a ) ( y - P )  ( y - a ) { a - 0 ) ( r - 0 ) (a- f i )
hence,
Doku (*21 ~ r ) e ' 1' t )e~a  | P 0k„(k2l -  P )e ' ft




= k„ g o *»(* 2i - r ) e  n | A * I 3 ( a - k 2])e a  | £><,*» (*n  - p)e  *  
- r ( r - a ) ( r - P )  - a { y - a ) ( a - p )  - p ( y - P) { a- 0 )
t=0
= k_ Dok n ( k 2> ~ r ) e  * Dph» ( g - * 2i)e *  ~ l ) e *
y { y - a ) { y - p )  a { y - a ) { a - p )  P { y - P ) { a - P )
^ 0^ 13(^21 x) ^  ^21) ^ 0^ 13(^21
r ( r - a ) ( y - P )  a ( y - a ) { a ~ p )  p { y - p ) { a ~ p )
Therefore,
(^21 y) , ^21 )
A u ~ k M  \ y { y - a ) { y - p )  ' a { y - a ) { a - P )  ' p ( y - p ) ( a ~ p )
(*21 -r)e'” (or—*21)« -at
i.e.
__________________________________________ ( k ^ - p y *
y ( y - a ) ( y - p )  a ( y - a ) ( a - p ) p { y - p ) ( a - p )
Au = k mkuD0{U + V + W-Ue~r' -Ve~a - W e ' * }









BasicV algorithms run on Acorn Archimedes RISC processor for calculation of 
pharmacokinetic data
Program MACRQHOURS
1 0  R E M  P R O G R A M  F O R  S I M U L A T I O N  O F  M A C R O M O L E C U L A R  D I S P O S I T I O N
2 0  R E M  ----------------------------------------------------------------------------------------------------------------------------------------
3 0  R E M  C  W P O U T O N  a n d  P  R  S N E L L ,  A P R I L  1 9 9 1
4 0  R E M ----------------------------------------------------------------------------------------------------------------------;-----------------
5 0  R E M
6 0  R E M  > A D F S : : 0 . $ . M A C R O D I S P
7 0  O N  E R R O R  P R O C e r r o r
8 0  D I M  A ( 1 0 0 0 , 4 ) , A A ( 2 0 )  , B ( 2 0 ) , X W ( 2 0 )
9 0  P R O C o r i g i n a l  
1 0 0  P R O C p a r a m  
1 1 0  P R O C s i z e  
1 2 0  P R O C c u b e  
1 3 0  P R O C a s s i g n  
1 4 0  P R O C t i m e s  
1 5 0  P R O C c a l c  
1 6 0  P R I N T :
P R I N T :
I N P U T  T A B ( 1 5 ) " D O  Y O U  W I S H  T O  P R I N T  T O  D I S C ?  ( Y / N ? ) " ; P C H O I C E $
1 7 0  I F  P C H O I C E $ « " Y "  T H E N  1 8 0  E L S E  2 1 0
1 8 0  P R O C f i l e n a m e
1 9 0  P R O C d i s c
2 0 0  P R O C d i s c g r a p h
2 1 0  P R I N T :
I N P U T " D O  Y O U  W I S H  T O  E N T E R  N E W  E X P E R I M E N T A L  T I M E S ?  ( Y / N ? ) " ; T C H O I C E $  
2 2 0  I F  T C H O I C E $ = " Y "  T H E N  1 4 0  E L S E  2 3 0  
2 3 0  P R I N T :
I N P U T " D O  Y O U  W I S H  T O  E N T E R  A  N E W  M O L E C U L A R  R A D I U S ?  ( Y / N ? ) " ; R C H O I C E $  
2 4 0  I F  R C H O I C E $ « " Y "  T H E N  1 1 0  E L S E  2 5 0  
2 5 0  P R I N T :
I N P U T " D O  Y O U  W I S H  T O  U S E  N E W  P A R A M E T E R S ?  ( Y / N ? ) " ; P C H O I C E $
2  6 0  I F  P C H O I C E $ « " Y "  T H E N  1 0 0  E L S E  2 7 0  
2 7 0  P R I N T :
I N P U T " A R E  Y O U  S U R E  Y O U  W A N T T O  Q U I T ?  ( Y / N ? ) " ; F C H O I C E $
2 8 0  I F  F C H O I C E $ « " Y " T H E N  2 9 0  E L S E  2 1 0  
2 9 0  E N D  
3 0 0  :
3 1 0  D E F  P R O C o r i g i n a l  
3 2 0  D O S E = l  
3 3 0  G F R - 1 2 5  
3 4 0  B L F R - 2  
3 5 0  V C = 5 6 0 0  
3 6 0  H R A D I U S = 3 5 . 5  
3 7 0  K 2 1 = * l . 7 8 5 7 1 E - 4  
3 8 0  K 1 3 = 0 . 2 5 7 1 4 2 8  
3 9 0  K 3 1 = 2 . 5 7 1 4 2 8 6  
4 0 0  K M = 0
4 1 0  K F I L T = 0 . 0 0 7 3 3 3  
4 2 0  A F I L T = 1 7 . 6 1 2  
4 3 0  N F I L T = 2  
4 4 0  K L Y M P H - 0 . 0 1 9 5 3 2
A19
4 5 0  A L Y M P H - 1 4 . 7 1 1  
4  6 0  N L Y M P H = 1  
4 7 0  E N D P R O C
4 8 0  :
4  9 0  D E F  P R O C p a r a m  
5 0 0  R E P E A T  
5 1 0  C L S :
0 % = & O A
5 2 0  P R I N T  T A B ( 1 5 , 3 ) " C U R R E N T  V A L U E S  O F  P A R A M E T E R S  A R E  A S  F O L L O W S "
5 3 0  P R I N T
5 4 0  P R I N T  T A B ( 2 0 ) " B )  G F R  -  " ; G F R ; "  ( m l / m i n ) "
5 5 0  P R I N T  T A B ( 2 0 ) " C )  B L F R  -  " ; B L F R ; "  ( m l / m i n ) "
5 6 0  P R I N T  T A B ( 2 0 ) " D )  V C  -  " ; V C ; "  ( m l ) "
5 7 0  P R I N T  T A B ( 2 0 ) " E )  K 2 1  -  " ; K 2 1 ; "  ( m i n ^ - l ) "
5 8 0  P R I N T  T A B ( 2 0 ) " F )  K 1 3  -  " ; K 1 3 ; "  ( m i n ^ - 1 ) "
5 9 0  P R I N T  T A B ( 2 0 ) " G )  K 3 1  -  " ; K 3 1 ; "  ( m i n A- l ) "
6 0 0  P R I N T  T A B ( 2 0 ) " H )  K M -  " ; K M ; "  ( m i n ^ - l ) "
6 1 0  P R I N T  T A B ( 2 0 ) " I ) K F I L T  -  " ; K F I L T
6 2 0  P R I N T  T A B ( 2 0 ) " J )  A F I L T  -  " ; A F I L T
6 3 0  P R I N T  T A B ( 2 0 ) " K )  N F I L T  -  " ; N F I L T
6 4 0  P R I N T  T A B ( 2 0 ) " L )  K L Y M P H  -  " ; K L Y M P H
6 5 0  P R I N T  T A B ( 2 0 ) " M )  A L Y M P H  -  " ; A L Y M P H
6 6 0  P R I N T  T A B ( 2 0 ) " N )  N L Y M P H  -  " ; N L Y M P H
6 7 0  P R I N T :
P R I N T :
P R I N T :
P R I N T
6 8 0  I N P U T  T A B ( 1 5 ) " D O  Y O U  W I S H  T O  A L T E R  A N Y  P A R A M E T E R S ?  ( Y / N ? ) " ; C P A R A M $
6 9 0  I F  C P A R A M $ » " Y "  T H E N  7 0 0  E L S E  1 0 2 0
7 0 0  P R I N T :
P R I N T
7 1 0  I N P U T  T A B ( 1 5 ) " T Y P E  T H E  R E L E V A N T  L E T T E R  A N D  P R E S S  R E T U R N " ; P A R A M $
7 2 0  P R I N T :
P R I N T
7 3 0  C A S E  P A R A M $  O F
7 4 0  W HEN " B "
7 5 0  I N P U T  T A B ( 1 5 ) " T Y P E  N E W  V A L U E  O F  G F R  ( m l / m i n )  " ; G F R
7 6 0  W HEN " C "
7 7 0  I N P U T  T A B ( 1 5 ) " T Y P E  N EW  V A L U E  O F  B L F R  ( m l / m i n )  " ; B L F R
7 8 0  W HEN " D "
7 9 0  I N P U T  T A B ( 1 5 ) " T Y P E  N E W  V A L U E  O F  V C  ( m l )  " ; V C
8 0 0  W HEN " E "
8 1 0  I N P U T  T A B ( 1 5 ) " T Y P E  N EW  V A L U E  O F  K 2 1  ( m i n * - l )  " ; K 2 1
8 2 0  W HEN " F "
8 3 0  I N P U T  T A B ( 1 5 ) " T Y P E  N EW  V A L U E  O F  K 1 3  ( m i n ^ - 1 )  " ; K 1 3
8 4 0  W HEN " G "
8 5 0  I N P U T  T A B ( 1 5 ) " T Y P E  N EW  V A L U E  O F  K 3 1  ( m i n ^ - l )  " ; K 3 1
8 6 0  W HEN " H "
8 7 0  I N P U T  T A B ( 1 5 ) " T Y P E  NEW  V A L U E  O F  KM ( m i n A- l )  " ; K M
8 8 0  W HEN " I "
8 9 0  I N P U T  T A B ( 1 5 ) " T Y P E  N EW  V A L U E  O F  K F I L T  " ; K F I L T
9 0 0  W HEN " J "
9 1 0  I N P U T  T A B ( 1 5 ) " T Y P E  NEW  V A L U E  O F  A F I L T  " ; A F I L T
9 2 0  WHEN " K "
9 3 0  I N P U T  T A B ( 1 5 ) " T Y P E  NEW  V A L U E  O F  N F I L T  " ; N F I L T
9 4 0  WHEN " L "
9 5 0  I N P U T  T A B ( 1 5 ) " T Y P E  NEW  V A L U E  O F  K L Y M P H  " ; K L Y M P H
9 6 0  WHEN " M "
A20
9 7 0  I N P U T  T A B ( 1 5 ) " T Y P E  NEW  V A L U E  O F  A L Y M P H  A L Y M P H
9 8 0  WHEN " N "
9 9 0  I N P U T  T A B ( 1 5 ) " T Y P E  NEW V A L U E  O F  N L Y M P H  " ; N L Y M P H
1 0 0 0  E N D C A S E  
1 0 1 0  U N T I L  C P A R A M $ = " N "
1 0 2 0  E N D P R O C  
1 0 3 0  :
1 0 4 0  D E F  P R O C s i z e  
1 0 5 0  C L S :
P R I N T :
P R I N T
1 0 6 0  I N P U T " E N T E R  A  V A L U E  F O R  T H E  H Y D R O D Y N A M IC  R A D I U S  ( A n g s t r o m s )  " ; H R A D I U S  
1 0 7 0  K 1 2 - E X P  ( - K L Y M P H *  ( H R A D I U S - A L Y M P H )  ' 'N L Y M P H )  * B L F R / V C  
1 0 8 0  K E X C R = E X P ( - K F I L T * ( H R A D I U S - A F I L T )  ' ' N F I L T ) * G F R / V C  
1 0 9 0  P R I N T :
P R I N T :
P R I N T  T A B ( 2 0 ) " C A L C U L A T E D  V A L U E  O F  K 1 2  *  " ; K 1 2  
1 1 0 0  P R I N T :
P R I N T  T A B ( 2 0 ) " C A L C U L A T E D  V A L U E  O F  K E X C R  -  " ; K E X C R  
1 1 1 0  A A ( 3 ) - 1
1 1 2 0  A A ( 2 )  — ( K 1 2 + K 2 1 + K 1 3 + K 3 1 + K E X C R + K M )
1 1 3 0
A A ( 1 )  - ( K 2 1 * K 3 1 )  +  ( K 2 1 * K M ) + ( K 1 2 * K 3 1 )  +  ( K 1 2 * K M )  +  ( K 1 3 * K M )  +  ( K 1 3 * K 2 1 )  +  ( K E X C R * K 3 1 )  +  ( K E  
X C R * K M ) + ( K E X C R * K 2 1 )
1 1 4 0  A A ( 0 )  — ( ( K 1 3 * K 2 1 * K M )  +  ( K E X C R * K 2 1 * K 3 1 )  +  ( K E X C R * K 2 1 * K M ) )
1 1 5 0  P R I N T :
P R I N T  " T H E  C O E F F I C I E N T S  O F  T H E  C U B I C  E Q U A T I O N  A R E : "
1 1 6 0  F O R  K  -  3  T O  0  S T E P  - 1  
1 1 7 0  P R I N T :
P R I N T  T A B ( 2 0 )  " A " ; K ; "  -  " ; A A ( K )
1 1 8 0  N E X T  
1 1 9 0  P R I N T :
P R I N T :
P R I N T  T A B ( 2 0 ) " P R E S S  A N Y  K E Y  T O  C O N T I N U E " :
I F G E T  
1 2 0 0  E N D P R O C  
1210  :
1 2 2 0  D E F  P R O C c u b e
1 2 3 0  R E M  N E W T O N  R A P H S O N  R O U T I N E  W I T H  S Y N T H E T I C  D I V I S I O N  
1 2 4 0  R E M  F O R  S O L U T I O N  O F  C U B I C  E Q U A T I O N S  
1 2 5 0  C L S  
1 2 6 0  N - 3 :
N W - 3  
1 2 7 0  P R I N T :
P R I N T " T H E  R A N G E  O F  S E A R C H  I S  D E F I N E D  A S  - 1 0  T O  1 0 "  
1 2 8 0  M I N X  -  - 1 0  
1 2 9 0  M A X X  -  1 0  
1 3 0 0  P R I N T :
P R I N T " S T A R T I N G  G U E S S  O F  R O O T  I S  0 . 5 " :
X I  -  0 . 5  
1 3 1 0  P R I N T :
P R I N T " T H E  C O N V E R G E N C E  V A L U E  O F  F  I S  S E T  A T  I E - 1 4 " :  
E P S  =  I E - 1 4
1 3 2 0  R E M  C A L C U L A T E S  T H E  F U N C T I O N  I N  T H E  R A N G E  O F  S E A R C H  
1 3 3 0  D X  -  ( M A X X - M I N X ) / 1 0 0  
1 3 4 0  F O R  K -  0  T O  1 0 0
A21
1 3 5 0  X  -  M I N X  +  K * DX
1 3 6 0  A ( K , 1 )  -  X
1 3 7 0  P R O C s u b c u b e :
A ( K , 2 )  -  F  
1 3 8 0  N E X T  K 
1 3 9 0  P R O C r o o t f i n d  
1 4 0 0  P R I N T :
P R I N T " P R E S S  A N Y  K E Y  T O  C O N T I N U E " :
I F G E T  
1 4 1 0  X W ( N ) « X 1
1 4 2 0  R E M  S Y N T H E T I C  D I V I S I O N  
1 4 3 0  I F  N = 1  G O T O  1 7 0 0  
1 4 4 0  B ( N - 1 ) - A A ( N )
1 4 5 0  F O R  R  -  1  T O  N - l
1 4 6 0  B ( N - l - R ) = A A ( N - R ) + B ( N - R ) * X 1
1 4 7 0  N E X T
1 4 8 0  N - N - l
1 4 9 0  F O R  J J - N  T O  0  S T E P  - 1  
1 5 0 0  A A ( J J )  - B ( J J )
1 5 1 0  N E X T
1 5 2 0  R E M  C H E C K  F O R  C O M P L E X  R O O T S
1 5 3 0  I F  N < > 2  G O T O  1 6 8 0
1 5 4 0  W W - A A ( l ) ~ 2 - 4 * A A ( 2 ) * A A ( 0 )
1 5 5 0  I F W W > 0  G O T O  1 6 8 0
1 5 6 0  P R I N T " T H I S  E Q U A T I O N  H A S  C O M P L E X  R O O T S " :  
P R I N T
1 5 7 0  X W ( 2 ) — A A ( 1 )  /  ( 2 * A A ( 2 ) )
1 5 8 0  X W ( 1 ) - S Q R ( - W W ) / ( 2 * A A ( 2 ) )
1 5 9 0  P R I N T " T H E  " ; N W ; "  R O O T S  A R E : "
1 6 0 0  F O R  J K - N W  T O  3  S T E P  - 1  
1 6 1 0  P R I N T  X W ( J K )
1 6 2 0  N E X T
1 6 3 0  R E M  P R I N T  C O M P L E X  R O O T S  
1 6 4 0  P R I N T  X W ( 2 ) ; " + " ; X W ( 1 ) ; " i "
1 6 5 0  P R I N T  X W ( 2 ) ; " - " ; X W ( l )  ; " i "
1 6 6 0  P R I N T :
P R I N T :
P R I N T " P R E S S  A N Y  K E Y  T O  C O N T I N U E " :
I F G E T  
1 6 7 0  G O T O  2 3 0  
1 6 8 0  I F  N > 0  G O T O  1 3 2 0  
1 6 9 0  R E M  P R I N T  T H E  R O O T S  
1 7 0 0  P R I N T " T H E  " ; N W ; "  R O O T S  A R E : "
1 7 1 0  F O R  J K  -  NW T O  1  S T E P  - 1  
1 7 2 0  P R I N T  X W ( J K ) ; "  " ;
1 7 3 0  N E X T  
1 7 4 0  P R I N T :
P R I N T " P R E S S  A N Y  K E Y  T O  C O N T I N U E " :
I F G E T  
1 7 5 0  E N D P R O C  
1 7 6 0  :
1 7 7 0  D E F  P R O C s u b c u b e  
1 7 8 0  F = 0 :
F P = 0
1 7 9 0  F O R  KK  »  N  T O  0  S T E P  - 1
1 8 0 0  F  =  F  +  A A ( K K )  * X ~ K K
1 8 1 0  I F  K K - 0  T H E N  E N D P R O C
1 8 2 0  F P  -  F P  +  K K * A A ( K K )  *  X A ( K K - 1 )
1 8 3 0 N E X T  KK
1 8 4 0 E N D P R O C
1 8 5 0 :
1 8 6 0 D E F  P R O C r o o t f i n d
1 8 7 0 P R I N T " C O N V E R G E N C E  T O  R O O T " ; ( N W -  
P R I N T
- N + l ) :
1 8 8 0 F O R  I T E R = 0  T O  4 0 0  S T E P  2
1 8 9 0 X - X l :
P R O C s u b c u b e
1 9 0 0 P R I N T " I t e r a t i o n  n o .  I T E R ; " x - " ; X l ; "  f ( x ) " ; F
1 9 1 0 A  ( I T E R , 3 ) - X I ;  
A ( I T E R , 4 ) = 0
1 9 2 0 A ( I T E R + 1 , 3 ) “ X I : 
A ( I T E R + 1 , 4 ) - F
1 9 3 0 I F  A B S ( F ) < E P S  T H E N  1 9 9 0  E L S E 1 9 4 0
1 9 4 0 X 1 - X 1 - F / F P
1 9 5 0 N E X T  I T E R
1 9 6 0 P R I N T " E X C E E D S  I T E R A T I O N  L I M I T :  
P R I N T :
P R I N T " I T E R - " ; I T E R :
P R I N T " E P S = " ; E P S :
P R I N T " F - " ; F
N O  C O N V E R G E N C E " :
1 9 7 0 I N P U T " E N T E R  N E W  C O N V E R G E N C E  V A L U E  " ; E P S
1 9 8 0 G O T O  1 8 6 0
1 9 9 0 E P S  -  I E - 1 4
2 0 0 0 E N D P R O C
2 0 1 0 :
2 0 2 0 D E F  P R O C a s s i g n
2 0 3 0 I F  X W ( 1 ) > X W ( 2 )  A N D  X W ( 2 ) > X W ( 3 )  
A L P H A —X W ( 2 ) :
B E T A —X W ( 3 )
T H E N  GAMMA—X W ( 1 ) :
2 0 4 0 I F  X W ( 1 ) > X W ( 3 )  A N D  X W ( 3 ) > X W ( 2 )  
A L P H A —X W ( 3 )  :
T H E N  GAMMA—X W ( 1 ) :
B E T A —X W ( 2 )
2 0 5 0 I F  X W ( 2 ) > X W ( 1 )  A N D  X W ( 1 ) > X W ( 3 )  
A L P H A —X W ( 1 ) :
B E T A —X W ( 3 )
T H E N  GAMMA—X W ( 2 ) :
2 0 6 0 I F  X W ( 2 ) > X W ( 3 )  A N D  X W ( 3 ) > X W ( 1 )  
A L P H A —X W ( 3 ) :
B E T A - X W ( 1 )
T H E N  G A M M A -X W ( 2 ) :
2 0 7 0 I F  X W ( 3 ) > X W ( 1 )  A N D  X W ( 1 ) > X W ( 2 )  
A L P H A —X W ( 1 ) :
B E T A - X W ( 2 )
T H E N  GAMMA—XW( 3 ) :
2 0 8 0 I F  X W ( 3 ) > X W ( 2 )  A N D  X W ( 2 ) > X W ( 1 )  
A L P H A —X W ( 2 ) :
B E T A - X W ( 1 )
T H E N  GAMMA—XW( 3 ) :
2 0 9 0 P R I N T :
P R I N T " G A M M A  -  " ; G A M M A ; "  A L P H A  =  " ; A L P H A ; "  B E T A  =  " ; B E T A
2 1 0 0 P R I N T :
P R I N T :
P R I N T  T A B ( 2 0 ) " P R E S S  A N Y  K E Y  T O C O N T I N U E " :
I F G E T
2 1 1 0 E N D P R O C
2 1 2 0 ;
A23
2 1 3 0 D E F  P R O C t i m e s
2 1 4 0 C L S
2 1 5 0 I N P U T  T A B ( 2 0 ) " T Y P E
2 1 6 0 I N P U T  T A B ( 2 0 ) " T Y P E
2 1 7 0 I N P U T  T A B ( 2 0 ) " T Y P E
2 1 8 0 P * * P H O U R S * 6 0
2 1 9 0 Q = Q H O U R S * 6 0
2 2 0 0 R - R H O U R S * 6 0
2 2 1 0 E N D P R O C
2 2 2 0 J
I N I T I A L  T I M E  ( H O U R S )  " ; P H O U R S  
F I N A L  T I M E  ( H O U R S )  " ; Q H O U R S  
T I M E  I N C R E M E N T  ( H O U R S )  " ; R H O U R S
2 2 3 0  D E F  P R O C c a l c
2 2 4 0  P R I N T " A  T A B L E  O F  C P ,  A P ,  A L  A N D  AH I N I T I A L L Y  W I L L  B E  P R I N T E D  T O  S C R E E N "  
2 2 5 0  P R I N T " T O  E S T A B L I S H  W H E T H E R  T H E  E X P E R I M E N T A L  T I M E S  A R E  A P P R O P R I A T E "
2 2 6 0  P R I N T :
P R I N T  T A B ( 2 0 ) " P R E S S  A N Y  K E Y  T O  C O N T I N U E " :
I F G E T  
C L S
P R I N T  " T I M E  ( H O U R S )  C P  A P  A L  A H "
P R I N T  " --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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3 5 8 0  U N T I L  Y N 1 $ « " Y "  O R  Y N 1 $ - " N "
3 5 9 0  I F  Y N 1 $ - " N "  T H E N  3 6 7 0  
3 6 0 0  O S C L I ( " A C C E S S  " + F I L E $ )
3 6 1 0  O S C L I ( " D E L E T E  " + F I L E 3 )
3 6 2 0  O S C L I ( " A C C E S S  G " + F I L E $ )
3 6 3 0  O S C L I ( " D E L E T E  G " + F I L E $ )
3 6 4 0  O S C L I ( " A C C E S S  G L " + F I L E $ )
3 6 5 0  O S C L I ( " D E L E T E  G L " + F I L E $ )
3 6 6 0  E N D P R O C
3 6 7 0  R E P E A T
3 6 8 0  F I L E 1 $ - F I L E $
3 6 9 0  C L S :
P R I N T :
I N P U T "  N e w  d a t a  f i l e  n a m e  " ; F I L E $
3 7 0 0  U N T I L  F I L E $ < > " "  AN D  F I L E $ O F I L E l $
3 7 1 0  WHEN 2 0 1
3 7 2 0  C L S :
P R I N T " W R I T E  P R O T E C T  T A B  I S  O N  -  P L E A S E  R E M O V E "  
3 7 3 0  P R I N T " P R E S S  A N Y  K E Y  T O  C O N T I N U E " :
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3 7 4 0
3 7 5 0
3 7 6 0
3 7 7 0
3 7 8 0
3 7 9 0
3 8 0 0
3 8 1 0
3 8 2 0
3 8 3 0
3 8 4 0
3 8 5 0
3 8 6 0
3 8 7 0
3 8 8 0
3 8 9 0
3 9 0 0
3 9 1 0
3 9 2 0
3 9 3 0
3 9 4 0
3 9 5 0
3 9 6 0
3 9 7 0
3 9 8 0
3 9 9 0
I F G E T
WHEN 6 7 7 9 8  
R E P E A T  
C L S :
P R I N T " D a t a  f i l e  n o t  f o u n d  -  f i l e s  o n  d i s k  a r e : - "
P R I N T :
P R I N T "  " ;
" I N F O  A D F S :
0 . $ . *
P R I N T :
P R I N T " ( 1 )  E n t e r  n e w  f i l e n a m e "
P R I N T :
P R I N T " ( 2 )  C h a n g e  t h e  d i s k "
P R I N T :
P R I N T :
I N P U T  " P l e a s e  e n t e r  y o u r  c h o i c e :  " ; s e l e c t i o n s  
C A S E  s e l e c t i o n s  O F  
W H E N  " 1 "
F I L E S - F I L E 1 S  
R E P E A T  
P R I N T :
I N P U T " N e w  d a t a  f i l e  n a m e  " ; F I L E 1 $
U N T I L  F I L E 1 S O " "  A N D  F I L E $ O F I L E l $
F I L E S - " " :
W H EN  " 2 "
C L S :
P R I N T  T A B ( 1 0 , 1 0 ) ; " P r e s s  a n y  k e y  w h e n  d i s k  h a s  b e e n  c h a n g e d " :  
I F G E T  
" M O U N T  1  
E N D C A S E
U N T I L  s e l e c t i o n $ « " l "  O R  s e l e c t i o n $ - " 2 "
O T H E R W I S E
P R I N T
R E P O R T :
P R I N T  "  A T  L I N E " ; E R L ; "  ( E r r o r  N o .  " ; E R R ; " ) " ;
P R I N T "  -  P R E S S  A N Y  K E Y  T O  C O N T I N U E " :
I F G E T
E N D C A S E
E N D P R O C
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Appendix A4.1
Program : PA IJI.9
1 0 C L S
2 0 I N P U T " T Y P E  V A L U E  O F  B  " ; B
3 0 I N P U T " T Y P E  V A L U E  O F  C  " ; C
4 0 I N P U T " T Y P E  V A L U E  O F  D " ; D
5 0 C L S
6 0 I N P U T " E N T E R  L O W E R  L I M I T  O F X  " ; P
7 0 I N P U T " E N T E R  U P P E R  L I M I T  O F X  " ; Q
8 0 I N P U T " E N T E R  S T E P  I N C R E M E N T "  ; R
9 0 F O R  X - P  T O  Q S T E P  R
1 0 0 V —X ' ' 3 - B * X * 2 + C * X - D
1 1 0 P R I N T  X ; "  " ; V
1 2 0 N E X T
1 3 0 P R I N T  " D O  Y O U  W I S H  T O  T R Y  O T H E R  !
1 4 0 * F X  1 5 , 1
( Y / N ? )
1 5 0  I F  G E T $ « " Y "  T H E N  6 0  E L S E  1 6 0  
1 6 0  S T O P  
1 7 0  E N D
Appendix A4.2
Program: CUBE4
1 0  C L S
2 0  I N P U T  " T Y P E  V A L U E  O F  K 1 2 " ; K 1 2
3 0  I N P U T  " T Y P E  V A L U E  O F  K 2 1 " ; K 2 1
4 0  I N P U T  " T Y P E  V A L U E  O F  K 1 3 " ; K 1 3
5 0  I N P U T  " T Y P E  V A L U E  O F  K 3 1 " ; K 3 1
6 0  I N P U T  " T Y P E  V A L U E  O F  K E L " ; K E L
7 0  I N P U T  " T Y P E  V A L U E  O F  K M " ; K M
8 0  C L S
9 0  B - K 1 2 + K 2 1 + K 1 3 + K 3 1 + K E L + K M
100
C =  ( K 2 1 * K 3 1 )  +  ( K 2 1 * K M )  +  ( K 1 2 * K 3 1 )  +  ( K 1 2 * K M )  +  < K 1 3 * K M )  +  ( K 1 3 * K 2 1 )  +  ( K E L * K 3 1 )  +  ( K E L * K M )  +  
( K E L * K 2 1 )
1 1 0  D « ( K 1 3 * K 2 1 * K M ) + ( K E L * K 2 1 * K 3 1 ) + ( K E L * K 2 1 * K M )
1 1 5  P R I N T  " T H E  C O E F F I C I E N T S  O F  T H E  C U B I C  E Q U A T I O N  A R E : "
1 2 0  P R I N T  B ; "  " ; C ; "  " ; D
1 4 0  B 1 - 2 * B
1 5 0  R l - ( B l + S Q R ( ( B l ~ 2 ) - ( 1 2 * C ) ) ) / 6
1 6 0  R 2 - ( B l - S Q R ( ( B l /' 2 ) - ( 1 2 * C ) ) ) / 6
1 7 0  P R I N T  " O N E  O F  T H E  R O O T S  O F  T H E  C U B I C  E Q U A T I O N  L I E S  B E T W E E N  T H E  
F O L L O W I N G  V A L U E S : "
1 8 0  P R I N T  R l ; "  " ; R 2
2 0 0  P R I N T
2 1 0  P R I N T
2 2 0  P R I N T
2 3 0  P R I N T  " D O  Y O U  W I S H  T O  C A L C U L A T E  F O R  A  D I F F E R E N T  S E T  O F  R A T E  C O N S T A N T S ?  
( Y / N ) "
2 4 0  * F X  1 5 , 1
2 5 0  I F  G E T $ = * " Y "  T H E N  2 0  E L S E  2 6 0  
2 6 0  S T O P
2 7 0  E N D
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Appendix A5
Skeleton solutions of the physiological one and two-compartment pharmacokinetic 
models
A5.1 Skeleton solution of the physiological one-compartment pharmacokinetic 
model.
Using the description presented in 2.3.2.1, the differential equation describing the 
physiological one-compartment pharmacokinetic model is,
Taking the Laplace transform of equation A5.1.1 gives
therefore,




hence taking the inverse Laplace transform gives,
A p = D0e ktxcrt A5.1.3
Therefore,
A5.1.4
and A -  D  -  AELIM ~  ^ 0U A5.1.5
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where all notation is as defined in subsection 2.3.2, and where the reader is referred to 
part 2.3.2.3 and Appendix A1 to observe how the principle of Laplace transforms 
operates.
A5.2 Skeleton solution of the physiological two-compartment pharmacokinetic 
model
Using the description presented in 2.3.2.1, the differential equations describing the 
physiological two-compartment pharmacokinetic model are,
Taking the Laplace transforms of equations A5.2.1 and A5.2.2 respectively and re­
arranging gives,
- ^ 7  =  - ( * 1 2  + k ^ c r ) A P + * 2  Aat A5.2.1
dt
A5.2.2
(S + k n +kexcr)a] ^2\a2 ~ ^0 A5.2.3
- k u a, + (5 +  &21 )a2 = 0 A5.2.4
hence the determinant of the system is given by,
= s,2 +  ( ^ 1 2  + ^ 2 1  ^  excr)  S  k  21^< excr A5.2.5
= s 2 + (# !  + ft2)s + ft]7T2 =  {s + jux){s + 7r2) say A5.2.6
so that K\ + — k ] 2 + ^ 2 1  ~^^excr A5.2.7
and K\ K2 — k2] k {'21 excr A5.2.8
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which upon solving give,
Tty
_  ( ^ 1 2  “*” ^2 1  ^ e x c r  )  J\ ( ^ ] 2  "*"^21 ^  excr )  ^ ^ 2 \ ^ e_ _





0  5 + £,
with ;r, > k 2 > 0  
(.s + k 2l)D0 A5.2.11
J  (s + ^ X s  + ^ J
which upon separating by the method of partial fractions and then taking the inverse 
Laplace transform gives,
D 0 {(*21 -  *2 )e_*J' -  (*21 -  K\ )« '* ’' }
and therefore C,=
Similarly f l 2 =
U i - * 2)
*>.{(*2, - Z 2)e~*2' - ( * 2 1
r.(*, - x 2)
s + *i2 + k mr D0




which upon separating by the method of partial fractions and then taking the inverse 
Laplace transform gives,
A * ,2  t * - *
U l - ^ 2)
A5.2.15
Also, therefore,
^ eum ~  Do A p A l
.All notation is as defined in subsection 2.3.2, and the reader is referred to part 2.3.2.3 
and Appendix Al to observe how the principle of Laplace transforms operates.
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